Improving the efficacy and safety of adoptive cell therapy

By using CXCR antagonists and TRAIL antagonists and other means to mobilize and activate immune cells during the cell therapy manufacturing process, the problems of high failure rate, toxicity and poor efficacy of cell therapy products in the prior art are solved, and the product acquisition is improved rate, reproduction and penetration reduce costs and toxicity risks.

CN113286811BActive Publication Date: 2024-12-06ANGELES THERAPEUTICS INC
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN201980062149.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-30
Filing Date
2019-07-30
Publication Date
2024-12-06
Estimated Expiration
2039-07-30

AI Technical Summary

Technical Problem

Existing cell therapy products such as CAR-T, SIR-T, TFP-T, Ab-TCR-T and TCR-T have high failure rates, poor proliferation, poor tissue penetration, poor efficacy and high cost during the manufacturing process. Problem, and adoptive immunotherapy is highly toxic and it is difficult to control the reproduction and proliferation of cells.

Method used

Immune cells are mobilized by using CXCR antagonists, cytokines, β2 adrenergic agonists, tyrosine kinase inhibitors or chemotherapy drugs prior to collection of immune cells and activate immunity with bispecific or multispecific adapters Cells, which bind to interfere or block TRAIL activity to reduce toxicity, use agents that interfere or block TRAIL, such as TRAIL antagonists, to prevent or improve toxicity caused by the therapy.

Benefits of technology

Improve the yield, reproduction, activation, proliferation, diversity, tissue penetration, durability and safety of cell therapy products, reduce manufacturing time and cost, and control the reproduction and proliferation of adoptive transfer cells, reducing toxicity risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113286811B_ABST
    Figure CN113286811B_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to the preparation and use of immune effector cells (e.g., T cells, NK cells) that are genetically engineered to express immune receptors (e.g., chimeric antigen receptors, synthetic immune receptors, T cell receptors, etc.) to treat diseases associated with target antigen expression.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 62 / 712,102, filed on July 30, 2018, the disclosure of which is incorporated herein by reference in its entirety.

[0003] Sequence Listing

[0004] This application contains a sequence listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy entitled "SEQ-1-3059_ST25" was created on July 30, 2019, and is 4,053,956 bytes in size. Technical Field

[0005] The present disclosure generally relates to the use of immune effector cells (e.g., T cells, NK cells) genetically engineered to express chimeric antigen receptors (CARs) for treating diseases associated with tumor antigen expression. Background Art

[0006] Adoptive cell transfer (ACT) therapy using immune cells, particularly T cells transduced with chimeric antigen receptors (CARs) and recombinant TCRs, has shown promise in trials for hematological malignancies and solid tumors. However, there is a high failure rate in the manufacture of cell therapy products, resulting in poor yield, poor proliferation, growth, and tissue (e.g., tumor) penetration of the product after administration, poor efficacy, and increased costs.

[0007] There is also a medical need for cell therapy (e.g., immune cell therapy, e.g., CAR-T, SIR-T, Ab-TCR-T, TFP-T, TIL or TCR-T) with improved efficacy and reduced toxicity. The efficacy of adoptive immunotherapy is closely related to the propagation and proliferation of T cells after inputting the patient, wherein adoptive immunotherapy uses conventional and next-generation chimeric antigen receptors (e.g., SIR, zSIR, AbTCR and TFP), and natural (e.g., tumor infiltrating lymphocytes) or genetically modified T cell receptors (e.g., NY-ESO-1TCR) T cells. Thus, compared with patients whose adoptive transferred T cells fail to reproduce or reproduce poorly, patients whose adoptive transferred T cells are robustly propagated in vivo have a greater likelihood of manifesting disease response. Compared with hematological malignancies, the T cell propagation failure of input is a greater problem in the adoptive immunotherapy of solid tumors, and may play a role in the poor overall response of solid tumors to adoptive immunotherapy. Improve the in vivo propagation strategy of the T cell of adoptive transfer and include the use of lymphocyte depletion chemotherapy.For example, usually before the T cell of adoptive transfer is infused, fludarabine and cyclophosphamide are applied to the patient.But, the use of lymphocyte depletion chemotherapy is relevant with significant toxicity (for example, pancytopenia, fever, infection risk, neurotoxicity) and death.In addition, although lymphocyte depletion chemotherapy has been applied, the T cell of adoptive transfer still fails to reproduce.A problem relevant to the immunocyte of adoptive transfer is excessive stimulation and proliferation, and this is relevant with toxicity such as cytokine release syndrome, neurotoxicity (comprising death).In addition, the overstimulation of the T cell of adoptive transfer and proliferation are relevant with early stage T cell exhaustion and disease recurrence.

[0008] Therefore, it is necessary to improve the yield, breeding, activation, proliferation, breeding, diversity, tissue (for example, tumor) penetrability, persistence, efficacy and safety of cell therapy products (for example, immune cell therapy products, for example, CAR-T, SIR-T, TFP-T, Ab-TCR-T and TCR-T products etc.). Specifically, it is necessary to improve the novel method for manufacturing cell therapy products, to improve yield, reduce manufacturing time, improve in vivo breeding and efficacy and reduce costs. In addition, it is necessary to have such a method: wherein the breeding, activation and proliferation of the adoptively transferred immune cells can be controlled after they are infused to the subject. Finally, it is necessary to improve the penetration of the adoptively transferred cells into the disease site (for example, tumor). Summary of the Invention

[0009] The present disclosure relates to a method for improving the yield, reproduction, activation, proliferation, reproduction, diversity, tissue (e.g., tumor) penetration, persistence, efficacy and safety of a cell therapy product (e.g., an immune cell therapy product, e.g., CAR-T, SIR-T, TFP-T, Ab-TCR-T and TCR-T products, etc.). The present disclosure relates to improving the yield, reproduction, activation, proliferation, reproduction, diversity, tissue (e.g., tumor) penetration, persistence and efficacy of an immune cell therapy (such as genetically modified CAR-T, TCR-T, SIR-T, Ab-TCR-T cell therapy or NK cell therapy) by using mobilized immune cells to manufacture a cell therapy product. In various embodiments, the method includes mobilizing immune cells before collecting immune cells (e.g., leukocyte apheresis) from a donor. In various embodiments, immune cells are mobilized by administering a CXCR antagonist (e.g., Mozibil or Plerixafor), a cytokine (e.g., G-CSF, GM-CSF, or Sargramostim, Filgrastim (Neulasta), or Pegfilgastrim (Pegfilgastrim)), a β2 adrenergic agonist (e.g., epinephrine), a tyrosine kinase inhibitor (e.g., Dasatinib), a chemotherapy drug (e.g., Cyclophosphamide, Doxorubicin), or a combination of the above agents to the donor from whom the immune cells are harvested prior to collection of the immune cells. In various embodiments, immune cells are mobilized by exercising the subject (i.e., the donor). In certain embodiments, immune cells are mobilized from autologous donors. In other embodiments, immune cells are mobilized from allogeneic donors.

[0010] The present disclosure is also at least partially directed to, for the purpose of adoptive cell therapy, and improving the propagation and / or activation (e.g., in vitro and in vivo propagation and / or activation) of immune cells (e.g., immune T cells, e.g., CAR-T cells or TCR-T cells or TIL or NK cells or CAR-NK cells or macrophage cells or macrophage-CAR cells). Some embodiments described herein provide, by exposing immune cells to bispecific or multispecific adapters (engagers) to propagate and / or activate immune cells, the adapter containing at least one antigen binding domain capable of engaging immune cells and at least one antigen binding domain capable of engaging antigen presenting cells (APCs) or antigen presenting substrates (APSs) (e.g., antigen-conjugated beads).

[0011] The present disclosure is also at least partially directed to, for the purpose of adoptive cell therapy, improving the propagation and / or activation (e.g., in vitro and in vivo propagation and / or activation) of immune cells (e.g., immune T cells, e.g., CAR-T cells, CAR-NK cells or macrophage-CAR cells). Some embodiments described herein provide, by culturing with cells and / or cell lines derived from mantle cell lymphoma, to propagate and / or activate immune cells. Exemplary cell lines derived from mantle cell lymphoma include, but are not limited to REC-1, MINO, JEKO-1 and GRANTA-519. In a preferred embodiment, the immune cells (e.g., T cells) express CAR targeting antigens expressed on B and plasma cell lineage cells (e.g., CD19, CD20, CD22 and BCMA), and are propagated / activated by co-culturing with REC-1 cells.

[0012] The present disclosure also relates to methods for preventing or improving the toxicity caused by or attributable to therapy by interfering with and / or blocking the activity of TRAIL (TNFSF10), wherein therapy is, for example, cell therapy or immunotherapy, for example, CAR-T therapy or rantumomab therapy. In certain embodiments, the therapy relates to a bispecific or multispecific adapter for activating immune cells (e.g., T cells). Exemplary bispecific adapters for activating immune cells include rantumomab, CD3 x CD123 DART, and BCMA x CD3 BiTE. In certain embodiments, the therapy is a cell therapy, in which cells typically express recombinant receptors such as chimeric receptors, for example, chimeric antigen receptors (CARs), or other transgenic receptors such as T cell receptors (TCRs).

[0013] In certain embodiments, the activity of TRAIL is interfered with or blocked by administering a TRAIL / TNFSF10 antagonist. In certain embodiments, the TRAIL antagonist is an antibody, antibody fragment, small molecule, peptide, or nucleic acid. In certain embodiments, the TRAIL antagonist is an agent that binds to TRAIL (TNFSF10) or its receptor, death receptor 5 (DR5 or TNFRSF10B) or death receptor 4 (DR4 or TNFRSF10A), such as an antibody, antibody fragment, or non-immunoglobulin antigen binding scaffold such as DARPIN, affibody, affilin, adnectin, affitin, obodies, repebody, fynomer, alphabody, avimer, atrimer, centyrin, pronetin, anticalin, kunitz domain, armadillo repeat protein, or a fragment thereof.

[0014] In certain embodiments, the TRAIL antagonist is a soluble TRAIL receptor (e.g., DR5-SP-ECD-hlgFc; SEQ ID NO: 2428, DR4-SP-ECD-hlgFc; SEQ ID NO: 2441, DcR1-SP-ECD-hlgFc; SEQ ID NO: 2448; or DcR2-SP-ECD-hlgFc; SEQ ID NO: 2455). In certain embodiments, the TRAIL antagonist is a nucleic acid that targets TRAIL (e.g., an shRNA targeting TRAIL or a gRNA targeting TRAIL) or its receptors DR5 (e.g., an shRNA targeting DR5 or a gRNA targeting DR5) and DR4 (e.g., an shRNA targeting DR4 or a gRNA targeting DR4). Provided herein are target sequences for gRNAs targeting TRAIL (SEQ ID NOs: 2060-2109), DR4 (SEQ ID NOs: 2111-2160), and DR5 (SEQ ID NOs: 2162-2211). Provided herein are target sequences for shRNAs targeting TRAIL (SEQ ID NOs: 2213-2216), DR4 (SEQ ID NOs: 2217-2220), and DR5 (SEQ ID NOs: 2221-2224). Also provided herein are sequences for shRNA constructs targeting TRAIL (SEQ ID NOs: 2226-2230), DR4 (SEQ ID NOs: 2231-2233), and DR5 (SEQ ID NOs: 2234-2237).

[0015] In certain embodiments, the TRAIL antagonist is a small molecule compound that interferes with the signal transduction pathway activated by binding of TRAIL to its receptor DR5 or DR4. In certain embodiments, the TRAIL antagonist is an agent that changes the expression of TRAIL or its receptor. In certain embodiments, the TRAIL antagonist is an agent that downregulates the expression of TRAIL or its receptor DR5 and / or DR4. As an example, a TRAIL antagonist can interfere with the expression of TRAIL, DR5 and / or DR4 at the transcriptional, post-transcriptional, translational or post-translational levels. In certain embodiments, the TRAIL antagonist is included in the manufacture of a cell therapy product. In other embodiments, the cell therapy product is exposed to the TRAIL antagonist before being administered to a subject. In other embodiments, the TRAIL antagonist is incorporated into a cell therapy product. In exemplary embodiments, a cell therapy product (e.g., a CAR-T cell product, a TCR-T product, or a TIL) can be genetically engineered to express a) a soluble TRAIL receptor (e.g., DR5-SP-ECD-hlgFc; SEQ ID NO: 2428, DR4-SP-ECD-hlgFc; SEQ ID NO: 2441, DcR1-SP-ECD-hlgFc; SEQ ID NO: 2448; or DcR2-SP-ECD-hlgFc; SEQ ID NO: 2455); b) a scFV targeting TRAIL, DR5, and / or DR5; c) a shRNA targeting TRAIL, DR5, or DR4; d) a gRNA targeting TRAIL, DR5, or DR4; e) ectopic overexpression of DcR1 or DcR2; f) ectopic overexpression of DR5 (e.g., SEQ ID NO: 2370, 2391) or DR4 (e.g., SEQ ID NO: 2392). NOs: 2275 and 2385); or g) ectopically overexpressing a fusion protein containing the extracellular TRAIL-binding domain fused to the transmembrane and cytosolic domains of CD27, CD28, 41BB, OX40, GITR, or BCMA (e.g., SEQ ID NOs: 2429-2440).

[0016] The TRAIL antagonist can be administered to the subject before, simultaneously with, or after administration of the cell and / or immunotherapy product (e.g., CAR-T cells or rantuzumab).

[0017] In certain embodiments, TRAIL antagonists are administered to prevent the toxicity of a cell or immunotherapy product. In other embodiments, TRAIL antagonists are administered preemptively when early signs of toxicity of a cell or immunotherapy product occur. In other embodiments, TRAIL antagonists are administered after signs and symptoms of toxicity of a cell or immunotherapy product occur. In other embodiments, TRAIL antagonists are administered to treat the signs and symptoms of toxicity of a cell or immunotherapy product. In other embodiments, in addition to preventing and treating the toxicity of a cell or immunotherapy product, TRAIL antagonists are used to improve their effectiveness, e.g., to improve the survival, proliferation, and reproduction of a cell therapy product, to prevent exhaustion, and to improve their long-term persistence and anti-tumor activity in vivo.

[0018] The present disclosure also relates to methods for preventing and treating immune disorders such as rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, Still's disease, macrophage activation syndrome, hemophagocytic lymphohistiocytosis (HLH), systemic lupus erythematosus (SLE), Kawasaki disease, and inflammatory bowel disease by administering a TRAIL antagonist (e.g., a TRAIL antagonist described herein, e.g., an agent that interferes with and / or blocks the activity of TRAIL (TNFSF10) or its receptor DR5) to a subject. Specifically, the present disclosure relates to methods for preventing and treating immune disorders caused by macrophage activation. In certain embodiments, the present disclosure relates to methods for preventing and treating immune disorders caused by T cell-induced macrophage activation.

[0019] The present disclosure also provides methods for generating antibodies against TNFRSFs from CD27 (TNFRSF7, Gene ID: 939; SEQ ID NO: 2254), CD28 (Gene ID: 940; SEQ ID NO: 2255), 41BB (TNFRSF9, CD137; Gene ID: 3604; SEQ ID NO: 2256), OX40 (TNFRSF4, Gene ID: 7293; SEQ ID NO: 2257), DcR2 (TNFRSF10D, Gene ID: 8793; SEQ ID NO: 2251), DcR1 (TNFRSF10C, Gene ID: 8794; SEQ ID NO: 2250), BCMA (TNFRSF17, Gene ID: 608; SEQ ID NO: 2259), and GITR (TNFRSF18; Gene ID: 8784; SEQ ID NO: 2260). NO: 2258), and the use of such compositions and methods for modifying the phenotype, differentiation state, and functional activity of immune effector cells (e.g., genetically modified antigen-specific T cells, such as CART cells, TCR-modified T cells, and SIR-T cells).

[0020] The present disclosure provides compositions and methods for disrupting or downregulating the expression of one or more genes from a group consisting of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10), and death receptor 5 (DR5 or TNFRSF10B), or inhibiting their activity, as well as uses of such compositions and methods for modifying the phenotype, differentiation state, functional activity, and toxicity of immune effector cells (e.g., genetically modified antigen-specific T cells, such as CART cells).

[0021] The present disclosure also provides methods that result in the expression of proteins from genes encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, JAK1, JAK3, STAT5b, STAT 3. Compositions and methods for expressing mutant forms of one or more genes in a collection of IL2RG, CARD11, BRAF, TRAIL (TNFSF10), death receptor 5 (DR5 or TNFRSF10B) or death receptor 4 (DR4 or TNFRSF10A), and the use of such compositions and methods for modifying the phenotype, differentiation state, functional activity and toxicity of immune effector cells (e.g., genetically modified antigen-specific T cells, such as CAR-T cells, TCR-modified T cells and SIR-T cells).

[0022] Specifically, the present disclosure provides methods and compositions for supporting the therapeutic effects of cell therapy products (e.g., chimeric antigen receptor (CAR) T cells and TCR-modified T cells). While not being bound by theory, inhibition or disruption of the activity of one or both alleles of one or more of the BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10), and death receptor 5 (DR5 or TNFRSF10B) genes results in changes in the phenotype, differentiation, proliferation, function, and / or toxicity of immune cells (e.g., genetically modified antigen-specific T cells, such as CART cells, TCR-modified T cells, and SIR-T cells).

[0023] Specifically, the present disclosure provides methods and compositions for supporting the therapeutic effects of genetically modified antigen-specific T cells (e.g., chimeric antigen receptor (CAR) T cells and TCR-modified T cells and SIR-T cells, etc.) by treatment with chemical inhibitors of EZH2, MLL2, MLL3, MLL4, BRD9, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, when used alone or in combination.

[0024] Thus, the present disclosure provides cells (e.g., cell populations, such as immune effector cell populations) that are genetically engineered to express an antigen-specific receptor, such as a chimeric antigen receptor (CAR), a TCR receptor fusion protein (TFP), a synthetic immunoreceptor (SIR), an antibody-TCR, a natural TCR, or an artificial TCR, wherein the antigen-specific receptor comprises an antigen binding domain, a transmembrane domain, and optionally an intracellular signaling domain, and wherein the BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., , Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2(G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1 and HDAC2, JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, TRAIL and / or DR5, the expression and / or function of one or more of which has been reduced, eliminated or altered.

[0025] In certain embodiments, immune cells are collected from donors who have been administered a CXCR4 antagonist (e.g., plerixafor), a cytokine (e.g., G-CSF, GM-CSF, or sargramostim, Neulasta, or Pegfilgastrim), a β2 agonist (e.g., epinephrine), a tyrosine kinase inhibitor (e.g., dasatinib), a chemotherapy drug (e.g., cyclophosphamide, doxorubicin, etc.), alone or in combination, prior to collection of the immune cells.

[0026] In certain embodiments, the donor is an autologous donor, and in other embodiments, the donor is an allogeneic donor. In one aspect, the cell of the present disclosure is a human cell. In one aspect, the cell of the present disclosure (e.g., genetically modified immune effector cells, e.g., CART cells) includes BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and DR5 inhibitors.

[0027] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR), and BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA 4. Inhibitors of CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, wherein the inhibitors are: (1) gene editing systems that target genes encoding EZH2, MLL2, MLL3, MLL4, BRD9, methylcytosine dioxygenase (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, (2) a gene editing system that targets one or more sites within genes encoding EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 or their regulatory elements (e.g., BRD9 or its regulatory elements); (3) a gene editing system that targets genes encoding EZH2, MLL2, MLL3, MLL4, BRD9, methylcytosine dioxygenase (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR , FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2(G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 or their regulatory elements (e.g., BRD9 or its 5' or 3' untranslated region or its promoter); 2) one or more sites within an RNA (e.g., mRNA) encoding one or more components of the gene editing system; or (4) a combination thereof.

[0028] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor and an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, wherein the inhibitor is a gene editing system that targets genes encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5. One or more sites within a gene or RNA of a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or a regulatory element thereof (e.g., BRD9 or a regulatory element thereof), and wherein the gene editing system is selected from the group consisting of a CRISPR / Cas9 system, a zinc finger nuclease system, a TALEN system, and a meganuclease system.

[0029] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR), and an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, wherein the inhibitor is a gene editing system that targets a gene encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5. The invention relates to a method for treating a patient's condition in which the patient's condition is treated with CRISPR / Cas system comprising a gRNA molecule comprising one or more sites within a gene / RNA of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or a regulatory element thereof (e.g., BRD9 or a regulatory element thereof), and wherein the gene editing system is a CRISPR / Cas system comprising a gRNA molecule comprising a targeting sequence that hybridizes to a target sequence of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In certain embodiments, the targeting sequence is a targeting sequence listed in Tables 4a and 4b. In certain embodiments, the gRNA molecule has a sequence listed in Table 8.

[0030] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR), and BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5. The invention relates to an inhibitor of a gene encoding a cytosine dioxygenase (CMD) gene, wherein the inhibitor is an siRNA or shRNA specific for BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or a nucleic acid encoding the siRNA or shRNA. In certain embodiments, the siRNA or shRNA comprises a sequence complementary to the mRNA sequence of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, e.g., a target sequence of an shRNA listed in Table 5.

[0031] In certain embodiments, the cells of the present disclosure include immunoreceptors (e.g., CAR, SIR, TFP, Ab-TCR or TCR), and inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, wherein the inhibitor is a small molecule. In certain embodiments, the small molecule is a molecule listed in Table 6.

[0032] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR), and an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, wherein the inhibitor is a protein, e.g., BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, F A dominant-negative binding partner of BXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or a nucleic acid encoding a dominant-negative binding partner of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5.

[0033] In certain embodiments, the cells of the present disclosure comprise an immunoreceptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR), and an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, wherein the inhibitor is a protein, e.g., a dominant negative (e.g., catalytically inactive) BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5. , Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or nucleic acids encoding such dominant negative BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. Exemplary dominant negative mutants of DR5 are provided in SEQ ID NOs: 2260 and 2318-2330.

[0034] In one aspect, the present disclosure provides a method for altering the phenotype, differentiation state and / or therapeutic effect of an immune cell (e.g., a cell expressing an immune receptor, e.g., a cell of any one of the preceding claims, e.g., a cell expressing CAR19), the method comprising reducing the level or activity of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in the cell. In certain embodiments, the step comprises contacting the cell with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5. In certain embodiments, the inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 disclosed herein are selected from: (1) gene editing systems, which targets one or more sites within genes / RNAs encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, or their corresponding regulatory elements;(2) nucleic acids (e.g., siRNA or shRNA) that inhibit the expression of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5; 3) proteins (e.g., dominant negative, e.g., catalytically inactive) BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or BRD9 , EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 binding partners; (4) small molecules that inhibit BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 binding partners; (5) small molecules that inhibit BRD9, EZH2, MLL2, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 binding partners; L3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 expression and / or function; (5) nucleic acids encoding any one of (1)-(3); and, (6) any combination of (1)-(5). ;

[0035] In one aspect, the present disclosure provides a method for altering the phenotype, differentiation state and / or therapeutic effect of an immune cell (e.g., a cell expressing an immune receptor, e.g., a cell of any one of the preceding claims, e.g., a cell expressing CAR19), the method comprising reducing the level or activity of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in the cell. In certain embodiments, the step includes contacting the cell with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In certain embodiments, the contact occurs ex vivo. In certain embodiments, the contact occurs in vivo. In certain embodiments, the contact occurs in vivo before the nucleic acid encoding the immune receptor is delivered into the cell. In certain embodiments, the contact occurs in vivo after the cell has been administered to a subject in need thereof.

[0036] In one aspect, the present disclosure provides a method of increasing the diversity of an immune cell (e.g., a cell expressing an immune receptor, e.g., a cell of any one of the preceding claims, e.g., a cell expressing CAR19), the method comprising a step of reducing the level or activity of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in the cell. In certain embodiments, the step includes contacting the cell with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In certain embodiments, the contacting occurs ex vivo. In certain embodiments, the contacting occurs in vivo. In certain embodiments, the contacting occurs in vivo before the nucleic acid encoding the immune receptor is delivered into the cell. In certain embodiments, the contacting occurs in vivo after the cell has been administered to a subject in need thereof.

[0037] In one aspect, the present disclosure provides a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a cell as described herein, e.g., an immune effector cell (e.g., T cell or NK cell) comprising an immune receptor, and optionally, administering to the subject an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In certain embodiments, the subject receives pretreatment with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 prior to initiation of immunotherapy or cell therapy. In certain embodiments, the subject receives concurrent treatment with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, and immune and / or cellular therapy. In certain embodiments, following administration of the immune and / or cell therapy, the subject is treated with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5.

[0038] In certain embodiments, the subject suffers from a disease associated with tumor antigen expression, eg, a proliferative disease, a precancerous condition, cancer, and non-cancer related indications associated with tumor antigen expression.

[0039] The present disclosure provides uses of the compositions and / or methods described herein for treating cancer.

[0040] The present disclosure provides inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, as well as JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD 11 and / or BRAF mutants, as well as wild type and mutants of CD28 (Gene ID: 940), 41BB (TNFRSF9, CD137; Gene ID: 3604), OX40 (TNFRSF4, Gene ID: 7293), DcR2 (TNFRSF10D, Gene ID: 8793), DcR1 (TNFRSF10C, Gene ID: 8794), BCMA (TNFRSF17, Gene ID: 608) and GITR (TNFRSF18; Gene ID: 8784), wherein the subject has received, is receiving or will receive immune and / or cell therapy.

[0041] The present disclosure further provides a method for making an immune cell (e.g., an immune effector cell), the method comprising introducing a nucleic acid encoding an immune receptor into the immune effector cell such that the nucleic acid (or a portion thereof encoding the immune receptor) is integrated into the genome of the cell into a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 gene (e.g., within ... t3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes), such that the expression and / or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 is reduced or eliminated.

[0042] The present disclosure further provides a method for manufacturing an immune cell (e.g., an immune effector cell for adoptive cell therapy), the method comprising ex vivo contacting the immune cell individually or in combination with BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitors. In certain embodiments, the inhibitor is a BRD9 inhibitor. In certain embodiments, the inhibitor is a TRAIL inhibitor.

[0043] The present disclosure further provides a method for manufacturing immune cells (e.g., immune effector cells, e.g., for adoptive cell therapy), the method comprising administering, to the donor from whom the immune cells were harvested, either alone or in combination, a CXCR antagonist such as Mozibil (plerixafor), a cytokine (e.g., G-CSF or GM-CSF), a β2 agonist (e.g., epinephrine), a tyrosine kinase inhibitor (e.g., a Src kinase inhibitor, e.g., dasatinib), a chemotherapy drug (e.g., cyclophosphamide, doxorubicin, etc.), prior to collecting (i.e., leukapheresis) the immune cells for manufacturing. The present disclosure further provides a method for manufacturing immune cells for adoptive cell therapy, the method comprising exercising the donor from whom the immune cells were harvested, thereby increasing the heart rate to about 30% (e.g., 40%, 50%, 60%, 80%, 100%, 125%, 150%) higher than the donor's heart rate at rest.

[0044] The present disclosure further provides a vector comprising a sequence encoding an immune receptor, and a sequence encoding an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5.In certain embodiments, the inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 is: (1) a gene editing system that targets genes encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. , Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 or its corresponding regulatory elements; (2) nucleic acids (e.g., siRNA or shRNA) that inhibit BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 or its corresponding regulatory elements. AT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 expression; (3) protein (e.g., dominant negative, e.g., catalytically inactive) BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMA RCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, or a binding partner of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2(G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5; and (4) a nucleic acid encoding any one of (1)-(3), or a combination thereof.In certain embodiments, the sequence encoding an immune receptor and the sequence encoding an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 are separated by a 2A site.

[0045] The present disclosure further provides a gene editing system that is specific for the sequence of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes or their regulatory elements (e.g., BRD9, BCOR, PRDM1, TRAIL genes or their regulatory elements). In certain embodiments, the gene editing system is specific for the sequence of the BRD9 gene or its RNA. In certain embodiments, the gene editing system is: (1) CRISPR / Cas gene editing system, (2) zinc finger nuclease system, TALEN system and meganuclease system. In certain embodiments, the gene editing system is a CRISPR / Cas gene editing system.In certain embodiments, the gene editing system comprises: a gRNA molecule containing a targeting sequence specific for BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes or their regulatory elements, and Cas9 protein; a gRNA molecule containing a targeting sequence specific for BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes or their regulatory elements, and a nucleic acid encoding the Cas9 protein; encoding Nucleic acids encoding a gRNA molecule and a Cas9 protein, wherein the gRNA molecule contains a targeting sequence specific for BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes or their regulatory elements; or encoding a gRNA molecule and a Cas9 protein. The nucleic acid of RNA molecule and the nucleic acid encoding Cas9 protein, the gRNA molecule contains BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 gene or its regulatory element has a specific targeting sequence. In certain embodiments, the gene editing system further includes template DNA. In certain embodiments, the template DNA includes a nucleic acid sequence encoding an immune receptor (for example, an immune receptor as described herein).

[0046] In certain embodiments, the present disclosure also provides a method for treating or preventing a disease in a subject with immune cell therapy, the method comprising the steps of: i) checking the expression of a ligand of a co-stimulatory receptor in cells causing the disease or cells associated with the disease (e.g., cancer cells or stromal cells); ii) identifying the ligand of a co-stimulatory receptor expressed in cells causing the disease or cells associated with the disease (e.g., cancer cells or stromal cells); iii) enhancing the expression of one or more co-stimulatory receptors in immune cells, wherein the ligand of the co-stimulatory receptor is expressed in cells causing the disease or cells associated with the disease; iv) administering immune cells from step (iii) to the subject to prevent or treat the disease. In certain embodiments, at the mRNA level, the expression of a ligand in cells or tissues causing the disease or associated with the disease is checked. Methods for checking gene expression at the mRNA level are known in the art and include, but are not limited to, RT-PCR, Northern blots, RNA-Seq, and gene expression microarrays, etc. In certain embodiments, the expression of a ligand in cells or tissues causing the disease or associated with the disease is checked at the protein level. Methods for checking the expression of protein are known in the art, and include, but are not limited to, immunohistochemistry, flow cytometry, tissue microarray, immunoblotting and mass spectrometry etc. In certain embodiments, the ligand is composed of one or more of TRAIL, CD70, CD80, CD86, 41BBL, OX40L, GITRL and TNFSF13B / TALL-1 / BAFF, but are not limited thereto. In certain embodiments, the costimulatory receptor is composed of one or more of the following items or includes one or more of the following items, but are not limited thereto: a receptor containing the extracellular ligand binding domain of DcR1, DcR2, DR4, DR5, CD27, CD28, 41BB, OX40, GITR and BCMA. In certain embodiments, the costimulatory receptor is composed of one or more of the following items or includes one or more of the following items, but are not limited thereto: DcR1, DcR2, CD27, CD28, 41BB, OX40, GITR and BCMA. In certain embodiments, the co-stimulatory receptor consists of or comprises one or more of the following, but is not limited thereto: a receptor comprising an extracellular ligand binding domain of DcR1, DcR2, DR4, DR5, CD27, CD28, 41BB, OX40, GITR and BCMA, wherein the extracellular ligand binding domain is fused to the cytosolic domain of the co-stimulatory receptor (e.g., CD27, CD28, 41BB, OX40, GITR and BCMA) via a transmembrane domain.Table 1 provides the SEQ ID NOs of several exemplary fusion proteins containing the extracellular domains of DR5, DR4, DcR1, and DcR2 fused to the cytosolic domains of CD27, CD28, 41BB, OX40, GITR, and BCMA. In certain embodiments, the immune cell is a T cell, e.g., a CAR-T cell or a TCR-T cell or a TIL. In one exemplary embodiment, the CAR-T cell expresses a CAR targeting CD19 and co-expresses CD27, wherein the cells causing the disease and / or associated with the disease express CD19 and CD70. In another exemplary embodiment, the CAR-T cell expresses a CAR targeting mesothelin and co-expresses DcR1, wherein the cells causing the disease and / or associated with the disease express mesothelin and TRAIL. In another exemplary embodiment, the CAR-T cell expresses a CAR targeting Her2 and co-expresses 41BB, wherein the cells causing the disease and / or associated with the disease express Her2 and 41BBL. In another exemplary embodiment, the T cell expresses a TCR targeting the NYESO-1 / HLA-A2 complex and co-expresses OX40, wherein the disease-causing and / or disease-associated cells express NYESO-1 / HLA-A2 and OX40L. In an exemplary embodiment, the NK-T cell expresses a CAR targeting CD19 and co-expresses CD27, wherein the disease-causing and / or disease-associated cells express CD19 and CD70.

[0047] The present disclosure further provides a kind of compositions for preparing immune cells (for example, immune effector cells, such as cells expressing immune receptors, for example, CAR-T, SIR-T, TCR-T cells etc.) in vitro, it includes BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitor, for example, BRD9, CBFb and / or YY1 inhibitor.Described inhibitor can be used individually or in combination.

[0048] The present disclosure further provides a kind of for preparing immune effector cell in vitro, the composition of the different banks of the cell (for example, CAR-T, SIR-T, TCR-T cell etc.) expressing immunoreceptor, it comprises BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitor, for example, BRD9, CBFb and / or YY1 inhibitor.Described inhibitor can be used individually or in combination.

[0049] Table 6 presents the targets, names and Cas numbers of various exemplary chemical inhibitors targeting different genes that can be used in the methods of the present disclosure.

[0050] The present disclosure further provides a cell population comprising one or more cells described herein, wherein the cell population comprises a higher percentage of stem-like T cells or Tscm cells (e.g., CD45RA+CD62L+CCR7+CD27+CD95+ T cells) compared to a cell population that does not comprise one or more cells in which the expression and / or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in the cells has been reduced or eliminated.

[0051] The present disclosure is also at least partially related to, for the purpose of adoptive cell therapy, improving the propagation and / or activation (for example, in vitro and in vivo propagation and / or activation) of immune cells (for example, immune effector T cells, for example, CAR-T cells or TCR-T cells or TIL).Some embodiments described herein provide, by exposing immune cells to bispecific or multispecific linkers to propagate and / or activate immune cells, the linker containing at least one antigen-binding domain (for example, a first antigen-binding domain) capable of linking immune cells, and at least one antigen-binding domain (for example, a second antigen-binding domain) capable of linking antigen-presenting cells (APC) or antigen-presenting substrates (APS) (such as antigen-conjugated beads).In certain embodiments, the APC is a hematopoietic cell.In certain embodiments, the bispecific linker is a bispecific antibody, for example, lantumomab. In certain embodiments, the method further comprises exposing the immune cell to an agonist, such as an antibody (e.g., Utomilumab) or a ligand (e.g., 41BBL), capable of activating a co-stimulatory receptor (e.g., CD28, 41BB, CD27, etc.) on an immune cell (e.g., T cell or NK cell).

[0052] In certain embodiments, the bispecific or multispecific linker includes at least one binding domain capable of binding to and activating a T cell receptor (TCR) complex of a T cell. In certain embodiments, the bispecific or multispecific linker includes at least one binding domain capable of binding to and activating a CD3 subunit of a TCR complex. In certain embodiments, the bispecific or multispecific linker includes at least one binding domain capable of binding to and activating a CD3-ε subunit of a TCR complex. In certain embodiments, the bispecific or multispecific linker includes at least one binding domain capable of binding to and activating a co-stimulatory receptor (i.e., a co-stimulatory receptor) provided on a T cell. The exemplary co-stimulatory receptors that the bispecific linker can bind to include CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, TNFR-I, TNFR-II, Fas, CD30, and CD40. In certain embodiments, the bispecific or multispecific adaptor activates signaling through a TCR complex in the presence of an APC or APS. In certain embodiments, the bispecific or multispecific adaptor activates T cells via signaling through a co-stimulatory receptor in the presence of an APC or APS.

[0053] In certain embodiments, the bispecific or multispecific linker comprises at least one binding domain capable of binding to hematopoietic cells. In certain embodiments, the bispecific or multispecific linker comprises at least one binding domain capable of binding to lymphoid lineage hematopoietic cells. In certain embodiments, the bispecific or multispecific linker comprises at least one binding domain capable of binding to B-lymphoid lineage hematopoietic cells. Exemplary B-lineage lymphoid cells bound by the bispecific or multispecific linker include immature B cells, mature B cells and plasma cells, and combinations thereof. In certain embodiments, the bispecific or multispecific linker comprises at least one binding domain capable of binding to an antigen expressed on B-lymphoid lineage hematopoietic cells, e.g., a second binding domain. In certain embodiments, at least one binding domain of the bispecific or multispecific linker binds to CD3e (or CD3ε), and at least one binding domain (e.g., a second antigen binding domain) binds to CD19. In certain embodiments, the bispecific linker is lantumomab. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3e (or CD3ε) and at least one binding domain (e.g., a second antigen binding domain) binds to CD22. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3e (or CD3ε) and at least one binding domain (e.g., a second antigen binding domain) binds to CD20 / MS4A1. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3e (or CD3ε) and at least one binding domain (e.g., a second antigen binding domain) binds to CD23. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3e (or CD3ε) and at least one binding domain (e.g., a second antigen binding domain) binds to BCMA. In certain embodiments, the bispecific adapter is BI 836909 (AMG 420). In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3 epsilon (or CD3 epsilon) and at least one binding domain (e.g., a second antigen binding domain) binds to CS1 / SLAMF7. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3 epsilon (or CD3 epsilon) and at least one binding domain (e.g., a second antigen binding domain) binds to CD138. In certain embodiments, at least one binding domain of the bispecific or multispecific adapter binds to CD3 epsilon (or CD3 epsilon) and at least one binding domain (e.g., a second antigen binding domain) binds to CD123.In certain embodiments, at least one binding domain of the bispecific or multispecific adaptor binds CD3e (or CD3ε) and at least one binding domain (e.g., a second antigen binding domain) binds MPL.

[0054] In certain embodiments, the bispecific or multispecific linker comprises: at least one binding domain capable of binding to an activating receptor (e.g., CD3) and / or a co-stimulatory receptor (e.g., CD28, 41BB, etc.) on T cells, and at least one binding domain capable of binding to a non-hematopoietic cell (e.g., breast cell, lung cell, colon cell, skin cell, etc.) or cell line (e.g., MCF7, H460, SW480, etc.).

[0055] In certain embodiments, the bispecific or multispecific linker comprises at least one binding domain capable of binding to and activating an NK cell receptor and at least one binding domain capable of binding to an antigen expressed on an APC or APS.

[0056] In certain embodiments, activation and propagation of T cells comprises exposing them to a bispecific or multispecific adaptor (e.g., an antibody) that binds a T cell activation or co-stimulatory receptor (e.g., TCR or CD28) in the presence of cells expressing a cognate ligand (e.g., an antigen), wherein the cognate ligand is bound by a second antigen binding domain of the bispecific or multispecific adaptor (e.g., an antibody).

[0057] In certain embodiments, activation and propagation of T cells comprises exposing them to a bispecific or multispecific adaptor (e.g., an antibody) that binds a T cell activating or co-stimulatory receptor (e.g., TCR or CD28) in the presence of a solid substrate expressing a cognate ligand (e.g., an antigen or an anti-idiotypic antibody), wherein the cognate ligand is bound by a second antigen binding domain of the bispecific or multispecific adaptor (e.g., an antibody).

[0058] In certain embodiments, the method comprises activating / propagating immune cells (e.g., T cells) by exposing them to two different bispecific or multispecific adaptors, wherein at least one antigen binding domain of the first bispecific or multispecific adaptor binds to and activates an activating cell receptor (e.g., a T cell receptor or a CD3 receptor complex), and at least one antigen binding domain of the second bispecific or multispecific adaptor binds to and activates a co-stimulatory receptor (e.g., 41BB or CD28), and at least one antigen binding domain of both bispecific or multispecific adaptors binds to at least one antigen (e.g., CD19, CD22, CD20 / MS4A1 and / or BCMA, etc.) expressed on APCs, such as hematopoietic cells (e.g., B cells, plasma cells, or lymphoma cell lines, etc.) or non-hematopoietic cells (e.g., breast cells, lung cancer cell lines, etc.) or APSs (e.g., CD19-extracellular domain-coated beads or CD19 anti-idiotypic antibody-coated beads).

[0059] In certain embodiments, from a blood sample from a subject (e.g., a cancer patient), the immune cell colony used in the method described herein is obtained (e.g., obtained). In one embodiment, immune cell colony is obtained by apheresis. In one embodiment, immune cell colony is obtained from a subject by apheresis, and the subject has been trained or applied CXCR antagonists (e.g., Mozibil or Plerixafor) before collecting immune cells, cytokines (e.g., G-CSF, GM-CSF or Sargramostim, Neulasta or Pegfilgastrim), β2 adrenergic agonists (e.g., epinephrine), tyrosine kinase inhibitors (e.g., dasatinib), chemotherapy drugs (e.g., cyclophosphamide, doxorubicin) or a combination of the above agents.

[0060] In certain embodiments, the immune cell colony includes immune effector cells, e.g., immune effector cells as described herein. Exemplary immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, natural killer T (NKT) cells, or a combination thereof.

[0061] In certain embodiments, the immune cell population comprises peripheral blood mononuclear cells (PBMC) or umbilical cord blood cells, tissue-resident lymphocytes, tumor-infiltrating lymphocytes, bone marrow-resident monocytes, or a combination thereof.

[0062] In certain embodiments, the immune cell population includes primary T cells or lymphocyte subsets, including, for example, anergic T cells, naive T cells, T-regulatory cells, Th-17 cells, T stem cells, tissue-resident T cells, tumor-infiltrating T cells, or a combination thereof.

[0063] In certain embodiments, the immune cell colony includes T cells that have been genetically modified to express natural or synthetic receptors targeting specific antigens. An exemplary natural receptor includes a T cell receptor (TCR) targeting NY-ESO1 or WT1. Exemplary synthetic receptors include CAR or next-generation CAR (e.g., K13-CAR, SIR, zSIR, Ab-TCR, TFP, etc.) or recombinant TCR (rTCR).

[0064] The present disclosure further relates to novel nucleic acid constructs and their integration into immune cells. Specifically, the present disclosure relates to the following discovery: immune cells (preferably T cells, for example, primary human T cells) that are optionally genetically modified to express at least one immune receptor (for example, CAR, SIR, AbTCR, TFP, TCR, etc.) and one or more signaling molecules (for example, JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF) or its mutant form, have the performance that makes these cells very suitable for use in human or animal therapy. In certain embodiments, a nucleic acid construct or multiple constructs encoding immune receptors and signaling molecules or their variants can be on the same or different vectors. In certain embodiments, in immune effector cells expressing endogenous immune receptors (for example, TCR), the signaling molecules or their variants are expressed. In certain embodiments, in immune effector cells expressing exogenous (or genetically modified) immune receptors (for example, CAR, SIR, AbTCR, TFP or cTCR, etc.), the signaling molecules or their variants are expressed. In certain embodiments, the signaling molecule or variant thereof is transiently expressed in immune effector cells. In certain embodiments, the signaling molecule or variant thereof is stably expressed in immune effector cells.

[0065] Table 1

[0066]

[0067]

[0068]

[0069] Table 2

[0070] BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 Depicted is a Matador cytotoxicity assay using different CD19 CAR-T cell products generated using Perixafor-mobilized blood cells against RAJI cells stably expressing LucPPe.

[0072] Figure 2 Depicted is a Matador cytotoxicity assay performed on Nalm6 cells stably expressing LucPPe using different CD19 CAR-T cell products generated using Perixafor mobilized blood cells.

[0073] Figure 3 The effects of TRAIL antibodies on PMA-induced IL1α production are depicted.

[0074] Figure 4 Depicted is the blocking of IL1α production by THP1 cells by TRAIL antibodies when co-cultured with CD19 CAR-T cells in the presence of CD19-expressing BV173 cells.

[0075] Figure 5 Depicted is the blocking of IL1α production by TRAIL antibodies in PMA-differentiated THP1 cells when co-cultured with CD19 CAR-T cells in the presence of CD19-expressing BV173 cells. DETAILED DESCRIPTION

[0076] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0077] The terms "a," "an," and "the" refer to one or more than one (i.e., at least one) of the grammatical object of the article. As an example, "an element" means one element or more than one element.

[0078] When referring to a measurable value such as an amount, a duration, or the like, the term "about" is intended to encompass variations of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±1%, or in some cases ±0.1% of the specified value, as such variations are suitable for performing the disclosed methods.

[0079] The term "chimeric antigen receptor" or alternatively "CAR" refers to a set of polypeptides, usually two in the simplest embodiment, which when in an immune effector cell provide the cell with specificity for a target cell (usually a cancer cell) and the generation of intracellular signals.

[0080] In certain embodiments, CAR comprises at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain"), wherein the cytoplasmic signaling domain comprises a functional signaling domain derived from a stimulatory molecule and / or a co-stimulatory molecule as defined below. In certain aspects, the collection of polypeptides is adjacent to each other. In certain embodiments, the collection of polypeptides includes a dimerization switch that can couple the polypeptides to each other when a dimerization molecule is present, for example, the antigen binding domain can be coupled to the intracellular signaling domain. In one aspect, the stimulatory molecule is a zeta chain associated with a T cell receptor complex. In one aspect, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one co-stimulatory molecule as defined below. In one aspect, the co-stimulatory molecule is selected from the co-stimulatory molecules described herein, for example, 4lBB or 4-1BB (ie, CD137), CD27, GITR, OX40, BCMA, and / or CD28. In one aspect, CAR includes a chimeric fusion protein containing an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the intracellular signaling domain comprises a functional signaling domain derived from a stimulatory molecule. In one aspect, CAR includes a chimeric fusion protein containing an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the intracellular signaling domain comprises a functional signaling domain derived from a costimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, CAR includes a chimeric fusion protein containing an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the intracellular signaling domain comprises two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one aspect, CAR includes a chimeric fusion protein containing an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the intracellular signaling domain includes at least two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one aspect, CAR is included in an optional leader sequence at the amino terminus (N-terminus) of the CAR fusion protein. In one aspect, CAR is further included in a leader sequence at the N-terminus of the extracellular antigen binding domain, wherein the leader sequence is optionally cut from the antigen binding domain (e.g., scFv) during CAR cell processing and localization to the cell membrane.As used herein, the term "CAR" or "CARs" also encompasses newer approaches to conferring antigen specificity to cells, including, but not limited to, antibody-TCR chimeric molecules or AbTCR (WO 2017 / 070608 A1), TCR receptor fusion proteins or TFPs (WO 2016 / 187349 A1), chimeric T cell receptors or cTCRs, and synthetic immunoreceptors (PCT / US17 / 64379).

[0081] The CAR comprising an antigen binding domain (e.g., scFv or TCR) targeting a specific tumor marker (maker) X (such as those described herein) is also referred to as XCAR. For example, the CAR comprising an antigen binding domain targeting CD19 is referred to as CD19CAR.

[0082] The term "signaling domain" refers to a functional portion of a protein that acts as an effector, either by producing second messengers or by responding to such messengers, to transmit information within the cell to regulate cellular activity via a defined signaling pathway.

[0083] The term "costimulatory ligand" or "ligand of a costimulatory receptor" refers to a protein or polypeptide that binds to a costimulatory receptor (e.g., a costimulatory receptor expressed herein, e.g., DcR1, DcR2, CD27, CD28, 41BB, OX40, GITR, BCMA). Exemplary costimulatory ligands include CD70, CD80, CD86, 41BBL, OX40L, GITRL, BAFF, and TRAIL. The binding of a costimulatory ligand to its corresponding receptor on an immune cell can lead to the initiation of a signal transduction pathway that promotes the proliferation, activation, cytokine secretion, and / or differentiation of immune cells. Some costimulatory ligands (such as TRAIL) may bind to more than one receptor. Thus, TRAIL binds to at least four receptors, DcR1, DcR2, DR4, and DR5. It is known that the binding of TRAIL to DcR2 activates the NF-κB pathway without inducing cell death. In contrast, binding of TRAIL to DR4 and DR5 is known to activate NF-κB and, depending on the cellular context, cell death.

[0084] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or intact immunoglobulins, and can be derived from natural or recombinant sources. Antibodies can be tetramers of immunoglobulin molecules.

[0085] The term "antibody fragment" refers to at least a portion of an antibody that retains the ability to specifically interact with an epitope of an antigen (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab'h), Fv fragments, scFv antibody fragments, disulfide-linked Fvs (sdFv), Fd fragments consisting of VH and CHI domains, linear antibodies, single domain antibodies such as sdAb (VL or VH), Camelid VHH domains, multispecific antibodies formed from antibody fragments (such as a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region), and isolated CDRs or other epitope-binding fragments of antibodies.

[0086] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are continuously linked, for example, via a synthetic linker, such as a short flexible polypeptide linker, and are capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, scFvs as used herein can have the VL and VH variable regions in either order, for example, with respect to the N-terminal and C-terminal ends of the polypeptide, the scFv can comprise VL-linker-VH or can comprise VH-linker-VL.

[0087] As used herein, the term "binding domain" or "antibody molecule" refers to a protein comprising at least one immunoglobulin variable domain sequence, e.g., an immunoglobulin chain or a fragment thereof. The term "binding domain" or "antibody molecule" encompasses antibodies and antibody fragments. In one embodiment, the antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence in the plurality of immunoglobulin variable domain sequences has binding specificity to a first epitope, and a second immunoglobulin variable domain sequence in the plurality of immunoglobulin variable domain sequences has binding specificity to a second epitope. In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibodies have specificity for no more than two antigens. The bispecific antibody molecule is characterized in that a first immunoglobulin variable domain sequence with binding specificity to a first epitope, and a second immunoglobulin variable domain sequence with binding specificity to a second epitope.

[0088] The term "antibody heavy chain" refers to the larger of the two polypeptide chains present in an antibody molecule in their naturally occurring conformation and generally determines the class to which the antibody belongs.

[0089] The term "antibody light chain" refers to the smaller of the two polypeptide chains present in an antibody molecule in their naturally occurring conformation. Kappa (κ) and lambda (λ) light chains represent the two major antibody light chain isotypes.

[0090] The term "recombinant antibody" refers to an antibody produced using recombinant DNA technology, for example, an antibody expressed by a bacteriophage or yeast expression system.

[0091] The term "antigen" or "Ag" refers to a molecule that elicits an immune response.

[0092] The term "anti-cancer effect" refers to a biological effect that can be manifested in a variety of ways, including, but not limited to, for example, a reduction in tumor volume, a reduction in the number of cancer cells, a reduction in the number of metastases, an increase in life expectancy, a reduction in cancer cell proliferation, a reduction in cancer cell survival, or an improvement in various physiological symptoms associated with a cancerous condition. An "anti-cancer effect" can also be manifested as the ability of peptides, polynucleotides, cells, and antibodies to prevent cancer from occurring in the first place. The term "anti-tumor effect" refers to a biological effect that can be manifested in a variety of ways, including, but not limited to, for example, a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in tumor cell proliferation, or a reduction in tumor cell survival.

[0093] The term "autologous" refers to any substance originating from the same individual that is later reintroduced into that individual.

[0094] The term "allogeneic" refers to any substance that originates from an animal other than the same species as the individual into which the substance is to be introduced.

[0095] The term "cancer" refers to a disease characterized by the uncontrolled growth of abnormal cells.

[0096] The terms "tumor" and "cancer" are used interchangeably herein, e.g., both terms include solid and liquid tumors, e.g., disseminated or circulating tumors. The terms "cancer" or "tumor" as used herein include pre-malignant, as well as malignant cancers and tumors.

[0097] As used herein, the term "derived from" indicates a relationship between a first molecule and a second molecule. It generally refers to structural similarity between the first molecule and the second molecule and does not imply or include a limitation on the process or source of the first molecule derived from the second molecule. For example, in the case of an intracellular signaling domain derived from a CD3 zeta molecule, the intracellular signaling domain retains sufficient CD3 zeta structure to have the desired function, i.e., the ability to generate a signal under appropriate conditions. It does not imply or include a limitation on a particular process for generating the intracellular signaling domain, for example, it does not mean that, in order to provide the intracellular signaling domain, one must start with the CD3 zeta sequence and delete undesirable sequences, or impose mutations, to arrive at the intracellular signaling domain.

[0098] The phrase "a disease associated with tumor antigen expression as described herein" includes, but is not limited to, a disease associated with tumor antigen expression as described herein, or a condition associated with cells expressing tumor antigens as described herein, including, for example, a proliferative disease such as cancer or a malignant tumor, or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or preleukemia; or a non-cancer-related indication associated with cells expressing tumor antigens as described herein. Non-cancer-related indications associated with tumor antigen expression as described herein include, but are not limited to, for example, autoimmune diseases (e.g., lupus), inflammatory disorders (allergies and asthma), and transplantation. In certain embodiments, cells expressing tumor antigens express or express mRNA encoding tumor antigens at any time. In one embodiment, cells expressing tumor antigens produce tumor antigen proteins (e.g., wild type or mutant), and the tumor antigen proteins may be present at normal levels or at reduced levels. In one embodiment, cells expressing tumor antigens produce detectable levels of tumor antigen proteins at one point and subsequently produce substantially undetectable tumor antigen proteins.

[0099] The term "conservative sequence modification" refers to amino acid modifications that do not significantly affect or alter the binding properties of the antibody or antibody fragment containing the amino acid sequence.

[0100] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex or CAR) to its cognate ligand (or a tumor antigen in the case of a CAR), thereby mediating a signal transduction event, for example, but not limited to, signal transduction via the TCR / CD3 complex, or signal transduction via an appropriate NK receptor or the signaling domain of the CAR. Stimulation can mediate changes in the expression of certain molecules.

[0101] The term "stimulatory molecule" refers to a molecule expressed by an immune cell (e.g., T cell, NK cell, B cell), which provides at least some aspects of the immune cell signal transduction pathway, regulating the cytoplasmic signal transduction sequence of immune cell activation in a stimulating manner. In one aspect, the signal is a primary signal, which is initiated, for example, by the binding of a TCR / CD3 complex to a peptide-carrying MHC molecule, and which results in mediating T cell responses, including but not limited to proliferation, activation, differentiation, etc. The primary cytoplasmic signal transduction sequence (also referred to as "primary signal transduction domain") that acts in a stimulating manner can contain a signal transduction motif referred to as an immunoreceptor tyrosine activation motif or ITAM. In a specific CAR of the present disclosure, the intracellular signal transduction domain in any one or more CARs of the present disclosure includes an intracellular signal transduction sequence, for example, the primary signal transduction sequence of CD3-ζ. In one specific CAR of the present disclosure, the primary signaling sequence of CD3-ζ is a sequence provided as SEQ ID NO (DNA): 431 and SEQ ID NO (protein): 1858, or equivalent residues from non-human species (e.g., mouse, rodent, monkey, ape, etc.). In one specific CAR of the present disclosure, the primary signaling sequence of CD3-ζ is a sequence provided as SEQ ID NO (DNA): 432 and SEQ ID NO (protein): 1859, or equivalent residues from non-human species (e.g., mouse, rodent, monkey, ape, etc.).

[0102] The term "antigen presenting cell" or "APC" refers to any cell that presents an antigen that can be recognized by an immune cell, such as an auxiliary cell (e.g., B-cell, dendritic cell, etc.) or a cell line (e.g., a cancer cell line, e.g., a breast cancer cell line, e.g., an MCF7 cell line). APCs may display foreign antigens in complex with major histocompatibility complexes (MHC) on their surface. T cells can recognize these complexes using their T cell receptors (TCRs). APCs process antigens and present them to T cells. APCs can present antigens independently of MHC. As an example, B lymphocytes or B cell lines expressing CD19 (e.g., REC-1) can act as APCs for T cells expressing CARs, such as FMC63-BBz CAR (SEQ ID NO: 2822) against CD19. APCs can present antigens that are recognized by immune cells in the presence of bispecific or multispecific adapters. As an example, B lymphocytes or B cell lines expressing CD19 (e.g., REC-1) can act as APCs for T cells in the presence of a CD3xCD19 bispecific antibody (e.g., rantumomab). The APCs can be normal cells, immortalized cells, or cancer cells. The APCs can be cell lines. Table 7D shows the SEQ ID NOs for several antigens that can be expressed on the surface of cells to act as antigen-presenting cells for the methods of the present disclosure.

[0103] The term "antigen presenting substrate" or "APS" refers to any substrate that presents an antigen that can be recognized by an immune cell, such as beads, microbeads, agarose beads, magnetic beads, membranes, plates, bubbles, nanoparticles. The APS may display foreign antigens complexed with major histocompatibility complexes (MHC) on its surface. T cells can recognize these complexes using their T cell receptors (TCRs). The APS can present antigens independently of MHC. As an example, beads or plates coated with the extracellular domain of CD19 can serve as APSs for T cells expressing CARs, such as FMC63-BBz CAR (SEQ ID NO: 2822) against CD19. The APS may present antigens that are recognized by immune cells in the presence of a bispecific or multispecific linker. As an example, beads or plates coated with the extracellular domain (ECD) of CD19 can serve as APSs for T cells in the presence of a CD3 x CD19 bispecific antibody (e.g., rantumomab). In Table 7D are shown the SEQ ID NOs of several antigens that can be conjugated to substrates (eg, beads or membranes) to serve as antigen presentation substrates for use in the methods of the present disclosure.

[0104] The term "intracellular signaling domain" as used herein refers to the intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes the immune effector function of a CAR-containing cell (e.g., a CAR-T cell).

[0105] The term "costimulatory molecule" refers to a corresponding binding partner on a T cell that specifically binds to a co-stimulatory ligand, thereby mediating a co-stimulatory response of the T cell, such as, but not limited to, proliferation.

[0106] A "costimulatory intracellular signaling domain" can be the intracellular portion of a costimulatory molecule. The intracellular signaling domain can comprise the entire intracellular portion of the molecule from which it is derived or the entire native intracellular signaling domain, or a functional fragment or derivative thereof.

[0107] A "CXCR4 signaling inhibitor" is an exogenous factor, such as a drug compound or molecule, that inhibits or prevents the activation of CXCR4 by its ligand, CXC motif ligand 12 (CXCL12), thereby blocking or inhibiting CXCR4 signaling in a cell.

[0108] Standard in vitro or ex vivo CXCL12 / CXCR4 assays (such as chemotaxis or increased free intracellular Ca) were used. 2+ ), suitable CXCR4 signaling inhibitors can be identified. For example, when CXCR4 on the cell surface is exposed to CXCL12, the lack of intracellular free Ca 2+ A rapid, transient increase in CXCR4 expression may indicate the presence of an inhibitor of CXCR4 signaling.

[0109] Preferred examples of CXCR4 signaling inhibitors include, but are not limited to, CXCR4 antagonists and / or CXCL12 antagonists.

[0110] In the present disclosure, a "CXCR4 antagonist" is defined as a molecule that inhibits CXCR4 signaling by binding to or interacting with CXCR4, thereby preventing or inhibiting the binding and / or activation of CXCR4 by CXCL12, thereby inhibiting CXCR4 signaling. Preferred examples of CXCR4 antagonists include, but are not limited to, anti-CXCR4 antibodies, examples of which are well known in the art. For example, preferred anti-CXCR4 antibodies include, but are not limited to, BMS-936564 / MDX-1338 (Kuhne et al. (2013) Clin Cancer Res 19(2):357-366).

[0111] Additionally, CXCR4 antagonists include peptides such as LY2510924 (Eli Lilly) or small organic compounds such as 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (AMD3100; plerixafor), N,N-dipropyl-N-[4-({[(1H-imidazol-2-yl)methyl)benzyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl)benzyl]-N-methylbutane-1,4-diamine tris(2R,3R)-tartrate (KRH-3955), ([5-(4-methyl-1-piperazinyl)-2-({methyl[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[1,2-a]pyridin-3-yl]methanol) (GSK812397; Jenkinson et al., Antimicrobial Agents Chemother. 2010, 54(2): 817) and N′-(1H-benzimidazol-2-ylmethyl)-N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD11070; Moyle et al. Clin. Infect. Dis. 48: 798-805)).

[0112] In the present disclosure, a "CXCL12 antagonist" is defined as a molecule that inhibits CXCR4 signaling by binding to CXCL12 or inhibiting the binding and / or activation of CXCL12 to CXCR4, thereby inhibiting CXCR4 signaling. CXCL12 can be produced, for example, by stromal cells in cancerous tumors that express fibroblast activation protein (FAP). Preferred examples of CXCL12 antagonists include, but are not limited to, anti-CXCL12 antibodies well known in the art. Examples of such anti-CXCL12 antibodies include, but are not limited to, anti-CXCL12 antibodies (MAB310) or SDF-1 antibodies from R&D Systems. Other examples of CXCL12 antagonists include, but are not limited to, NOX-A12.

[0113] Other suitable CXCR4 and CXCL12 antagonists include non-antibody specific binding molecules such as adnectins, affibodies, avimers, anticalins, tetranectins, DARPins, mTCRs, genetically modified Kunitz-type inhibitors, nucleic acid aptamers and spiegelmers, peptide aptamers and cyclic peptides and bicyclic peptides (Ruigrok et al. Biochem. J. (2011) 436, 1-13; Gebauer et al. Curr Opin Chem Biol. (2009) (3): 245-55). Suitable specific binding molecules for use as CXCR4 and CXCL12 antagonists can be generated using standard techniques.

[0114] CXCR4 signalling is mediated by activation of phosphoinositide 3-kinase.Other suitable inhibitors of CXCR4 signalling include PI 3-kinase inhibitors, such as inhibitors of the pi 10 delta or pi 10 gamma isoforms of PI3K.

[0115] The term "4-1BB" refers to a member of the TNFR superfamily having an amino acid sequence provided as GenBank Acc. No. AAA62478.2, or equivalent residues from a non-human species (e.g., mouse, rodent, monkey, ape, etc.); and a "4-1BB costimulatory domain" is defined as amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or equivalent residues from a non-human species (e.g., mouse, rodent, monkey, ape, etc.). In one aspect, the "4-1BB costimulatory domain" is the sequence provided as SEQ ID NO: 1857, or equivalent residues from a non-human species (e.g., mouse, rodent, monkey, ape, etc.).

[0116] As used herein, the term "immune cell" refers to a cell that participates in an immune response. Examples of immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, monocytes, macrophages, and bone marrow-derived phagocytes.

[0117] As used herein, the term "immune effector cell" refers to a cell that participates in an immune response, such as a cell that promotes immune effector responses. Examples of immune effector cells include T cells, such as α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, monocytes, macrophages, and bone marrow-derived phagocytes.

[0118] As used herein, the term "immune effector function or immune effector response or immune response" refers to, for example, a function or response of an immune effector cell that enhances or promotes an immune attack on a target cell. For example, an immune effector function or response refers to the property of a T or NK cell to promote killing of a target cell or inhibition of its growth or proliferation. For T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.

[0119] As used herein, the term "immunotherapy" refers to a form of therapy involving the use of immune cells or immune cell products. Examples of immunotherapy include bispecific T cell engagers (e.g., rantuzumab), DART, PD-1 inhibitors, PDL-1 inhibitors, CAR-T, CAR-NK, macrophage-CAR, TCR-T and TIL therapies, and vaccination regimens.

[0120] As used herein, the term "cell therapy", "adoptive cell therapy", "cellular therapy" or "immune cell therapy" refers to a form of therapy involving the use of cells (e.g., immune cells) in the prevention and / or treatment of a disease. Examples of cell therapies include allogeneic stem cell transplantation, CAR-T, CAR-NK, macrophage-CAR, TCR-T and TIL therapies, and T cell vaccination regimens. One form of cell therapy is immune cell therapy, for example, CAR-T cell therapy. Since bispecific T cell engagers also engage T cells, they are also considered to be a form of immune cell therapy.

[0121] As used herein, the terms "cell therapy product," "cellular therapy product," or "immune cell therapy product" refer to a product used for cell therapy purposes.

[0122] The term "encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA or mRNA) to serve as a template for synthesizing other polymers and macromolecules in biological processes, and the resulting biological properties, wherein the other polymers and macromolecules have a defined nucleotide sequence (e.g., rRNA, tRNA and mRNA) or a defined amino acid sequence. Unless otherwise indicated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence.

[0123] The terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, substance, or composition as described herein that is effective to achieve a particular biological result.

[0124] The term "endogenous" refers to any substance that originates from, or is produced within, an organism, cell, tissue, or system.

[0125] The term "exogenous" refers to any substance that is introduced from, or produced outside of, an organism, cell, tissue, or system.

[0126] The term "expression" refers to the transcription and / or translation of a specific nucleotide sequence driven by a promoter.

[0127] The term "transfer vector" refers to a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid into a cell. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and the like.

[0128] The term "expression vector" refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed.

[0129] The term "lentivirus" refers to a genus of the Retroviridae family.

[0130] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, and particularly includes self-inactivating lentiviral vectors.

[0131] The term "homologous" or "identity" refers to the subunit sequence identity between two polymeric molecules (eg, between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules).

[0132] “Humanized” forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof that contain minimal sequence derived from non-human immunoglobulin (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies).

[0133] "Fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, wherein the entire molecule is of human origin or consists of the same amino acid sequence as the human form of the antibody or immunoglobulin.

[0134] The term "isolated" means altered or removed from its natural state.

[0135] The term "operably linked" or "transcriptional control" denotes a functional linkage between a regulatory sequence and a heterologous nucleic acid sequence, resulting in the expression of the latter.

[0136] The term "parenteral" administration of the immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection, intratumoral or infusion techniques.

[0137] The term "mobilized" cell (for example, the mobilized immune cell, the mobilized immune effector cell or the mobilized T cell) represents the cell mobilized from its normal position.For example, the administration of CXCR antagonists can be used for mobilizing the immune cells from bone marrow, lymphoid organs, tissue and tumor into peripheral circulation, from which they can be collected by leukocyte apheresis and used for immune cell therapy applications, for example, the CAR-T cells described in the present disclosure or the manufacture of TCR-T cells or TIL. Other exemplary mobilization agents that can be used to mobilize cells include cytokines (for example, G-CSF, GM-CSF or sargramostim, Neulasta or Pegfilgastrim etc.), chemotherapy drugs (such as cyclophosphamide).Tyrosine kinase inhibitors (for example, dasatinib), β2 adrenergic agonists (for example, epinephrine) and exercise.

[0138] The term "mobilizing agent" refers to an agent that can be used to mobilize cells from their normal location. Exemplary mobilizing agents that can be used to mobilize cells include cytokines (e.g., G-CSF, GM-CSF, or sargramostim, Neulasta, or Pegfilgastrim, etc.), chemotherapy drugs (e.g., cyclophosphamide). Tyrosine kinase inhibitors (e.g., dasatinib), β2 adrenergic agonists (e.g., epinephrine), and exercise.

[0139] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids containing known analogs of natural nucleotides, which have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as sequences explicitly indicated.

[0140] The terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to a compound composed of amino acid residues covalently linked by peptide bonds.

[0141] The term "promoter" refers to a DNA sequence that is recognized by the synthetic machinery of the cell or introduced synthetic machinery and is required to initiate specific transcription of a polynucleotide sequence.

[0142] The term "promoter / regulatory sequence" refers to a nucleic acid sequence that is operably linked to a gene product expression sequence. In some cases, the sequence may be a core promoter sequence, and in other cases, the sequence may also include enhancer sequences and other regulatory elements required for gene product expression. The promoter / regulatory sequence may, for example, be one that expresses a gene product in a tissue-specific manner.

[0143] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.

[0144] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell essentially only when an inducer corresponding to the promoter is present in the cell.

[0145] The term "tissue-specific" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoded or specified by a gene, causes the gene product to be produced in a cell substantially only if the cell is of the tissue type corresponding to the promoter.

[0146] The terms "cancer-associated antigen" or "tumor antigen" interchangeably refer to molecules (usually proteins, carbohydrates, or lipids) that are expressed on the surface of cancer cells, either intact or as fragments (e.g., MHC / peptides), and which can be used to preferentially target pharmacological agents to cancer cells.

[0147] The terms "tumor-supporting antigen" or "cancer-supporting antigen" interchangeably refer to a molecule (usually a protein, carbohydrate, or lipid) expressed on the surface of a cell, that is, which is not itself cancerous but supports cancer cells, for example, by promoting their growth or survival (e.g., resistance to immune cells).

[0148] The term "flexible polypeptide linker" or "linker" used in the context of scFv refers to a peptide linker composed of amino acids such as glycine and / or serine residues, which is used alone or in combination to connect the variable heavy chain and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly / Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)n, where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5 and n=6, n=7, n=8, n=9 and n=10. In one embodiment, the flexible polypeptide linker includes, but is not limited to, or (Gly4Ser)3 (SEQ ID NO (DNA): 411 and SEQ ID NO (protein): 1838). In another embodiment, the linker includes multiple repeats of (Gly2Ser), (GlySer) or (Gly3Ser). Linkers described in WO 2012 / 138475 (incorporated herein by reference) are also included within the scope of the present disclosure.

[0149] As used herein, the 5' cap (also referred to as RNA cap, RNA 7-methylguanosine cap, or RNA m 7 The G-cap) is a modified guanine nucleotide that is added to the "front" or 5' end of eukaryotic messenger RNA shortly after transcription begins.

[0150] As used herein, "in vitro transcribed RNA" refers to RNA, preferably mRNA, that has been synthesized in vitro.

[0151] As used herein, "poly (A)" is a series of adenosines attached to an mRNA by polyadenylation. In preferred embodiments of constructs for transient expression, poly A is between 50 and 5000 (SEQ ID NOs: 341-343), preferably greater than 64, more preferably greater than 100, and most preferably greater than 300 or 400. The poly (A) sequence can be chemically or enzymatically modified to modulate mRNA function, such as localization, stability, or translation efficiency.

[0152] As used herein, the term "prevention" refers to the prophylactic or protective treatment of a disease or disease state.

[0153] As used herein, "polyadenylation" refers to the covalent attachment of a polyadenylyl moiety, or a modified variant thereof, to a messenger RNA molecule.

[0154] The term "signal transduction pathway" refers to the biochemical connections between various signal transduction molecules that play a role in the transmission of a signal from one part of a cell to another. The phrase "cell surface receptor" includes molecules and complexes of molecules that are capable of receiving a signal and transmitting the signal across the cell membrane.

[0155] The term "subject" is intended to include living organisms (eg, mammals, humans) in which an immune response can be elicited.

[0156] The term "substantially purified" cells refers to cells that are substantially free of other cell types.

[0157] As used herein, "transient" refers to expression of a non-integrated transgene for a period of hours, days, or weeks, wherein the period of expression is less than the period of expression of the gene if integrated into the genome or contained within a stable plasmid replicon in the host cell.

[0158] As used herein, the term "treating" means reducing or ameliorating the progression, severity and / or duration of a proliferative disorder, or ameliorating one or more symptoms (preferably, one or more identifiable symptoms) of a proliferative disorder by administering one or more therapies (e.g., one or more therapeutic agents such as a CAR of the present disclosure).

[0159] As used herein, the term "therapeutic" refers to treatment. A therapeutic effect is achieved by the reduction, inhibition, alleviation or eradication of a disease state.

[0160] As used herein, the term "regulatory T cells" or "TREGs" refers to T cells that regulate or suppress other cells in the immune system. Tregs control immune responses to self and foreign substances (antigens) and help prevent autoimmune diseases.

[0161] In the context of the present disclosure, "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder" refers to an antigen that is common to a particular hyperproliferative disorder. In certain aspects, the hyperproliferative disorder antigens of the present disclosure are derived from cancer, including but not limited to primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia, uterine cancer, cervical cancer, bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, etc.

[0162] The term "transfection" or "transformation" or "transduction" refers to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is a cell that has been transfected, transformed, or transduced with exogenous nucleic acid. The cell includes the primary subject's cell and its progeny.

[0163] The term "specifically binds" refers to an antibody or ligand that recognizes and binds to a binding partner (eg, tumor antigen) protein present in a sample, but does not substantially recognize or bind to other molecules in the sample.

[0164] As used herein, the term "membrane anchor" or "membrane attachment domain" refers to a polypeptide or moiety, such as a myristoyl group, that is sufficient to anchor an extracellular or intracellular domain to the plasma membrane.

[0165] As used herein, the term "switch domain", for example, when referring to RCAR, refers to an entity, typically a polypeptide-based entity, that associates with another switch domain in the presence of a dimerization molecule. As used herein, the term "dimerization molecule", for example, when referring to RCAR, refers to a molecule that promotes the association of a first switch domain with a second switch domain.

[0166] As used herein, "refractory" refers to a disease, such as cancer, that does not respond to treatment.

[0167] Range: In this disclosure, various aspects of the disclosure may be presented in a range format. It should be understood that the description in range format is for convenience and brevity only and should not be construed as an inflexible limitation on the scope of the disclosure. Therefore, the description of a range should be considered to have specifically disclosed all possible subranges and individual numerical values ​​within that range. For example, a description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes things with 95%, 96%, 97%, 98%, or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the width of the range.

[0168] As used herein, the term "Tet" refers to a gene family of the 10-11 translocation methylcytosine dioxygenase family, and proteins encoded by said genes. Tet includes, for example, Tet1, Tet2, and Tet3.

[0169] As used herein, the term "Tet2" refers to the gene, tet methylcytosine dioxygenase 2, and the protein tet2 methylcytosine dioxygenase encoded by the gene, which catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine.

[0170] Table 3: Nucleic acid reference SEQ of exemplary genes disclosed herein.

[0171]

[0172]

[0173]

[0174]

[0175] As used herein, the term "X inhibitor" or "inhibitor X" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of the corresponding "X" gene and / or protein, wherein "X" represents BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, or DR5. In embodiments, an "X" inhibitor is a molecule that inhibits the expression of "X," e.g., reduces or eliminates the expression of "X." In embodiments, an "X" inhibitor is a molecule that inhibits the function of "X." An example of an "X" inhibitor that inhibits the expression of "X" is a gene editing system, for example, as described herein, which targets nucleic acids within the "X" gene or its regulatory elements, thereby modifying the nucleic acids at or near the gene editing system binding site to reduce or eliminate the expression of "X". Another example of an "X" inhibitor that inhibits the expression of "X" is a nucleic acid molecule, for example, an RNA molecule, for example, a short hairpin RNA (shRNA) or a short interfering RNA (siRNA), which can hybridize with the mRNA of "X" and cause a reduction or elimination of "X" translation. "X" inhibitors also include nucleic acids encoding molecules that inhibit the expression of "X" (for example, nucleic acids encoding anti-"X" shRNA or siRNA, or nucleic acids encoding one or more, for example, all components of an anti-"X" gene editing system). An example of a molecule that inhibits the function of "X" is a molecule that inhibits one or more activities of "X", for example, a protein or a small molecule. One example is a small molecule inhibitor of "X". Another example is a dominant negative "X" protein. Another example is a dominant negative form of an "X" binding partner. Another example is a molecule, such as a small molecule, that inhibits a binding partner of "X." Inhibitors of "X" also include nucleic acids encoding inhibitors of the function of "X."

[0176] As used herein, the term "BRD9 inhibitor" represents a molecule or set of molecules (for example, a system) that reduces or eliminates the function and / or expression of BRD9. In embodiments, a BRD9 inhibitor is a molecule that suppresses the expression of BRD9, for example, to reduce or eliminate the expression of BRD9. In embodiments, a BRD9 inhibitor is a molecule that suppresses the function of BRD9. An example of a BRD9 inhibitor that suppresses BRD9 expression is a gene editing system, for example, as described herein, which targets nucleic acids or their regulatory elements within the BRD9 gene, thereby modifying nucleic acids at or near the gene editing system binding site, to reduce or eliminate the expression of BRD9. Another example of a BRD9 inhibitor that suppresses BRD9 expression is a nucleic acid molecule, for example, an RNA molecule, for example, a short hairpin RNA (shRNA) or a short interfering RNA (siRNA), which can hybridize with the mRNA of BRD9 and cause the reduction or elimination of BRD9 translation. BRD9 inhibitors also include nucleic acids encoding molecules that suppress BRD9 expression (for example, nucleic acids encoding anti-BRD9 shRNA or siRNA, or one or more nucleic acids encoding anti-BRD9 gene editing systems, for example, all components). An example of a molecule that inhibits BRD9 function is a molecule that inhibits one or more activities of BRD9, e.g., a protein or a small molecule. One example is a small molecule inhibitor of BRD9. Another example is a dominant negative BRD9 protein. Another example is a dominant negative form of a BRD9 binding partner. Another example is a molecule that inhibits a BRD9 binding partner, e.g., a small molecule. BRD9 inhibitors also include nucleic acids encoding inhibitors of BRD9 function.

[0177] As used herein, the term "Tet inhibitor" or "Tet[x] inhibitor" (e.g., "Tet1 inhibitor," "Tet2 inhibitor," or "Tet3 inhibitor") refers to a molecule or collection of molecules (e.g., a system) that reduces or eliminates the function and / or expression of the corresponding Tet (e.g., Tet1, Tet2, and / or Tet3, e.g., Tet2).

[0178] As used herein, the term "MLL2 inhibitor" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of MLL2. As used herein, the term "MLL3 inhibitor" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of MLL3. As used herein, the term "MLL4 inhibitor" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of MLL4. As used herein, the term "EZH2 inhibitor" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of EZH2.

[0179] As used herein, the term "TRAIL inhibitor" or "TRAIL antagonist" refers to a molecule or set of molecules (e.g., a system) that reduces or eliminates the function and / or expression of TRAIL and / or its receptors DR5 and / or DR4. In an embodiment, a TRAIL inhibitor is a molecule that inhibits the expression of TRAIL and DR5 (e.g., reduces or eliminates the expression of TRAIL and / or DR5). In an embodiment, a TRAIL inhibitor is a molecule that inhibits the function of TRAIL and / or DR5. An example of a TRAIL inhibitor that suppresses TRAIL expression is a gene editing system, e.g., as described herein, which targets nucleic acids or regulatory elements within the TRAIL gene, thereby modifying the nucleic acids at or near the gene editing system binding site to reduce or eliminate the expression of TRAIL. Another example of a TRAIL inhibitor that suppresses TRAIL expression is a nucleic acid molecule, e.g., an RNA molecule, e.g., a short hairpin RNA (shRNA) or a short interfering RNA (siRNA), which can hybridize with the mRNA of TRAIL and cause a reduction or elimination of TRAIL translation. TRAIL inhibitors also include nucleic acids encoding molecules that inhibit TRAIL expression (e.g., nucleic acids encoding anti-TRAIL, e.g., TRAIL shRNA or siRNA, or nucleic acids encoding one or more, e.g., all, components of anti-TRAIL, e.g., TRAIL gene editing systems). An example of a molecule that inhibits TRAIL function is a molecule that inhibits one or more activities of TRAIL, e.g., a protein or a small molecule. One example is a small molecule inhibitor of TRAIL. Another example is an antibody, an antibody fragment, a non-immunoglobulin binding scaffold that binds to TRAIL and / or DR5 and prevents signal transduction through DR5. Another example is a dominant negative TRAIL protein. Another example is a dominant negative mutant of the TRAIL receptor DR5. Another example is a soluble or decoy form of the TRAIL receptor DR4 (e.g., SEQ ID NO: 2441), DR5 (SEQ ID NO: 2428), DcR1 (SEQ ID NO: 2448), and DcR2 (SEQ ID NO: 2455). Another example is a mutant form of DR5 that lacks its cytoplasmic signaling domain, or in which the signaling domain of DR5 is replaced by the signaling domain of a co-stimulatory receptor (e.g., CD27, CD28, 41BB, GITR, BCMA, or OX40) (e.g., SEQ ID NOs: 2429-2440). Additional exemplary TRAIL antagonists include DcR1 (SEQ ID NO: 2360), DcR2 (SEQ ID NO: 2361), and a fusion receptor containing the TRAIL-binding extracellular domains of DcR1, DcR2, DR4, and DR5 (SEQ ID NOs: 2429-2461).Another example of a TRAIL inhibitor is a molecule that inhibits TRAIL binding partners (e.g., TRAIL receptors, e.g., DR5), e.g., small molecules. Another example of a TRAIL inhibitor is a molecule that inhibits the downstream signal transduction of TRAIL receptors (e.g., DR5), e.g., small molecules. An exemplary small molecule that inhibits the downstream signal transduction of TRAIL receptors is an NF-κB inhibitor, e.g., IKK-2 inhibitor IV (CAS 507475-17-4), IKK2 inhibitor VI (CAS 354811-10-2), LY2409881 or bortezomib. Other TRAIL inhibitors (including NF-κB inhibitors) are known in the art and can be used in alternative embodiments of the present disclosure. Known TRAIL signal transduction can activate many other signal transduction pathways, e.g., JNK pathway, and inhibitors of these pathways can be used in alternative embodiments of the present disclosure to improve the effectiveness and safety of immune effector cell therapy. Other examples of TRAIL inhibitors include dominant negative mutants of FADD (e.g., FADD death domain; SEQ ID NO (DNA): 2453, SEQ ID NO (protein): 2463) and Caspase 8 (e.g., Caspase 8D73A [SEQ ID NO (DNA): 2354, SEQ ID NO (protein): 2464], Caspase 8D73A / L74A; SEQ ID NO (DNA): 2355 and SEQ ID NO (protein): 2365; Caspase 8D73A / L74A / L75A; SEQ ID NO (DNA): 2356 and SEQ ID NO (protein): 2366. TRAIL inhibitors also include nucleic acids encoding inhibitors of TRAIL function (e.g., binding of TRAIL to its receptor, such as DR5, and / or downstream signaling of the TRAIL receptor). TRAIL inhibitors also include nucleic acids encoding molecules that inhibit TRAIL signaling (e.g., encoding anti-FADD or anti-caspase 8, for example, FADD shRNA or siRNA, or Caspase 8 shRNA or siRNA, or nucleic acids encoding one or more, for example, all, components of anti-FADD or Caspase 8, for example, a FADD gene editing system or a Caspase 8 gene editing system).

[0180] Inhibitors / antagonists of other molecules of the disclosure can be similarly described.

[0181] The term "system" as used herein in connection with gene editing refers to a group of molecules, such as one or more molecules, that work together to achieve a desired function.

[0182] As used herein, the term "gene editing system" refers to a system, e.g., one or more molecules, that directs and effects the alteration, e.g., deletion, of one or more nucleic acids at or near a site in genomic DNA targeted by the system. Gene editing systems are known in the art and are described more fully below.

[0183] As used herein, the term "binding partner" in the context of a binding partner of "X" (e.g., Tet1, Tet2, and / or Tet3, e.g., Tet2) refers to a molecule, such as a protein, that interacts with (e.g., binds to) "X" (e.g., Tet, e.g., Tet1, Tet2, and / or Tet3, e.g., Tet2 protein). Without being bound by theory, it is believed that Tet, e.g., Tet1, Tet2, and / or Tet3, e.g., Tet2, binds to one or more HDAC proteins. Such HDAC proteins are considered examples of binding partners of Tet, e.g., Tet1, Tet2, and / or Tet3, e.g., Tet2. Binding partners for other proteins disclosed herein are known in the art.

[0184] A "dominant negative" gene product or protein is one that interferes with the function of another gene product or protein. In one embodiment, a dominant negative DR5 is a mutant of DR5 that is unable to transmit a signal, such as a death-inducing signal.

[0185] The manufacture of cell therapy products (e.g., CAR-T or TCR-T or cell vaccines) typically begins with the collection of lymphocytes from a subject by leukapheresis and T-cell selection, followed by activation, modification, breeding, and cryopreservation of the final product. Although this process works well in proof-of-concept clinical trials, there are still several challenges that hinder the amplification and expansion of live cell therapies. The term "subject" is intended to include living organisms (e.g., mammals) in which an immune response can be elicited. Examples of subjects include humans, monkeys, chimpanzees, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, tissue-resident lymphocytes, tumor-resident lymphocytes, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue, and tumors.

[0186] The present disclosure relates to a method for improving the yield, propagation, activation, proliferation, multiplication, diversity, tissue (e.g., tumor) penetration, persistence, efficacy and safety of cell therapy products (e.g., immune cell therapy products, e.g., CAR-T, SIR-T, TFP-T, Ab-TCR-T and TCR-T products, etc.). In one embodiment, the present disclosure relates to improving the yield, propagation, activation, proliferation, multiplication, diversity, tissue (e.g., tumor) penetration, persistence and efficacy of immune cell therapies (such as genetically modified CAR-T, TCR-T, SIR-T, Ab-TCR-T cell therapy or NK cell therapy) by using mobilized immune cells for the manufacture of cell therapy products. In various embodiments, cells (e.g., immune cells, e.g., T cells or NK cells or macrophages / monocytes or dendritic cells) are mobilized by administering a CXCR antagonist (e.g., Mozibil or Plerixafor), a cytokine (e.g., G-CSF, GM-CSF or Sargramostim, Neulasta or Pegfilgastrim), a β2 adrenergic agonist (e.g., epinephrine), a tyrosine kinase inhibitor (e.g., dasatinib), a chemotherapy drug (e.g., cyclophosphamide, doxorubicin), or a combination of the above agents to the donor from whom the cells are harvested prior to collection of the cells (e.g., immune cells, e.g., T cells or NK cells or macrophages / monocytes or dendritic cells). In various embodiments, cells (e.g., immune cells, e.g., T cells or NK cells or macrophages / monocytes or dendritic cells) are mobilized by exercising the subject (i.e., the donor).

[0187] In one aspect, leukapheresis is used to obtain mobilized cells (e.g., immune cells, e.g., T cells or NK cells) from a subject. In one aspect, bone marrow is harvested to obtain mobilized cells (e.g., immune cells, e.g., T cells or NK cells) from a subject.

[0188] In one aspect, mobilized cells (eg, immune cells, eg, T cells or NK cells) are obtained from a subject who is a candidate for receiving a cell therapy product.

[0189] In one aspect, from a subject as a healthy donor, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained. In one aspect, from a subject suffering from a disease (e.g., cancer, infection or autoimmune disease), mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained.

[0190] In one aspect, from a subject who has received previous chemotherapy (e.g., anticancer drugs), mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained. In one aspect, from a subject who has not had a sufficient number of circulating (e.g., immune cells, e.g., T cells or NK cells or macrophages / monocytes or dendritic cells) cells before administering a mobilizing agent, mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained.

[0191] In one aspect, the patient has less than about 1000 x 10 6 / L (for example, less than 600x10 6 / L, 400x10 6 / L, 200x10 6 / L or 100x10 6 In one aspect, the method comprises obtaining mobilized cells (e.g., immune cells, e.g., T cells or NK cells) from a subject having less than about 800 x 10 CD3+ cells in the peripheral blood before administration of the mobilizing agent. 6 / L (for example, less than 400x10 6 / L, 200x10 6 / L, 100x10 6 / L, 50x10 6 / L) CD4+ cells in a subject, obtaining mobilized cells (eg, immune cells, eg, T cells or NK cells).

[0192] In one aspect, the patient has less than about 500 x 10 6 / L (for example, less than 400x10 6 / L, 200x10 6 / L, 100x10 6 / L or 50x10 6 In one aspect, the method comprises obtaining mobilized cells (e.g., immune cells, e.g., T cells or NK cells) from a subject having less than about 50 x 10 CD8+ cells in the peripheral blood before administration of the mobilizing agent. 6 / L (for example, less than 40x10 6 / L, 20x10 6 / L, 10x10 6 / L or 5x10 6

[00145] From a subject expressing CD3+ / CD16+ cells, the mobilized cells (eg, immune cells, eg, T cells or NK cells) are obtained.

[0193] In one aspect, the patient has less than about 50 x 106 / L (for example, less than 40x10 6 / L, 20x10 6 / L, 10x10 6 / L or 5x10 6 In one aspect, the method comprises the step of obtaining mobilized cells (e.g., immune cells, e.g., T cells or NK cells) from a subject with low quality peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) prior to administration of a mobilizing agent.

[0194] In one aspect, the mobilized cells (eg, immune cells, eg, T cells or NK cells) are obtained from a subject having poor peripheral blood cell (eg, immune cell, eg, T cell or NK cell) diversity prior to administration of the mobilizing agent.

[0195] In one aspect, mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject whose peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) have poor multifunctionality (e.g., antigen-induced production of IL2, TNFα, IFNγ, etc.) prior to administration of the mobilizing agent.

[0196] In one aspect, mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject that has or is expected to have a poor leukapheresis product yield without the administration of a mobilizing agent. In one aspect, mobilized cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject that has or is expected to have less than about 50 x 10 9 (For example, less than 40x10 9 , 20x10 9 , 10x10 9 etc.) white blood cells (WBC) in a subject, and obtaining mobilized cells (e.g., immune cells, e.g., T cells or NK cells).

[0197] In one embodiment, the method comprises obtaining cells (e.g., immune cells, e.g., T cells or NK cells) for making and using a cell therapy product from a subject (i.e., an autologous or allogeneic donor) that has received a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) prior to collecting the cells.

[0198] In another aspect of the present disclosure, the method includes obtaining cells (e.g., immune cells, e.g., T cells or NK cells) for making and using a cell therapy product from a subject (i.e., an autologous or allogeneic donor) who has received a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) to assist in mobilizing immune cells (e.g., T cells) into the peripheral circulation.

[0199] In another aspect of the present disclosure, the method includes obtaining cells (e.g., immune cells, e.g., T cells or NK cells) for making and using a cell therapy product from a subject (i.e., an autologous or allogeneic donor) who has received a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) to assist in mobilizing a specific subset of immune cells into the peripheral circulation.

[0200] In one aspect, from a subject who is a candidate for receiving a cell therapy product, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained. In one aspect, from a subject who is a healthy donor, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained. In one aspect, from a subject suffering from a disease (e.g., cancer, infection or autoimmune disease), cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained.

[0201] In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously received treatment for a disease (e.g., cancer, immune or infectious disease). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously received treatment for a cancer.

[0202] In one aspect, from a subject who has previously received treatment for a blood cancer (e.g., plasma cell disorder, myeloma, lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, MDS, etc.), cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained. In one aspect, from a subject who has previously received treatment for a solid tumor (e.g., lung cancer, breast cancer, gastrointestinal cancer, liver cancer, etc.), cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained. In one aspect, from a subject who has previously received treatment for an immune disorder, cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor) are obtained. In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously been treated for an infection (e.g., HIV-1 / AIDS).

[0203] In one aspect, from a subject who has previously received a chemotherapy drug (e.g., anticancer drug, e.g., alkylating agent, e.g., melphalan, cyclophosphamide, etc.), obtain cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor). Other anticancer drugs are known in the art and include etoposide, doxorubicin, cytarabine, fludarabine, vincristine, vinblastine, etc. In one aspect, from a subject who has previously received an immunomodulatory drug (IMiDs; e.g., lenalidomide), obtain cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor). In one aspect, from a subject who has previously received a steroid (e.g., dexamethasone), obtain cells (e.g., immune cells, e.g., T cells or NK cells) mobilized with a mobilizing agent (e.g., CXCR4 antagonists, e.g., plerixafor). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from subjects who have previously received an antibody (e.g., rituximab, alemtuzumab (CAMPATH), etc.). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from subjects who have previously received an antibody drug conjugate (e.g., ADCETRIS). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from subjects who have previously received a bispecific antibody (e.g., rantuzumab). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously received a targeted therapy (e.g., a tyrosine kinase inhibitor, e.g., ibrutinib). In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously received radiation therapy. In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who has previously received a radiolabeled antibody.

[0204] In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) that have been mobilized with a mobilizing agent (e.g., a CXCR4 antagonist, e.g., plerixafor) are obtained from a subject who had an insufficient number of circulating cells (e.g., immune cells, e.g., T cells or NK cells) prior to administration of the mobilizing agent.

[0205] In one aspect, the patient has less than about 1000 x 10 6 / L (for example, less than 600x10 6 / L, 400x10 6 / L, 200x10 6 / L or 100x10 6 In one aspect, the present invention provides a method for obtaining cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist from a subject having less than about 800 x 10 6 / L (for example, less than 400x10 6 / L, 200x10 6 / L, 100x10 6 / L, 50x10 6 In one aspect, the present invention provides a method for obtaining cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist from a subject having less than about 500 x 10 CD4+ cells in the peripheral blood before administration of the mobilizing agent. 6 / L (for example, less than 400x10 6 / L, 200x10 6 / L, 100x10 6 / L or 50x10 6 In one aspect, the present invention provides a method for obtaining cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist from a subject having less than about 50x10 CD8+ cells in the peripheral blood before administration of the mobilizing agent. 6 / L (for example, less than 40x10 6 / L, 20x10 6 / L, 10x10 6 / L or 5x10 6 In one aspect, the present invention provides a method for obtaining cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist from a subject having less than about 50x10 6 / L (for example, less than 40x10 6 / L, 20x10 6 / L, 10x10 6 / L or 5x10 6 In one aspect, from the subject of the poor quality of peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) before the administration of mobilizing agent, the cell (e.g., immune cells, e.g., T cells or NK cells) mobilized by CXCR4 antagonists is obtained. In one aspect, from the subject of the poor quality of peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) before the administration of mobilizing agent, the cell (e.g., immune cells, e.g., T cells or NK cells) mobilized by CXCR4 antagonists is obtained. In one aspect, from the subject of the poor diversity of peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) before the administration of mobilizing agent, the cell (e.g., immune cells, e.g., T cells or NK cells) mobilized by CXCR4 antagonists is obtained. By next generation sequencing and / or by multicolor flow cytometry to measure clone formation ability (clonality), the diversity of blood cells can be measured.

[0206] In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist are obtained from a subject whose peripheral blood cells (e.g., immune cells, e.g., T cells or NK cells) have poor multifunctionality (e.g., antigen-induced production of IL2, TNFα, IFNγ, etc.) prior to administration of the mobilizing agent.

[0207] In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist are obtained from a subject who has or is expected to have a poor yield of a leukapheresis product without the administration of a mobilizing agent. In one aspect, cells (e.g., immune cells, e.g., T cells or NK cells) mobilized by a CXCR4 antagonist are obtained from a subject who has or is expected to have less than about 50 x 10 9 (For example, less than 40x10 9 , 20x10 9 , 10x10 9 A subject with a low level of white blood cells (WBCs) such as leukemia cells (eg, T cells or NK cells) is provided with cells mobilized by a CXCR4 antagonist.

[0208] In one embodiment, before collecting (for example, leukocyte apheresis) cells and optionally on the same day, CXCR4 antagonists are administered to subjects (i.e., donors) subcutaneously with a dosage of 0.24mg / kg every day. In certain embodiments, before collecting cells and optionally on the same day, for example, subcutaneously, with a dosage of about 0.20mg / kg to 5mg / kg (for example, 0.01mg / kg / , 0.05mg / kg, 0.1mg / kg, 0.15mg / kg, 0.2mg / kg, 0.25mg / kg, 0.3mg / kg, 0.4mg / kg, 0.5mg / kg, 0.75mg / kg, 1mg / kg, 2mg / kg or 5mg / kg), CXCR4 antagonists are administered to subjects (i.e., donors). In certain embodiments, CXCR4 antagonists are administered to subjects (i.e., donors) by alternative routes of administration (for example, intravenous, intramuscular, intraperitoneal, transdermal and oral, etc.). In certain embodiments, before collecting cells, the CXCR4 antagonist is administered to the subject (i.e., donor) every day for about 1-10 days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days). In certain embodiments, cells (e.g., immune cells) are collected from the subject (i.e., donor) about 15 min to 96 h (e.g., 15 min, 2 h, 6 h, 12 h, 24 h, 36 h, or 48 h) after the last dose of CXCR4 antagonist is administered.

[0209] In one embodiment, the CXCR4 antagonist is Mozibil or Plerixafor. In one embodiment, before collecting (for example, leukocyte apheresis) cells and optionally on the same day, Perixafor is administered to subject (that is, donor) subcutaneously with a dosage of 0.24mg / kg every day. In certain embodiments, before collecting cells and optionally on the same day, for example, subcutaneously, with about 0.20mg / kg to 5mg / kg (for example, 0.01mg / kg / , 0.05mg / kg, 0.1mg / kg, 0.15mg / kg, 0.2mg / kg, 0.25mg / kg, 0.3mg / kg, 0.4mg / kg, 0.5mg / kg, 0.75mg / kg, 1mg / kg, 2mg / kg or 5mg / kg) dosage, Perixafor is administered to subject (that is, donor). In certain embodiments, Perixafor is administered to the subject (i.e., donor) prior to and optionally on the day of cell collection, e.g., intravenously, at a dose of about 0.20 mg / kg to 5 mg / kg (e.g., 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.75 mg / kg, 1 mg / kg, 2 mg / kg, or 5 mg / kg). In certain embodiments, Perixafor is administered to the subject (i.e., donor) prior to collecting cells and optionally on the same day, e.g., intramuscularly, at a dose of about 0.20 mg / kg to 5 mg / kg (e.g., 0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.75 mg / kg, 1 mg / kg, 2 mg / kg, or 5 mg / kg). In certain embodiments, Perixafor is administered to the subject (i.e., donor) daily for about 1-10 days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days) prior to collecting cells. In certain embodiments, cells (eg, immune cells) are collected from the subject (ie, donor) about 15 min to 96 h (eg, 15 min, 1 h, 2 h, 6 h, 12 h, 24 h, 36 h, 48 h, or 96 h) after administration of the last dose of Perixafor.

[0210] In other embodiments, the CXCR4 antagonist is BMS-936564 / MDX-1338, LY2510924, 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (AMD3100; plerixafor), N,N-dipropyl-N-[4-({[(1H-imidazol-2-yl)methyl)benzyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl)benzyl]-N-methylbutane -1,4-diamine tris(2R,3R)-tartrate (KRH-3955), ([5-(4-methyl-1-piperazinyl)-2-({methyl[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[1,2-a]pyridin-3-yl]methanol) (GSK812397) or N-(1H-benzimidazol-2-ylmethyl)-N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD11070). In one embodiment, the CXCR4 antagonist is BL-8040. Additional CXCR4 antagonists are known in the art, such as T140 analogs, NUCC-388, and CXCR4 antagonist III (Calbiochem), and can be used in alternative embodiments of the present disclosure.

[0211] In other embodiments, the CXCR4 antagonist is a CXCL12 antagonist. In further preferred embodiments, the CXCL12 antagonist is an anti-CXCL12 antibody. An example of an anti-CXCL12 antibody includes, but is not limited to, an anti-SDF-1 antibody. Examples of such CXCL12 antagonists include, but are not limited to, the RNA oligonucleotide NOX-A12 or tannic acid, or any other chemical that blocks the interaction between CXCL12 and CXCR4.

[0212] The CXCR4 antagonists described herein can be administered by continuous intravenous infusion in an amount sufficient to maintain serum concentrations at levels that result in >90% inhibition of CXCR4 binding to CXCL12 (see, e.g., Hendrix et al. JAcquir Immune Defic Syndr. 2004 Oct. 1;37(2):1253-62). Other CXCR4 signaling inhibitors described herein can also be used in this same manner.

[0213] In vivo administration (e.g., in batches at appropriate intervals) can be completed continuously or intermittently (e.g., in divided doses at appropriate intervals) at one dose. Methods for determining the most effective mode of administration and dosage are well known to those skilled in the art and will vary depending on the formulation used for treatment, the purpose of treatment, the target cell being treated, and the subject being treated. Single or multiple administrations can be performed at a dose level and mode selected by the physician. For example, the physician can adjust the dosage and duration of treatment with the CXCR4 antagonists of the present disclosure and other mobilizing agents based on peripheral blood lymphocyte counts.

[0214] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from subjects (i.e., autologous or allogeneic donors) who have received cytokines to assist in mobilizing a specific subset of immune cells into the peripheral circulation by leukapheresis. In one embodiment, the cytokine is G-CSF (filgrastim, Amgen). In certain embodiments, G-CSF is administered subcutaneously at a dosage of about 1-30 μg / kg (e.g., 1 μg / kg, 2 μg / kg, 5 μg / kg, 10 μg / kg, or 30 μg / kg) per day for about 1-10 days. In certain embodiments, G-CSF is administered intravenously at a dosage of about 1-30 μg / kg (e.g., 1 μg / kg, 2 μg / kg, 5 μg / kg, or 30 μg / kg) per day for about 1-10 days. In certain embodiments, cells (eg, immune cells, eg, T cells or NK cells) are collected from the subject (ie, donor) about 2 h to 96 h after administration of the last dose of G-CSF.

[0215] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from subjects (i.e., autologous or allogeneic donors) who have received cytokines to assist in mobilizing a specific subset of cells (e.g., immune cells, e.g., T cells or NK cells) into the peripheral circulation by leukapheresis. In one embodiment, the cytokine is pegfilgrastim (Neulasta, Amgen). In certain embodiments, pegfilgrastim is administered by subcutaneous injection at a dose of about 6 mg (e.g., 6 mg, 8 mg, 10 mg, 12 mg, or 16 mg). In certain embodiments, cells (e.g., immune cells, e.g., T cells or NK cells) are collected from subjects (i.e., donors) about 4 days after the dose of pegfilgrastim is administered.

[0216] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained by leukapheresis from a subject (i.e., an autologous or allogeneic donor) who has received GM-CSF to assist in mobilizing a specific subset of cells (e.g., immune cells, e.g., T cells or NK cells) into the peripheral circulation. In certain embodiments, GM-CSF is administered daily at a dose of about 250 μg / m 2 GM-CSF (Leukine) is administered at a dose of 1:100 mg / day (IV over 24 hours or subcutaneously) for about 1-10 days. In certain embodiments, cells (e.g., immune cells, e.g., T cells or NK cells) are collected from the subject (i.e., donor) about 2 hours to 96 hours after the last dose of GM-CSF is administered.

[0217] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from subjects (i.e., donors) who have received a combination of a CXCR4 antagonist (e.g., Perixafor) and a cytokine (e.g., G-CSF, GM-CSF, or pegfilgastrim) to assist in mobilizing a specific subset of cells (e.g., immune cells, e.g., T cells or NK cells) into the peripheral circulation by leukapheresis. In an exemplary embodiment, the subject receives a 10 μg / kg dose of G-CSF per day for 5 days, followed by a 0.25 mg / kg dose of Perixafor subcutaneously on the 5th day. Approximately 2 hours after the dose of Perixafor, the leukapheresis product is collected using a CS3000-Plus blood cell separator (Baxter Healthcare). In an exemplary embodiment, the subject receives a 12 mg dose of Pegfilgastrim by subcutaneous injection and a 0.25 mg / kg dose of Perixafor subcutaneously 4 days later. The leukapheresis product was collected approximately 2 hours after the dose of Perixafor using a CS3000-Plus blood cell separator (Baxter Healthcare) and used to manufacture cell therapy products (e.g., preparation of CAR-T cells).

[0218] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject (i.e., a donor) after chemomobilization by leukapheresis, e.g., a subject who has received chemotherapy and then received a CXCR4 antagonist (e.g., Perixafor) and / or a cytokine (e.g., G-CSF or GM-CSF) during recovery from chemotherapy to assist in mobilizing a specific subset of cells (e.g., immune cells, e.g., T cells or NK cells) into the peripheral circulation. Many chemomobilization regimens are known in the art and can be used in the methods of the present disclosure. Exemplary chemomobilization regimens include high-dose cyclophosphamide (HDC, 4 gm / m 2 ) or cyclophosphamide (4 gm / m 2 )+etoposide (600 mg / m 2 )(HDCE).

[0219] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject (i.e., a donor) who has received a β2 adrenergic receptor agonist to assist in mobilizing a specific subset of cells (e.g., immune cells, e.g., T cells or NK cells) into the peripheral circulation by leukapheresis. In an exemplary embodiment, the β2 adrenergic agonist is epinephrine. In an exemplary embodiment, the subject receives epinephrine at a dose of about 0.005 mg / kg / min to 0.02 mg / kg / min for about 30 minutes to 2 hours via intravenous infusion. After 30 min to 2 hours of epinephrine infusion, the leukapheresis product is collected.

[0220] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject (i.e., a donor) after exercise by leukapheresis. In an exemplary embodiment, the subject performs moderate to vigorous exercise on a treadmill for about 10 minutes to 1 hour, and leukapheresis products are collected 10 minutes to 1 hour after the moderate to vigorous exercise. In an exemplary embodiment, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject (i.e., a donor) after exercise by leukapheresis, and the exercise results in a heart rate that is more than 50-100% higher than the heart rate at rest.

[0221] In another aspect of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from a subject (i.e., a donor) after administration of a Src kinase inhibitor by leukocyte apheresis. An exemplary Src kinase inhibitor is dasatinib. In an exemplary embodiment, the subject receives dasatinib orally at a dose of about 40-140 mg, and about 1-5 hours after administration of dasatinib, cells (e.g., immune cells, e.g., T cells or NK cells) are obtained from the subject by leukocyte apheresis. In one embodiment, prior to leukocyte apheresis, dasatinib is administered to the subject for about 7 days (e.g., 6 days, 4 days, 2 days, etc.).

[0222] In one embodiment, from the subject of the mTOR inhibitor of having received low immune enhancing dosage, immune effector cell is obtained.In one embodiment, after enough time, or after fully applying the mTOR inhibitor of low immune enhancing dosage, harvest will be genetically modified to express CAR / TCR immune effector cell colonies (for example, T cell), so that in subject or from subject's harvested PD1 negative immune effector cells (for example, T cell) level, or PD1 negative immune effector cells (for example, T cell) / PD1 positive immune effector cells (for example, T cell) ratio at least temporarily increase.

[0223] The mobilized cells (e.g., immune cells, e.g., T cells or NK cells) of the present disclosure can be used for many cell therapy purposes. In one embodiment, the mobilized cells are administered to a subject in the absence of manipulation or genetic modification. In one embodiment, T regulatory cells (CD3+, CD4+, CD25+) are removed from the mobilized cells by removing CD25-positive T cells. 高 , CD127 低 In one embodiment, cells expressing CD25 are removed by using methods known in the art, such as immunomagnetic labeling and magnet-assisted cell sorting with magnetic beads labeled with CD25 antibodies. hi The mobilized T cells are then depleted of regulatory T cells (TREG).

[0224] In one embodiment, the mobilized cells (removing or not removing TREG) are genetically modified before being administered to a subject. In one embodiment, the mobilized cells (for example, immune cells, for example, T cells or NK cells or macrophages / monocytes or dendritic cells) are genetically modified to express natural or non-natural (for example, synthetic) immune receptors. The exemplary immune receptors that can be expressed in the mobilized cells of the present disclosure include natural TCR, recombinant TCR, chimeric antigen receptor (CAR) (including next generation CAR (for example, SIR, TFP, Ab-TCR, super CAR, TAC etc.)), synthetic notch (Notch) receptors etc. In one embodiment, the mobilized cells (removing or not removing TREG) are used to prepare cell vaccines.

[0225] In one embodiment, the mobilized cells are genetically modified to express an immune receptor that recognizes one or more antigens selected from the group consisting of: CD5, CD19; CD123; CD22; CD30; CD171; CS1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319 and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemia or lymphoma but not on hematopoietic progenitor cells, glycosylated CD43 epitope expressed on non-hematopoietic cancers, carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA ); protease serine 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha (FRa or FR1); folate receptor beta (FRb); receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); mutated elongation factor 2 (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); proteasome (prosome, macropain) subunit, beta type, 9 (LMP2); glycoprotein 100 (gp100);Oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl); tyrosinase; ephrin type A receptor 2 (EphA2); sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C 5 group, member D (G PRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor β3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation variant gene 6 on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutants; prostate-specific protein (prostein); survivin; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene);N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 IB 1 (CYP1B 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); proacrosin-binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of the IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A, member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12, member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); mucin-like hormone receptor-like 2 containing an EGF-like module (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL, biotin, c-MYC epitope tag, CD34, LAMP1 TROP2, GFRα4, CDH17, CDH6, NYBR1, CDH19, CD200R, Slea (CA19.9; sialyl Lewis antigen);Fucosyl-GM1, PTK7, gpNMB, CDH1-CD324, DLL3, CD276 / B7H3, IL11Ra, IL13Ra2, CD179b-IGLl1, TCRγ-δ, NKG2D, CD32 (FCGR2A), Tn ag, Tim1- / HVCR1, CSF2RA (GM-CSFR-α), TGFβR2, Lews Ag, TCR-β1 chain, TCR-β2 chain, TCR-γ chain, TCR-δ chain, FITC, luteinizing hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR), gonadotropin hormone receptor (CGHR or GR), CCR4, GD3, SLAMF6, SLAMF4, HIV1 envelope glycoprotein, HTLV1-Tax, CMV pp65, EBV-EBNA3c, KSHV K8.1, KSHV-gH, influenza A hemagglutinin (HA), GAD, PDL1, guanylate cyclase C (GCC), autoantibody-desmoglein 3 (Dsg3), autoantibody-desmoglein 1 (Dsg1), HLA, HLA-A, HLA-A2, HLA-B, HLA-C, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, HLA-DR, HLA-G, IgE, CD99, RasG12 V, tissue factor 1 (TF1), AFP, GPRC5D, claudin 18.2 (CLD18A2 or CLDN18A.2), CLDN6, P-glycoprotein, STEAP1, Liv1, connexin-4, Cripto, MPL, gpA33, BST1 / CD157, low-conductance chloride channel, CLDN6, MMP16, UPK1B, BMPR1B, Ly6E, STEAP1, WISP1, SLC34A2, and antigens recognized by TNT antibodies.

[0226] Methods of expressing immune receptors (e.g., TCR, CAR, SIR, TFP, Ab-TCR, etc.) to produce cell therapy products are described in this disclosure and are also known in the art.

[0227] In one embodiment, the mobilized cells of the present disclosure (e.g., immune cells, e.g., T cells or NK cells) are genetically modified to modify the expression of one or more genes. In an exemplary embodiment, the mobilized cells of the present disclosure are genetically modified to reduce or eliminate the expression of the Tet2 gene. In an exemplary embodiment, the mobilized cells of the present disclosure are genetically modified to reduce or eliminate the expression of TCR and HLA class I genes. In an exemplary embodiment, the mobilized cells of the present disclosure are genetically modified to reduce or eliminate the expression of TCR-α (TRAC) genes and / or β2 macroglobulin genes. In an exemplary embodiment, the mobilized cells of the present disclosure are genetically modified to change the expression of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10), and death receptor 5 (DR5 or TNFRSF10B). In an exemplary embodiment, the mobilized cells of the present disclosure are genetically modified to increase the expression of genes (e.g., vFLIP-K13, NEMO, cJun, JAK3, STAT5, etc.). Methods for altering the expression of genes to produce cell therapy products are described in the present disclosure and are known in the art.

[0228] In one embodiment, the mobilized cells of the present disclosure are used for the purpose of generating an immune response. In one embodiment, the mobilized cells of the present disclosure are used for the purpose of generating a T cell immune response.

[0229] In one embodiment, the mobilized cells of the present disclosure are further processed and purified into different subtypes before producing a cell therapy product. In one embodiment, the mobilized cells of the present disclosure are further processed and purified into different subtypes before producing a cell therapy product (e.g., CAR-T or TCR-T cells). hi Cells, the mobilized cells of the present disclosure are depleted of TREG (regulatory T cells). Methods for collecting, processing, selecting and depleting different cell subsets for the production of cell therapy products are described in the present disclosure and are also known in the art.

[0230] In one embodiment, in order to produce a cell therapy product, the mobilized cells of the present disclosure are activated in vitro and / or bred. In one embodiment, in order to produce a cell therapy product, the mobilized cells of the present disclosure are activated in vitro and / or bred for about 21 days (for example, 1 day, 2 days, 3 days, 5 days, 7 days, 9 days, 12 days, 14 days, 21 days etc.). In certain embodiments, in order to produce a cell therapy product, the mobilized cells of the present disclosure are activated in vitro and / or bred for more than 1 day (for example, more than 1 day, 2 days, 3 days, 5 days, 7 days, 9 days, 12 days, 14 days, 21 days etc.). In one embodiment, before being administered to a subject, the mobilized cells of the present disclosure are activated in vitro and / or bred. In one embodiment, before being administered to a patient, the mobilized cells of the present disclosure are activated in vitro and / or bred for about 21 days (for example, 1 day, 2 days, 3 days, 5 days, 7 days, 9 days, 12 days, 14 days, 21 days etc.). In certain embodiments, before being administered to a patient, the mobilized cells of the present disclosure are activated and / or propagated in vitro for more than 1 day (e.g., more than 1 day, 2 days, 3 days, 5 days, 7 days, 9 days, 12 days, 14 days, 21 days, etc.). In one embodiment, before being administered to a subject, the mobilized cells of the present disclosure are cryopreserved. Methods for activating and propagating cells for the production of cell therapy products are described in the present disclosure and are also known in the art. Methods for cryopreservation and administration of cell therapy products are also described in the present disclosure and are known in the art.

[0231] In one embodiment, under the culture conditions including CD3 antibody, CD28 antibody and IL2, the mobilized cells of the present disclosure are activated and / or propagated in vitro. In an exemplary embodiment, mobilized T cells are cultured in XVIVO culture medium (Lonza) supplemented with 10ng / ml CD3 antibody, 10ng / ml CD28 antibody and 30-100IU recombinant human-IL2. In an exemplary embodiment, CD3 / CD28 beads and 100IU recombinant human-IL2 can be used. In an exemplary embodiment, cells are cultured at 37°C in a 5% CO2 moisturizing incubator. In one embodiment, under the culture conditions including cytokines such as IL-7, IL-15, IL-21, IL12F or a combination thereof, the mobilized cells of the present disclosure are activated and / or propagated in vitro.

[0232] In one embodiment, the mobilized cells of the present disclosure are activated and / or propagated in vitro under culture conditions that promote the generation of central memory T cells.

[0233] In one embodiment, the mobilized cells of the present invention are activated and / or propagated in vitro under culture conditions that inhibit the production of TREG. In one embodiment, the mobilized cells of the present invention are activated and / or propagated in vitro under culture conditions that promote the production of TREG. In one embodiment, the mobilized cells of the present invention are activated and / or propagated in vitro under culture conditions that inhibit the production of suppressor T cells. In one embodiment, the mobilized cells of the present invention are activated and / or propagated in vitro under culture conditions that promote the production of suppressor T cells. Methods of activating and / or propagating T cells to promote or inhibit the production of TREG and suppressor T cells are known in the art.

[0234] In one embodiment, the mobilized cells of the present disclosure are used to produce cell therapy products expressing natural or synthetic T cell receptors. In one embodiment, the mobilized cells of the present disclosure are used to produce cell therapy products expressing chimeric antigen receptors (including next-generation CAR (e.g., SIR, TFP, Ab-TCR, TAC, super CAR, etc.)). In one embodiment, the mobilized cells of the present disclosure are used to produce cell therapy products expressing natural or synthetic NK cell receptors. In one embodiment, the mobilized cells of the present disclosure are used to produce cell therapy products expressing natural or synthetic macrophage receptors. In one embodiment, the mobilized cells of the present disclosure are used to produce vaccines, e.g., T cell vaccines. The method for producing cell therapy products expressing different receptors is described in the present disclosure and is also known in the art.

[0235] In one embodiment, the cell therapy product produced from the mobilized cells of the present disclosure is for autologous administration; that is, the cell therapy product is administered to the same subject from which the mobilized cells were harvested. In one embodiment, the cell therapy product produced from the mobilized cells of the present disclosure is for allogeneic administration; that is, the cell therapy product is administered to a subject different from the person from whom the mobilized cells were harvested. Methods of using the cell therapy product for autologous or allogeneic use are described in this disclosure and are also known in the art.

[0236] In one embodiment, the cell therapy products produced from the mobilized cells of the present disclosure are used to prevent and treat a variety of diseases (e.g., cancer, immune, degenerative and infectious diseases). In one embodiment, the cell therapy products produced from the mobilized cells of the present disclosure are used to prevent and treat a variety of diseases in combination with other agents (e.g., chemotherapy drugs; antibodies, cytokines, etc.).

[0237] In certain embodiments, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a higher yield of a cell therapy product (e.g., CAR-T, SIR-T, or TCR-T). In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a cell therapy product manufactured that is about 20% (e.g., 20%, 50%, 75%, 100%, etc.) higher in cell number than the cell (e.g., CAR-T, SIR-T, or TCR-T cells) in a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0238] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a shorter manufacturing time for a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a shorter manufacturing time for a cell therapy product than the manufacturing time of a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0239] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in fewer manufacturing failures of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in about 10% (e.g., 20%, 50%, 75%, 100%, etc.) fewer manufacturing failures of a cell therapy product compared to manufacturing failures of a cell therapy product manufactured from apheresis products collected without the use of a mobilizing agent.

[0240] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a lower manufacturing cost for a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a reduction in the manufacturing cost of the cell therapy product by about 10% (e.g., 20%, 50%, 75%, 100%, etc.) compared to the manufacturing failure of a cell therapy product manufactured from apheresis products collected without the use of a mobilizing agent.

[0241] In one embodiment, the application of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in an improvement in the diversity of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product. In one embodiment, the application of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in an increase in the diversity of a cell therapy product by about 10% (e.g., 20%, 50%, 75%, 100%, etc.) compared to a cell therapy product manufactured from apheresis products collected without the use of a mobilizing agent. The diversity of a cell therapy product can be measured by methods known in the art such as clonal analysis, multicolor flow cytometry, and the like.

[0242] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after the administration of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib, etc.) does not show a significant loss of cytotoxic activity, or shows improved cytotoxicity to its target cells, compared to the cell therapy product produced by the cell population (e.g., apheresis product) collected without the administration of a mobilizing agent. In one embodiment, the application of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a loss of no more than 50% (e.g., 20%, 25%, 45%, etc.) of the cytotoxicity of the cell therapy product compared to the cell therapy product produced by the apheresis product collected without the use of a mobilizing agent. The cytotoxicity of the cell therapy product can be measured using methods known in the art, such as the Matador cytotoxicity assay or the radiochromium release assay.

[0243] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after the administration of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib, etc.) shows improved target antigen-induced cytokine production (TNFα, IL2, IFNγ), or does not show a significant loss of target antigen-induced cytokine production (TNFα, IL2, IFNγ). In one embodiment, the application of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib) results in a target antigen-induced cytokine production loss of no more than 50% (e.g., 20%, 25%, 50%, etc.) of the cell therapy product compared to the cell therapy product produced by the apheresis product collected without the use of a mobilizing agent. The cytokine production of the cell therapy product is measured using methods known in the art, such as ELISA and flow cytometry, etc.

[0244] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after the administration of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib, etc.) shows improved in vivo efficacy or does not show a significant loss of in vivo efficacy compared to the cell therapy product produced by the cell population (e.g., apheresis product) collected without the administration of a mobilizing agent. In one embodiment, the application of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib) results in a loss of in vivo efficacy of the cell therapy product of no more than 50% (e.g., 20%, 25%, 50%, etc.) compared to the cell therapy product manufactured by the apheresis product collected without the use of a mobilizing agent. The in vivo efficacy of the cell therapy product is measured using methods known in the art, such as xenograft studies in immunodeficient mice.

[0245] In one embodiment, compared to the cell therapy product produced by the cell colony (such as apheresis product) collected without the use of a mobilizing agent, the cell therapy product produced by the cell colony (such as apheresis product) collected after the use of a mobilizing agent (such as, CXCR4 antagonists, G-CSF, GM-CSF or dasatinib, etc.) shows improved stem-like T cells or does not show a significant loss of stem-like T cells. In one embodiment, compared to the cell therapy product manufactured by the apheresis product collected without the use of a mobilizing agent, the application of a mobilizing agent (such as, CXCR4 antagonists, G-CSF, GM-CSF or dasatinib) causes the stem-like T cell loss in the cell therapy product to be no more than 50% (for example, no more than 20%, 25%, 50%, etc.). Using markers known in the art (such as, CD62L+, CD7+, Pgp+), the stem-like T cell population in the cell therapy product is measured by flow cytometry.

[0246] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after the administration of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib, etc.) shows improved naive T cells or does not show a significant loss of naive T cells compared to the cell therapy product produced by the cell population (e.g., apheresis product) collected without the administration of a mobilizing agent. In one embodiment, the application of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib) results in a loss of no more than 50% (e.g., no more than 20%, 25%, 50%, etc.) of naive T cells in the cell therapy product compared to the cell therapy product manufactured by the apheresis product collected without the use of a mobilizing agent. The naive T cell population in the cell therapy product is measured by flow cytometry using markers known in the art.

[0247] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after the administration of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib, etc.) shows improved central memory T cells or does not show a significant loss of central memory T cells compared to the cell therapy product produced by the cell population (e.g., apheresis product) collected without the administration of a mobilizing agent. In one embodiment, the application of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib) results in a loss of no more than 50% (e.g., no more than 20%, 25%, 50%, etc.) of central memory T cells in the cell therapy product compared to the cell therapy product manufactured by the apheresis product collected without the use of a mobilizing agent. The central memory T cell population in the cell therapy product is measured by flow cytometry using markers known in the art.

[0248] In one embodiment, the cell therapy product produced by the cell population (e.g., apheresis product) collected after administering a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib, etc.) shows improved effector T cells or does not show a significant loss of effector T cells compared to the cell therapy product produced by the cell population (e.g., apheresis product) collected without administering a mobilizing agent. In one embodiment, the application of a mobilizing agent (e.g., CXCR4 antagonist, G-CSF, GM-CSF or dasatinib) results in a loss of effector T cells in the cell therapy product of no more than 50% (e.g., no more than 20%, 25%, 50%, etc.). Using markers known in the art, the effector T cell population in the cell therapy product is measured by flow cytometry.

[0249] In one embodiment, compared with the cell therapy product produced by the cell colony (such as apheresis product) collected without the use of a mobilizing agent, the cell therapy product produced by the cell colony (such as apheresis product) collected after the use of a mobilizing agent (such as, CXCR4 antagonists, G-CSF, GM-CSF or dasatinib, etc.) does not show more enrichment of regulatory T cells (such as TREG). In one embodiment, compared with the cell therapy product manufactured by the apheresis product collected without the use of a mobilizing agent, the application of a mobilizing agent (such as, CXCR4 antagonists, G-CSF, GM-CSF or dasatinib) results in an increase of no more than 50% (for example, no more than 20%, 25%, 50% etc.) of regulatory T cells (TREG) colonies in the cell therapy product. Using markers known in the art, the TREG colonies in the cell therapy product are measured by flow cytometry.

[0250] In one embodiment, the application of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) does not result in a significant loss of multifunctionality (e.g., antigen-induced IL2, TNFα, IFNγ production) of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product, and / or results in improved multifunctionality (e.g., antigen-induced IL2, TNFα, IFNγ production). In one embodiment, the application of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a cell therapy product having a multifunctionality that is about 10% (e.g., 20%, 50%, 75%, 100%, etc.) higher than a cell therapy product manufactured from apheresis product collected without the use of a mobilizing agent.

[0251] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) does not result in a significant loss of in vivo proliferation of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product, and / or results in improved in vivo proliferation. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in about 10% (e.g., 20%, 50%, 75%, 100%, etc.) higher proliferation of the cell therapy product after administration to a subject compared to a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0252] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) does not result in a significant loss of persistence of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product, and / or results in improved persistence. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in a cell therapy product that is about 10% (e.g., 20%, 50%, 75%, 100%, etc.) longer in persistence after administration to a subject than a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0253] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in improved tissue (e.g., tumor) penetration of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product, or does not result in a significant loss of tissue (e.g., tumor) penetration. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in about 10% (e.g., 20%, 50%, 75%, 100%, etc.) greater tissue (e.g., tumor) penetration of the cell therapy product after administration to a subject, compared to a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0254] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in improved anti-tumor efficacy of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product, or does not result in a significant loss of anti-tumor efficacy. In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) results in an anti-tumor efficacy of the cell therapy product after administration to a subject that is about 10% greater (e.g., 20%, 50%, 75%, 100%, etc.) compared to a cell therapy product manufactured from an apheresis product collected without the use of a mobilizing agent.

[0255] In one embodiment, the use of a mobilizing agent (e.g., a CXCR4 antagonist, G-CSF, GM-CSF, or dasatinib) does not result in a significant increase in the toxicity (e.g., cytokine release syndrome, neurotoxicity, etc.) of a cell therapy (e.g., CAR-T, SIR-T, or TCR-T) product.

[0256] In some aspects of the present disclosure, using any number of technology known to those skilled in the art, such as FicollTM separation, immune effector cells, for example, T cells can be obtained from blood units collected by a subject. In a preferred aspect, blood cells from individual circulation are obtained by apheresis. Apheresis products generally contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells and platelets. In one aspect, the cells collected by apheresis can be washed to remove the plasma fraction, and optionally, cells are placed in appropriate buffer or culture medium for subsequent processing steps. In one embodiment, cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, washing solution lacks calcium, and may lack magnesium, or may lack many (if not all) divalent cations.

[0257] In one aspect, T cells are separated from peripheral blood lymphocytes by lysing red blood cells and removing mononuclear cells, for example, by centrifugation in a PERCOLL™ gradient or by reverse flow centrifugal elutriation.

[0258] In one embodiment, the mobilized cells are further enriched for cells expressing P-glycoprotein ((P-gp or Pgp; MDR1, ABCB1, CD243). In one embodiment, the mobilized cells are enriched for cells that stain with a dull dye that is a substrate for P-glycoprotein-mediated efflux, as described in Application No. PCT / US2017 / 042248, which is incorporated herein by reference. In certain embodiments, cells lacking expression of p-gp or p-gp activity are removed from the population.

[0259] The methods described herein may include more than one selection step, for example, more than one removal step.

[0260] The methods described herein can also include removing cells expressing tumor antigens (e.g., CD19, CD30, CD38, CD123, CD20 / MS4A1, CD14, or CD11b) from the population. Also provided are methods including removing cells expressing checkpoint inhibitors from the population.

[0261] The methods described herein may also include removing regulatory T cells (TREG) from the mobilized cells. Methods for removing TREG are known in the art and include removing T cells that express CD25.

[0262] In one embodiment, one or more T cell populations expressing IFN-γ, TNFα, IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10, IL-13, granzyme B, and perforin, or other appropriate molecules (e.g., other cytokines) can be selected. Methods for screening cell expression can be determined, for example, by the methods described in PCT Publication No. WO 2013 / 126712.

[0263] T cells for stimulation can also be frozen after the washing step.

[0264] It is also contemplated in the context of the present disclosure that a blood sample or apheresis product is collected from a subject in a time period prior to the cells that may be propagated as described herein. In one aspect, a blood sample or apheresis is collected from a generally healthy subject. In certain aspects, a blood sample or apheresis is collected from a generally healthy subject that is at risk of developing a disease but has not yet developed the disease, and the target cells are separated and frozen for future use.

[0265] In certain aspects, the T cells can be propagated, frozen, and used at a later time.In certain aspects, samples are collected from patients shortly after diagnosis of a particular disease as described herein, but prior to any treatment.

[0266] The present disclosure also provides BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 inhibitors and methods of use thereof. Specifically, the present disclosure provides immune effector cells, e.g., T cells expressing CAR and TCR, comprising BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 inhibitors, with And the use of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and DR5 inhibitors in combination with immune effector cell therapy products (e.g., CAR-T cells or TCR-T cells). The BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 inhibitors of the present disclosure, and methods of their use, are described in more detail below.

[0267] In one embodiment, the immune effector cell therapy product is a CAR-T cell or TCR-T cell or BiTE, wherein the CAR-T / TCR-T or BiTE targets, but is not limited to, one or more antigens selected from the group consisting of: CD5, CD19; CD123; CD22; CD30; CD171; CS1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemias or lymphomas but not on hematopoietic progenitor cells, glycosylated CD43 epitope expressed on non-hematopoietic cancers, carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-11Ra); prostate stem cell Testisin or PRSS21; vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha (FRa or FR1); folate receptor beta (FRb); receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); mutated elongation factor 2 (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); proteasome (Prosome, Macropain) subunit, beta type, 9 (LMP2); glycoprotein 100 (gpl00);Oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl); tyrosinase; ephrin type A receptor 2 (EphA2); sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM 7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); the hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6 on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutants; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutants; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor;Cyclin Bl; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B 1 (CYP1B 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, breakpoint X 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of the IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A, member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12, member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); mucin-like hormone receptor-like 2 containing an EGF-like module (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL, biotin, c-MYC epitope tag, CD34, LAMP1 TROP2, GFRα4, CDH17, CDH6, NYBR1, CDH19, CD200R, Slea (CA19.9; sialyl Lewis antigen);Fucosyl-GM1, PTK7, gpNMB, CDH1-CD324, DLL3, CD276 / B7H3, IL11Ra, IL13Ra2, CD179b-IGLl1, TCRγ-δ, NKG2D, CD32 (FCGR2A), Tn ag, Tim1- / HVCR1, CSF2RA (GM-CSFR-α), TGFβR2, Lews Ag, TCR-β1 chain, TCR-β2 chain, TCR-γ chain, TCR-δ chain, FITC, luteinizing hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR), gonadotropin hormone receptor (CGHR or GR), CCR4, GD3, SLAMF6, SLAMF4, HIV1 envelope glycoprotein, HTLV1-Tax, CMV pp65, EBV-EBNA3c, KSHVK8.1, KSHV-gH, influenza A hemagglutinin (HA), GAD, PDL1, guanylate cyclase C (GCC), autoantibodies to desmoglein 3 (Dsg3), autoantibodies to desmoglein 1 (Dsg1), HLA, HLA-A, HLA-A2, HLA-B, HLA-C, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, HLA-DR, HLA-G, IgE, CD99, Ras G12V, tissue factor 1 (TF1), AFP, GPRC5D, claudin 18.2 (CLD18A2 or CLDN18A.2), CLDN6, P-glycoprotein, STEAP1, Liv1, connexin-4, Cripto, MPL, gpA33, BST1 / CD157, low-conductance chloride channel, CLDN6, MMP16, UPK1B, BMPR1B, Ly6E, STEAP1, WISP1, SLC34A2, and antigens recognized by TNT antibodies.

[0268] The present disclosure provides inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5, as well as methods of enhancing immune effector cell function (e.g., CAR-expressing cell function) by using such compositions and / or other means as described herein. Any inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 known in the art is not indicated. Can be used as BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and DR5 inhibitor according to the present disclosure.In certain embodiments, the inhibitor of TRAIL and DR5 is also used to prevent, improve or treat the side effect (for example, CRS and neurotoxicity) of immunotherapy (for example, lantumomab) and immune effector cell therapy product (for example, CAR-T). Examples of inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 are described below.

[0269] According to the present disclosure, the gene editing system can be used as an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5. The present disclosure also encompasses the use of nucleic acids encoding one or more components of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and DR5 gene editing systems. Many gene editing systems such as CRISPR / Cas9, zinc finger nucleases, Talons, etc. are known in the art and can be used in the methods of the present disclosure.

[0270] The CRISPR / Cas system can be used to modify, for example, delete one or more nucleic acids or gene regulatory elements of a gene, or introduce premature termination, thereby reducing the expression of a functional gene (e.g., BRD9). The CRISPR / Cas system can alternatively be used like RNA interference to reversibly shut down genes. For example, in mammalian cells, RNA can guide the Cas protein to the BRD9 promoter, thereby spatially blocking RNA polymerase.

[0271] An exemplary gRNA molecule of the present disclosure comprises, e.g., consists of, a first nucleic acid having the sequence (wherein "n'" represents residues of a targeting sequence (e.g., as described herein, e.g., in Table 8) and can consist of 15-25 nucleotides, e.g., 20 nucleotides): nnnnnnnnnnnnnnnnnnGUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 2041); and a second nucleic acid sequence having the sequence: AACUUACCAAGGAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC, optionally having 1, 2, 3, 4, 5, 6, or 7 (e.g., 4 or 7, e.g., 7) additional U nucleotides at the 3' end (SEQ ID NO: 2042).

[0272] The second nucleic acid molecule may alternatively consist of a fragment of the above sequence, wherein such a fragment is capable of hybridizing to the first nucleic acid. An example of such a second nucleic acid molecule is: AACAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAG UGGCACCGAGUCGGUGC, optionally with 1, 2, 3, 4, 5, 6 or 7 (e.g., 4 or 7, e.g., 7) additional U nucleotides at the 3' end (SEQ ID NO: 2054).

[0273] Another exemplary gRNA molecule of the present disclosure comprises, e.g., consists of, a first nucleic acid having the sequence (wherein "n'" represents the residues of the targeting sequence (e.g., as described herein, e.g., in Table 8), and can consist of 15-25 nucleotides, e.g., consists of 20 nucleotides): nnnnnnnnnnnnnnnnnnnGUUUUAGAGCUA GAAAUAGCAAGUUAAAA UAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 2055), optionally with 1, 2, 3, 4, 5, 6 or 7 (eg, 4 or 7, eg, 4) additional U nucleotides at the 3' end.

[0274] Alternatively, gRNA can be obtained from commercial sellers such as Integrated DNA Technologies (IDT), wherein gRNA contains a target-specific sequence for guiding Cas9 protein to the genomic location of the gene. At the IDT website (www.idtdna.com), user-defined protospacer sequence design is used, and crRNA or crRNA XT that form gRNA duplexes with tracrRNA or sgRNA can be ordered, pre-designed or custom-designed, which are single RNA molecules consisting of crRNA and tracrRNA sequences. Using manufacturer's instructions and / or methods known in the art, crRNA or sgRNA can be used to edit genes.

[0275] In embodiments, the gRNA comprises a targeting sequence that is fully complementary to 15-25 nucleotides (e.g., 20 nucleotides) of the targeted gene (e.g., BRD9). In embodiments, 15-25 nucleotides (e.g., 20 nucleotides) of the targeted gene are located immediately adjacent to the 5' side of the protospacer sequence adjacent motif (PAM) sequence recognized by the Cas protein of the CRISPR / Cas system (e.g., in the case where the system comprises Streptococcus pyogenes (S. pyogenes) Cas9 protein, the PAM sequence comprises NGG, wherein N can be any one of A, T, G, or C). Examples of gRNA targeting sequences (including PAM sequences) for inhibiting target BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in various embodiments of the present disclosure are provided in Table 4b below.

[0276] In embodiments, the targeting sequence of the gRNA comprises, e.g., consists of, an RNA sequence complementary to the sequence listed in Table 4a. In embodiments, the gRNA comprises the sequence listed in Table 8.

[0277] In one embodiment, foreign DNA can be introduced into cells together with CRISPR / Cas systems, for example, encoding CAR (for example, as described herein) DNA;Depending on the foreign DNA sequence and chromosome sequence, the process can be used for integrating the DNA encoding CAR (for example, as described herein) into or near the site targeted by CRISPR / Cas systems.As demonstrated herein, in an embodiment, but not limited by theory, such integration can result in the expression of CAR and the destruction of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes.Such foreign DNA molecules are referred to herein as "template DNA". In an embodiment, the template DNA further comprises homology arms on the 5' side, 3' side, or both the 5' and 3' sides of the nucleic acid of the template DNA, which encode one or more target molecules (e.g., which encode a CAR described herein), wherein the homology arms are complementary to the genomic DNA sequence adjacent to the target sequence.

[0278] In one embodiment, the CRISPR / Cas system of the present disclosure includes Cas9 (for example, Streptococcus pyogenes Cas9) and the gRNA including a targeting sequence, and the targeting sequence hybridizes with the sequence of a target gene (for example, BRD9 gene). In one embodiment, the CRISPR / Cas system includes the nucleic acid of the gRNA encoding BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (for example, Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, and the nucleic acid encoding Cas protein (for example, Cas9, for example, Streptococcus pyogenes Cas9). In one embodiment, the CRISPR / Cas system comprises a gRNA directed against a target gene and a nucleic acid encoding a Cas protein (e.g., Cas9, e.g., Streptococcus pyogenes Cas9).

[0279] Examples of genomic target sequences for which gRNAs comprising complementary targeting sequences for use in the present disclosure are listed below in Table 4a. In embodiments, the inhibitor is a nucleic acid encoding a gRNA molecule specific for BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, DR4, and DR5, wherein the nucleic acid comprises a sequence of a target sequence from Table 4a, e.g., under the control of a U6- or H1-promoter. For example, the target sequence from Table 4a can be cloned into the pLenti-CRISPR-v2 vector (SEQ ID NO: 359) available from Addgene (plasmid #52961) and follow the instructions provided by the distributor. Lentiviral vectors encoding gRNA can be prepared and used according to the instructions provided by the distributor and the methods described in Sanjana NE, Shalem O, Zhang F. Nat Methods. 2014 Aug; 11(8): 783-4.

[0280] The pLenti-CRISPR-v2 carrier also co-expresses streptococcus pyogenes Cas9 and puromycin resistance gene. Alternatively, these gRNAs are expressed from a kind of vector, and streptococcus pyogenes Cas9 is expressed from another kind of vector. The method for expressing more than a kind of gRNA from same vector is known in the art (Kabadi AM et al., Nucleic Acids Research, 2014, the 42nd volume, the 19e147th phase, 2014) and can be used in the alternative embodiment of the present disclosure.

[0281] Table 4a: gRNA target sequences within the indicated targeted genes.

[0282]

[0283]

[0284] Table 4b: Target sequences and PAM sequences of different gRNAs targeting different genes

[0285]

[0286] In addition to Cas9 / CRISP, other gene editing methods (such as TALEN and zinc finger nucleases) can be used in alternative embodiments of the present disclosure.

[0287] BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 TALENs can be used in cells to generate double-strand breaks (DSBs). If the repair mechanism does not properly repair the break via non-homologous end joining, a mutation can be introduced at the break site.

[0288] TALENs specific for sequences of genes (e.g., BRD9) can be constructed using any method known in the art, including various approaches using modular assemblies. Zhang et al. (2011) Nature Biotech. 29: 149-53; Geibler et al. (2011) PLoS ONE 6: el9509; US 8,420,782; US 8,470,973, the contents of which are incorporated herein by reference in their entirety.

[0289] Like TALEN, ZFN can produce double-strand breaks in DNA, and if improperly repaired, it can produce frameshift mutations, thereby resulting in gene (for example, BRD9) expression in cells and a reduction in amount. ZFN can also be used together with homologous recombination to introduce nucleic acids encoding CARs with mutant genes or at or near the targeted sequence. As discussed above, the nucleic acids encoding CARs can be introduced as part of template DNA. In embodiments, template DNA is further included in the 5' side, 3' side or 5' and 3' homology arms on the nucleic acid of template DNA, which encode one or more target molecules (for example, CARs described herein), wherein the homology arms are complementary to the genomic DNA sequences joined to the target sequence.

[0290] Using any method known in the art, ZFNs specific for sequences in the BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 genes can be constructed. Without being bound by theory, it is believed that the use of gene-targeting gene editing systems (e.g., CRISPR / Cas gene editing systems) can allow for the inhibition of one or more functions of the targeted gene, e.g., causing an editing event that results in the expression of a truncated gene. Again without being bound by theory, such truncated genes / proteins can retain one or more functions of the targeted gene / protein while inhibiting one or more other functions. In this regard, gene editing systems targeting late exons or introns of targeted genes can be particularly preferred. In one aspect, gene editing system targeting of the present disclosure is targeted to late exons or introns of genes (e.g., BRD9). In one aspect, when applicable, gene editing system inhibitors of the present disclosure target exons or introns downstream of exon 8.

[0291] Without being bound by theory, it may also be preferred in other embodiments that targeting is targeted early exons or introns of the gene (e.g., BRD9 gene), for example, introducing an immature stop codon in the targeted gene, which causes the gene product to not express or express a completely non-functional gene product. In this regard, targeting is targeted early exons or introns of the gene editing system can be particularly preferred. In one aspect, gene editing system BRD9 inhibitors, for example, BRD9 inhibitors of the present disclosure, target early exons or introns of the BRD9 gene. In one aspect, gene editing system targeting of the present disclosure is an exon or intron upstream of exon 4 of the targeted gene. In embodiments, gene editing system inhibitors, for example, BRD9 inhibitors, target exon 1, exon 2 or exon 3 of the targeted gene (e.g., BRD9 gene), for example, exon 3.

[0292] Without being bound by theory, in other embodiments it may also be preferred to target gene sequences that are specific for one or more isoforms of the above genes, but not affect one or more other isoforms of the above genes. In embodiments, it may be preferred to specifically target isoforms of the above genes that contain catalytic and / or signaling domains.

[0293] According to the present disclosure, double-stranded RNA ("dsRNA") (e.g., siRNA or shRNA) can be used as inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. The present disclosure also encompasses the use of nucleic acids encoding the dsRNA BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitors.

[0294] Examples of nucleic acid sequences encoding shRNA sequences are provided in Table 5. Target sequences represent sequences within BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 genomic DNA (or surrounding DNA). In embodiments, the BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitor is an siRNA or shRNA that is specific for the target sequences listed below, or specifically specific for the mRNA complement thereof. In embodiments, the inhibitor is a shRNA encoded by a nucleic acid encoding an shRNA of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2(G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 of Table 5.

[0295] In embodiments, the inhibitor is a nucleic acid comprising an shRNA for BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 of Table 5 below, For example, it is under the control of the U6 or H1 promoter to produce shRNA of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In an embodiment, the present disclosure provides an siRNA or shRNA comprising a sequence that is an RNA analog (i.e., all T nucleic acid residues are replaced with U nucleic acid residues) of the target sequence of the shRNA (e.g., the target sequence of any shRNA of Table 5).

[0296] Table 5: Sequences of shRNAs targeting different genes

[0297]

[0298] Additional dsRNA inhibitors of the above genes, eg, shRNA and siRNA molecules, can be designed and tested using methods known in the art and as described herein.

[0299] In embodiments, it may be preferred to specifically target isoforms of a gene (eg, BRD9) that contain an active domain, such as a catalytic domain or a signaling domain.

[0300] Table 6 provides the names and Cas# targeted by several other chemical inhibitors that can be used in the present disclosure to generate diverse immune effector cell populations for cell therapy purposes and to modify the effects of BiTEs and other immunotherapy agents.

[0301] Table 6. Chemical inhibitors of different genes / proteins that can be used in the methods of the present disclosure.

[0302]

[0303]

[0304] According to the present disclosure, dominant negative mutants can be used as inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In embodiments, the dominant negative mutants of the above genes lack catalytic or signaling function. An example of a dominant negative BRD9 is a protein comprising or consisting of SEQ ID NO: 1823 having a mutation Q479H, according to the numbering of SEQ ID NO: 1822. An example of a dominant-negative BRD9 is a protein comprising or consisting of SEQ ID NO: 1823 with the mutation Q479H, according to the numbering of SEQ ID NO: 1821. An example of a dominant-negative BRD9 is a protein comprising or consisting of SEQ ID NO: 1820 with the mutation N216A, according to the numbering of SEQ ID NO: 1822. In embodiments, the dominant-negative BRD9 may include a combination of any of the aforementioned mutations. An example of a dominant-negative BCOR is a protein comprising or consisting of SEQ ID NO: 1829 and 1830 with the mutations V896L and A165P, according to the numbering of SEQ ID NO: 1828. In embodiments, the dominant-negative BCOR may include a combination of any of the aforementioned mutations. An example of a dominant-negative FBXW10 is a protein comprising or consisting of SEQ ID NO: 1826 with the mutation FBXW10-D318N, according to the numbering of SEQ ID NO: 1825. An example of a dominant negative DR5 is DR5-L363N represented by SEQ ID NO: 2370.

[0305] In embodiments, inhibitors of the present disclosure are dominant negative BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 binding partners, e.g., dominant negative BRD9 binding partners or dominant negative DR5 binding partners. In other embodiments, inhibitors of the present disclosure comprise nucleic acids encoding dominant negative binding partners (e.g., dominant negative BRD9-binding proteins or dominant negative DR5-binding proteins). An example of a DR5 binding protein that can function in a dominant negative manner is a deletion mutant of FADD (Fas-associated death domain) containing amino acids 80-208 (which encode the death domain of FADD) but lacking its death effector domain (SEQ ID NO: 2463). Another example is a dominant negative mutant of Caspase 8, for example, Caspase 8D73A (SEQ ID NO: 2464).

[0306] As described herein, the present disclosure provides vectors, e.g., vectors as described herein, encoding inhibitors, such as gene editing systems, shRNA or siRNA inhibitors, or dominant-negative inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, e.g., BRD9 (e.g., as described herein).

[0307] In the embodiment further comprising, for example, CAR or TCR, the nucleic acid may further comprise a sequence encoding CAR or TCR, for example, as described herein. In certain embodiments, the present disclosure provides a vector comprising a nucleic acid sequence encoding an inhibitor described herein, and comprising a nucleic acid sequence encoding a CAR or TCR molecule described herein. In an embodiment, the nucleic acid sequence is set on an independent vector. In other embodiments, two or more nucleic acid sequences are encoded by a single nucleic acid molecule in the same frame and are encoded as a single polypeptide chain. In this regard, two or more CARs can be separated, for example, by one or more peptide cleavage sites (for example, from a cleavage site or a substrate for an intracellular protease). Examples of peptide cleavage sites include F2A (SEQ ID NO: 1845), T2A (SEQ ID NO: 1846 and 1847) and P2A (SEQ ID NO: 1848). These peptide cleavage sites are collectively referred to herein as "2A sites".

[0308] In embodiments, the vector includes a nucleic acid sequence encoding a CAR described herein and a nucleic acid sequence encoding a shRNA described herein. In embodiments, the vector includes a nucleic acid sequence encoding a CAR or TCR described herein, and a nucleic acid sequence encoding a genome editing system described herein.

[0309] The present disclosure provides a method of increasing the therapeutic effect of a cell expressing a CAR or TCR (e.g., a cell expressing a CAR or TCR as described herein, e.g., a cell expressing CAR19 (e.g., CTL019)), the method comprising reducing or eliminating the function or expression of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In embodiments, the method comprises contacting the cell with a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitor as described herein.

[0310] The present disclosure provides a method for increasing the safety of cells expressing CAR or TCR (e.g., cells expressing CAR or TCR as described herein, e.g., cells expressing CAR19 (e.g., CTL019)), the method comprising reducing or eliminating the function or expression of TRAIL and / or DR5. In embodiments, the method comprises contacting the cells with a TRAIL and / or DR5 inhibitor as described herein.

[0311] The present disclosure further provides a method of making a cell expressing a CAR and / or TCR (e.g., a cell expressing a CAR and / or TCR with improved function (e.g., with improved efficacy, e.g., tumor targeting or proliferation)), the method comprising reducing or eliminating the expression or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in the cell. In embodiments, the method includes contacting the cell with BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitors as described herein. In embodiments, the contacting is completed in vitro. In embodiments, the contacting is completed in vivo. In embodiments, the contacting is completed while or after modifying the cell to express CAR or TCR (e.g., CAR or TCR as described herein).

[0312] The present disclosure further provides a method for manufacturing cells expressing CAR and / or TCR (e.g., cells expressing CAR and / or TCR with improved safety (e.g., with less tendency to cause cytokine release syndrome or neurotoxicity), the method comprising reducing or eliminating the expression or function of TRAIL and / or DR5 as described herein. In embodiments, the method comprises contacting the cell with a TRAIL and / or DR5 inhibitor as described herein. In embodiments, the contacting is completed ex vivo. In embodiments, the contacting is completed in vivo. In embodiments, the contacting is completed while or after modifying the cell to express CAR or TCR (e.g., CAR or TCR as described herein).

[0313] In embodiments, the present disclosure provides a method for inhibiting BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 in cells expressing a CAR / TCR (e.g., expressing a CAR / TCR as described herein). A method for reducing or eliminating the function or expression of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. In embodiments, the method comprises contacting the cell with a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 inhibitor as described herein.

[0314] In one embodiment, the present disclosure provides a method, e.g., the method described above, comprising introducing a nucleic acid encoding a CAR and / or TCR into a cell (e.g., an immune effector cell, e.g., a T cell) at a site within a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 gene, or at a site within a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 gene. 3), regulatory elements of ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 genes, such that the expression of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 is disrupted. For example, using gene editing targeting BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 genes as described above The system can accomplish integration at sites within the BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 genes.

[0315] In one embodiment, the present disclosure provides a method, for example, the method described above, comprising the steps of introducing into a cell a gene editing system, for example, a CRI targeting BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5. SPR / Cas gene editing system, for example, a CRISPR / Cas system comprising gRNA, wherein the gRNA has a targeting sequence complementary to the target sequence of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5 gene. In an embodiment, the CRISPR / Cas system is introduced into the cell as a ribonucleoprotein complex of gRNA and Cas enzyme, for example, by electroporation. In one embodiment, the method includes introducing into the cell a nucleic acid encoding one or more components of the CRISPR / Cas system. In one embodiment, the nucleic acid is provided on a vector encoding a CAR and / or TCR (e.g., a CAR and / or TCR as described herein).

[0316] In one embodiment, the present disclosure provides a method, e.g., the method described above, comprising the steps of introducing into a cell an inhibitory dsRNA, e.g., shRNA or siRNA, targeting BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, e.g., BRD9. In one embodiment, the method includes introducing a nucleic acid into the cell, wherein the nucleic acid encodes inhibitory dsRNA, such as shRNA or siRNA, targeting BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL and / or DR5, e.g., BRD9. In one embodiment, the nucleic acid is provided on a vector encoding CAR and / or TCR (e.g., CAR and / or TCR as described herein).

[0317] In other embodiments, a population of immune effector cells (e.g., T cells) that have been or will be genetically engineered to express a CAR / TCR can be treated ex vivo by contacting them with an amount of a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase gene (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B) inhibitor that improves their efficacy and reduces their side effects (e.g., CRS) when administered to a subject.

[0318] In one embodiment, the T cell population lacks one or more of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B). T cells lacking BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B), including T cells that do not express BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B). b, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B) RNA or protein, or cells with reduced or inhibited activity of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B).By genetic regimen, for example, administration of RNA interference agents, such as siRNA, shRNA, miRNA, to reduce or block BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 Expression of (DR5 or TNFRSF10B) can generate BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B)-deficient cells. Alternatively, by inhibiting BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10), and / or death receptor 5 (DR5 or TNFRSF10B) as described herein. Treatment with a cytotoxic agent can generate BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B)-deficient cells.

[0319] The present disclosure further provides signal transduction molecules, such as JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF and their mutants, and their methods of use in immunity and cell therapy. Specifically, the present disclosure provides immune effector cell therapy products, for example, expressing the T cells of CAR and TCR, which include JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF and their mutants, and the purposes of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF and their mutants associated with immune effector cell therapy products (for example, CAR-T and TCR-T cells). The disclosure of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF and their mutants, and their methods of use are described in more detail below. CAR, CAR T and TCR-T cells and methods of use are further described below.

[0320] In certain embodiments, the signaling molecule can elicit one or more of the following effects in an immune cell containing the one or more constructs:

[0321] a) Enhance the proliferation of such immune effector cells

[0322] b) Regulate (increase or decrease) cytokine secretion by immune effector cells

[0323] c) Reduced dependence on exogenous cytokines for survival and proliferation

[0324] d) Enhance the cytotoxicity of immune effector cells

[0325] e) Enhance the survival of immune effector cells

[0326] f) Blocking apoptosis of immune cells

[0327] g) Delaying the aging of immune cells

[0328] h) Delaying the exhaustion of immune cells

[0329] i) Enhance the persistence of immune cells in the body when administered to patients

[0330] j) When administered to a patient, it enhances the effectiveness of immune cells in the body

[0331] In certain embodiments, the signaling molecule can be selected from JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27 (TNFRSF7, Gene ID: 939), CD28 (Gene ID: 940), 41BB (TNFRSF9, CD137; Gene ID: 3604), OX40 (TNFRSF4, Gene ID: 7293), DcR2 (TNFRSF10D, Gene ID: 8793), DcR1 (TNFRSF10C, Gene ID: 8794), BCMA (TNFRSF17, Gene ID: 608) and GITR (TNFRSF18; Gene ID: 8784) or a mutated form of any one of the foregoing.

[0332] In certain embodiments, the signaling molecule may comprise a TRAIL binding domain, e.g., the extracellular domain of DR5 (extracellular domain) (SEQ ID NO: 2392); the extracellular domain of DR4 (SEQ ID NO: 2386), the extracellular domain of DcR1 (SEQ ID NO: 2375), or the extracellular domain of DcR1 (SEQ ID NO: 2380). In certain embodiments, the protein comprising the TRAIL binding domain may be linked to an intracellular signaling domain via a transmembrane domain. In certain embodiments, the intracellular signaling domain comprises the signaling domain of CD27, CD28, 41BB, BCMA, GITR, and OX40. Table 1 lists several exemplary cytoplasmic (CP) signaling domains and several exemplary fusion proteins containing an extracellular TRAIL binding domain and a cytoplasmic signaling domain.

[0333] In certain embodiments, the signaling molecule may be JAK1 (SEQ ID NO: 374 and SEQ ID NO: 1804) or a homolog or ortholog thereof.

[0334] In certain embodiments, the signaling molecule may be a mutated form of JAK1 or a homolog or ortholog thereof, optionally wherein the mutation:

[0335] i) results in altered signaling compared to wild-type JAK1 (e.g., phosphorylation of STATs)

[0336] ii) Leading to constitutively active signaling

[0337] Exemplary amino acids that may be mutated in JAK1 include one or more of amino acids V658 and / or S703

[0338] Exemplary amino acid substitutions in JAK1 that result in altered signaling include V658F (SEQ ID NO: 375) and S703I (SEQ ID NO: 376)

[0339] iii) resulting in a nucleic acid sequence encoding an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NO: 1804, 1805 or 1806;

[0340] In certain embodiments, the signaling molecule may be a mutated form of JAK3 or a homolog or ortholog thereof, optionally wherein the mutation

[0341] i) results in altered signaling (e.g., phosphorylation of STATs) compared to wild-type JAK3

[0342] ii) Leading to constitutively active signaling

[0343] Exemplary amino acids that can be mutated in JAK3 (DNA SEQ ID NO: 360 and protein SEQ ID NO: 1790) to result in altered signaling include one or more of M511, A573, R657, Q507, G491, V674, and V678.

[0344] Exemplary amino acid substitutions in JAK3 (DNA SEQ ID NO: 360 and protein SEQ ID NO: 1790) that result in altered signaling include one or more of M511, A573, R657, Q507, G491, V674, V678, M511I, A573V, R657W, Q507P, G491S, V674A, V678L

[0345] iii) the nucleic acid sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NOs: 1790-1797.

[0346] In certain embodiments, the signaling molecule may be Stat5b (NM_012448.3; SEQ ID NO: 368) or a homolog or ortholog thereof.

[0347] In certain embodiments, the signaling molecule may be a mutated form of Stat5b or a homolog or ortholog thereof, optionally wherein the mutation:

[0348] i) results in altered signaling compared to wild-type Stat5b

[0349] ii) Leading to constitutively active signaling

[0350] Exemplary amino acids in Stat5b (DNA SEQ ID NO: 368 and protein SEQ ID NO: 1798) that can be mutated to result in altered signaling include one or more of T628, N642, Y665, Q706, R659, I704, E579.

[0351] Exemplary amino acid substitutions in Stat5b (DNA SEQ ID NO: 368 and protein SEQ ID NO: 1798) that result in altered signaling include one or more of T628S (SEQ ID NO: 1799), N642H (SEQ ID NO: 1800), Y665F (SEQ ID NO: 1801), Q706L (SEQ ID NO: 1802), R659C (SEQ ID NO: 1803), I704L, and E579K.

[0352] iii) the nucleic acid sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NOs: 1798-1803.

[0353] In certain embodiments, the signaling molecule may be Stat3 or a homolog or ortholog thereof.

[0354] In certain embodiments, the signaling molecule may be a mutated form of Stat3 or a homolog or ortholog thereof, optionally wherein the mutation:

[0355] i) results in altered signaling compared to wild-type Stat3

[0356] ii) Leading to constitutively active signaling

[0357] Exemplary amino acids in Stat3 (DNA SEQ ID NO: 380 and protein SEQ ID NO: 1810) that can be mutated to result in altered signaling include one or more of D661, Y640, A702, S614, and G618.

[0358] Exemplary amino acid substitutions in Stat3 (DNA SEQ ID NO: 380 and protein SEQ ID NO: 1810) that result in altered signaling include one or more of D661Y (SEQ ID NO: 1811), Y640F (SEQ ID NO: 1812), A702T (SEQ ID NO: 1813), S614R (SEQ ID NO: 1814), and G618R (SEQ ID NO: 1815).

[0359] iii) the nucleic acid sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NOs: 1810-1815.

[0360] In certain embodiments, the signaling molecule can be BRAF (eg, NM_004333.4) or a homolog or ortholog thereof.

[0361] In certain embodiments, the signaling molecule may be a mutated form of BRAF or a homolog or ortholog thereof, optionally wherein the mutation:

[0362] i) results in altered signaling compared to wild-type BRAF (Examples provided)

[0363] ii) Leading to constitutively active signaling

[0364] Exemplary amino acids in BRAF (DNA SEQ ID NO: 388 and protein SEQ ID NO: 1818) that can be mutated to result in altered signaling include one or more of V600, K601, and E586.

[0365] Exemplary amino acid substitutions in BRAF (DNA SEQ ID NO: 388) and protein SEQ ID NO: 1818) that result in altered signaling include one or more of V600E (SEQ ID NO: 1819), V600D, V600K, V600R, V600any, K601E, K601any, E586K.

[0366] iii) the nucleic acid sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% identical to the amino acid sequence of SEQ ID NOs: 1818-1819.

[0367] In certain embodiments, the signaling molecule can be CARD11 (eg, CARDIAC®) or a homolog or ortholog thereof.

[0368] In certain embodiments, the signaling molecule may be a mutated form of CARD11 or a homolog or ortholog thereof, optionally wherein the mutation:

[0369] i) results in altered signaling compared to wild-type CARD11

[0370] ii) Leading to constitutively active signaling

[0371] Exemplary amino acids that can be mutated in CARD11 (DNA SEQ ID NO: 377 and protein SEQ ID NO: 1807) to result in altered signaling include one or more of S615 and E626.

[0372] Exemplary amino acid substitutions in CARD11 (DNA SEQ ID NO: 377 and protein SEQ ID NO: 1807) that result in altered signaling include one or more of S615F (SEQ ID NO: 1808) and E626K (SEQ ID NO: 1809).

[0373] iii) the nucleic acid sequence encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 1807-1809, or the amino acid sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NOs: 1807-1809;

[0374] Where the foregoing mutations are indicated with respect to human sequences, it is intended to further include mutations corresponding or analogous to homologous or orthologous residues or domains of homologs or orthologs, e.g., mouse JAK1, JAK3, STAT5b, BRAF or CARD11.

[0375] In certain embodiments, the T cells ectopically express or overexpress wild-type or mutant forms of one or more genes selected from the group consisting of: JAK1 (SEQ ID NOs: 371-374), JAK3 (SEQ ID NOs: 360-367), STAT5b (SEQ ID NOs: 368-373), STAT3 (SEQ ID NOs: 380-385), IL2RG (SEQ ID NOs: 386-387), CARD11 (SEQ ID NOs: 377-379), BRAF (SEQ ID NOs: 381-383), IL-2RG (SEQ ID NOs: 387-388), IL-3RG (SEQ ID NOs: 389-390), IL-4RG (SEQ ID NOs: 391-392), IL-5RG (SEQ ID NOs: 393-394), IL-6RG (SEQ ID NOs: 397-398), IL-7RG (SEQ ID NOs: 399-400), IL-8RG (SEQ ID NOs: 401-402), IL-9RG (SEQ ID NOs: 403-404), IL-11RG (SEQ ID NOs: 405-406), IL-12RG (SEQ ID NOs: 407-408), IL-13RG (SEQ ID NOs: 408-409), IL-14RG (SEQ ID NOs: 410-411), IL-15RG (SEQ ID NOs: 411-412), IL-17RG (SEQ ID NOs: NO: 388-389), CD27 (TNFRSF7, gene ID: 939), CD28 (gene ID: 940), 41BB (TNFRSF9, CD137; gene ID: 3604), OX40 (TNFRSF4, gene ID: 7293), DcR2 (TNFRSF10D, gene ID: 8793), DcR1 (TNFRSF10C, gene ID: 8794), BCMA (TNFRSF17, gene ID: 608) and GITR (TNFRSF18; gene ID: 8784). Using the methods described herein, for example, using lentiviral-mediated gene transfer, or transfection of DNA or RNA encoding the corresponding genes, T cells that ectopically express wild-type and mutant forms of the above genes can be generated.

[0376] The present disclosure further provides a vector comprising a sequence encoding a wild-type or constitutively active mutant form of a JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR gene or a TRAIL antagonist.

[0377] In certain embodiments, expression of nucleic acids encoding wild-type or constitutively active mutant forms of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR genes, or a TRAIL antagonist, can be regulated by a constitutive or inducible promoter.

[0378] The present disclosure further provides a vector comprising a sequence encoding an immune receptor, and a sequence encoding a wild-type or constitutively active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF and / or a wild-type and / or mutant of CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR gene.

[0379] In one embodiment, the sequence encoding the immune receptor and the sequence encoding the wild-type or constitutively active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF and / or the wild-type and / or mutant of CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR genes are separated by a 2A sequence. Several exemplary nucleic acid sequences encoding CAR / TCRs, 2A sequences and constitutively active mutants of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF are represented by SEQ ID NOs: 484-499.

[0380] These nucleic acid sequences can be cloned into suitable vectors (e.g., vectors described herein) for expression in immune cells. Other CAR / TCR and JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF wild-type and mutant and / or CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR genes can be similarly constructed to encode wild-type and / or mutant vectors.

[0381] The present disclosure further provides a vector comprising a sequence encoding an immune receptor and a sequence encoding a TRAIL antagonist. Several exemplary nucleic acid sequences encoding CAR / TCR, 2A sequences and TRAIL antagonists are represented by SEQ ID NOs: 2853-2863, 2865-2875, 2877-2887, 2889-2899, 2901-2911, 2913-2923, 2925-2935. The present disclosure further provides a vector comprising a sequence encoding a TRAIL antagonist, which can be used for genetically modifying immune cells, e.g., immune effector cells.

[0382] The present disclosure further provides a vector comprising a sequence encoding an immune receptor and a sequence encoding a mutant form of TRAIL receptor DR5, DR4, DcR1 and DcR2. The present disclosure further provides a vector comprising a sequence encoding a fusion protein of TRAIL receptor DR5 (SEQ ID NO: 2318-2330), DR4 (SEQ ID NO: 2331-2337), DcR1 (SEQ ID NO: 2338-2344) and DcR2 (SEQ ID NO: 2345-2351), which can be used to genetically modify immune cells, e.g., effector cells, to block or alter the activity of physiological TRAIL receptors.

[0383] In certain embodiments, the nucleic acid encoding the CAR / TCR and the nucleic acid encoding a wild-type or constitutively active mutant form of a JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR gene or a TRAIL antagonist can be on the same vector.

[0384] In certain embodiments, the nucleic acid encoding the CAR / TCR and the nucleic acid encoding a wild-type or constitutively active mutant form of a JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR gene or a TRAIL antagonist can be on different vectors.

[0385] In certain embodiments, the expression of the nucleic acid encoding the CAR / TCR and the nucleic acid encoding the wild-type or constitutively active mutant form of the JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR gene or a TRAIL antagonist can be regulated by different constitutive or inducible promoters.

[0386] In certain embodiments, expression of the nucleic acid encoding the CAR / TCR and the nucleic acid encoding a wild-type or constitutively active mutant form of a JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA and / or GITR gene or a TRAIL antagonist can be regulated by the same constitutive or inducible promoter.

[0387] In certain embodiments, the present disclosure provides cells that express an immune receptor (e.g., CAR, SIR, TFP, Ab-TCR, or TCR) and ectopically express or overexpress wild-type or mutant forms of one or more genes among JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, and / or BRAF and / or wild-type and / or mutant forms of CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR.

[0388] In certain embodiments, the cells of the present disclosure include immune receptors (e.g., CAR, SIR, TFP, Ab-TCR or TCR), and mutant forms of one or more genes in JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF. In certain embodiments, the cells of the present disclosure include immune receptors (e.g., CAR, SIR, TFP, Ab-TCR or TCR), and ectopic expression or overexpression of one or more genes in CD27, CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR. In certain embodiments, the immune cells (e.g., immune effector cells) also co-express BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, an inhibitor of TRAIL and / or DR5.

[0389] In one aspect, the present disclosure provides a method for changing the phenotype, differentiation state and / or therapeutic effect of immune cells (e.g., cells expressing immune receptors, e.g., cells of any one of the preceding claims, e.g., cells expressing CAR19), the method comprising increasing JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27, CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR in the cells and / or the step of activity. In certain embodiments, the steps include expressing wild type or constitutive active mutants of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and BRAF in the cells. In certain embodiments, the steps include expressing wild type or mutants of CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR in the cells.

[0390] In certain embodiments, wild-type and / or constitutively active mutants of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR of the present disclosure are ectopically expressed in cells as follows: 1) by introducing nucleic acid sequences (DNA or mRNA) encoding their wild-type or constitutively active mutants; 2) by altering one or more endogenous alleles using homologous recombination at a genomic locus. In certain embodiments, the immune cells (e.g., immune effector cells) also co-express BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, an inhibitor of TRAIL and / or DR5.

[0391] In one aspect, the present disclosure provides a method for increasing the diversity of cells expressing immune receptors (e.g., cells of any one of the preceding claims, e.g., cells expressing CAR19), the method comprising changing the expression and / or activity of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27, CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR in the cells. In certain embodiments, the steps include expressing wild-type or constitutively active mutants of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, and BRAF in the cells. In certain embodiments, the steps include expressing wild-type or mutants of CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR in the cells.

[0392] In certain embodiments, wild-type and / or constitutively active mutants of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR of the present disclosure are ectopically expressed in cells as follows: 1) by introducing nucleic acid sequences (DNA or mRNA) encoding their wild-type or constitutively active mutants; 2) by altering one or more endogenous alleles using homologous recombination at a genomic locus. In certain embodiments, the immune effector cells also co-express BRD9, EZH2, MLL2, MLL3, MLL4, an inhibitor of methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5.

[0393] In certain embodiments, genes and / or chemical inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, and / or wild-type and / or mutants of the signaling molecules JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, and / or BRAF, and / or CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR, may cause one or more of the following effects in immune cells:

[0394] 1. Enhance the proliferation of such immune effector cells

[0395] 2. Alteration of cytokine secretion by immune effector cells

[0396] 3. Reduce the dependence of survival and proliferation on exogenous cytokines

[0397] 4. Enhance the cytotoxicity of immune effector cells

[0398] 5. Enhance the survival of immune effector cells

[0399] 6. Blocking apoptosis of immune cells

[0400] 7. Delaying the aging of immune cells

[0401] 8. Delaying the exhaustion of immune cells

[0402] 9. When administered to patients, enhances the persistence of immune cells in the body

[0403] 10. When administered to patients, it enhances the effectiveness of immune cells in the body

[0404] 11. Enhance the penetration of immune cells into diseased organs or tissues (e.g., tumors)

[0405] 12. Prevent or ameliorate toxicities caused by administration of immune cells (e.g., CRS and neurotoxicity)

[0406] In one aspect, the present disclosure provides a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a cell as described herein, e.g., an immune cell, e.g., an immune effector cell (e.g., a T cell or a NK cell), comprising an immune receptor and co-expressing a constitutively active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF and / or wild type and / or mutant of CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR.

[0407] In one aspect, the present disclosure provides a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a cell as described herein, e.g., an immune effector cell (e.g., a T cell or a NK cell), the cell comprising an immune receptor and co-expressing a constitutively active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF and / or wild-type and / or mutant CD28, 41BB, OX40, DcR2, DcR1, BCMA and GITR. The subject is administered an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5.

[0408] In certain embodiments, the subject receives pretreatment with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5 prior to initiation of immunotherapy and / or cell therapy comprising a constitutively active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, and / or BRAF, and / or wild type and / or mutant of CD28, 41BB, OX40, DcR2, DcR1, BCMA, and GITR. In certain embodiments, the subject receives concurrent treatment with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5, and immune and / or cellular therapy. In certain embodiments, following administration of the immune and / or cell therapy, the subject is treated with an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5.

[0409] Provided herein are compositions and methods of use of materials for use in cell therapy products (e.g., T cells, NK cells) engineered with chimeric antigen receptor (CAR) genes, or natural or natural TCRs, for treating diseases such as cancer and immune disorders. In certain embodiments, the cells are genetically engineered to express CAR. The disclosure is not limited by CAR types. CAR as described herein encompasses the second generation CAR and next generation CAR (e.g., SIR, zSIR, Ab-TCR, and TFP) described in PCT / US2017 / 024843, WO 2014 / 160030 A2, WO 2016 / 187349 A1, PCT / US2016 / 058305, and PCT / US17 / 64379, which are incorporated herein by reference in their entirety. It should be noted that similar compositions of matter and methods of use can be used to treat diseases such as cancer and immune disorders using other immune effector cells (e.g., T cells), such as tumor infiltrating lymphocytes (TIL) or T cells engineered with recombinant TCR genes.

[0410] The sequences of some examples of the various components of the CARs (conventional and next-generation CARs) of the present disclosure are listed in Table 7a. Table 7a also lists the SEQ ID NOs of the DNA and proteins of several exemplary conventional CARs and next-generation CARs. Finally, Table 7a lists the SEQ ID NOs of the DNA and proteins of several exemplary conventional CARs, next-generation CARs, and TCRs, which also encode accessory modules comprising signaling proteins. For example, the construct CD8SP-FMC63-(vL-vH)-Myc-BBz-T2A-JAK3-M511I represented by SEQ ID NO (DNA): 484 and SEQ ID NO (protein): 1911, respectively, is a second-generation CAR comprising a CD8 signal peptide, a scFv fragment derived from the FMC63 monoclonal antibody targeting CD19, a Myc epitope tag, a 41BB costimulatory domain, a CD3z signaling domain, a T2A cleavage site, and a JAK3-M511I mutant. The constructs represented by DNA SEQ ID NOs: 485-490 and protein SEQ ID NOs: 1912-1917, respectively, have similar designs, except that the JAK3-M511I module is replaced with JAK3-A573V, STAT5b-T658F, JAK1-V658F, CARD11-S615F, STAT3-Y640F, and BRAF-V600E, respectively. The construct CD8SP-FMC63-vL-V5-[hTCRb-KACIAH]-F-P2A-SP-FMC63-vH-Myc-[hTCRa-CSDVP]-F-F2A-JAK3-M511I (SEQ ID NOs: 491 and 1918) is a double-chain SIR (synthetic immunoreceptor) targeting CD19 and co-expressing JAK-M511I. The construct CD8SP-FMC63-(vL-vH)-Myc-z-P2A-JAK3-M511I (SEQ ID NOs: 492 and 1919) is a first-generation CAR that co-expresses JAK3-M511I. The constructs represented by SEQ ID NOs: 493-496 are TFPs that target CD19 and co-express JAK3-M511I.Constructs CD8SP-FMC63-vL-[IgCL-TCRb-IAH-6MD]-F-P2A-SP-FMC63-vH-[IgG1-CH1-TCRa-SDVP-6MD]-F-F2A-JAK3-M511I (SEQ ID NOs: 497 and 1924) and CD8SP-FMC63-vL-[IgCL-TCRg-6MD]-F-P2A-SP-FMC63-vH-[IgG1-CH1-TCRd-6MD]-F-F2A-JAK3-M511I (SEQ ID NOs: 498 and 1925) are two antibody-TCRs (Ab-TCRs) that target CD19 and co-express JAK3-M511I. The construct NY-ESO-TCRa-F-P2A-NYESO-[hTCRb]-F-F2A-JAK3-M511I (SEQ ID NOs: 499 and 1926) is a recombinant TCR that targets the NY-ESO / HLA-A2 complex and co-expresses M511I. Table 7a also lists the SEQ ID NOs of several exemplary CARs, next-generation CARs, and TCRs expressing different TRAIL antagonists (e.g., DR5-Fc and DR5-fusion proteins). The above constructs represent exemplary constructs. The accessory module M511I can be replaced with other accessory modules of the present disclosure listed in Table 1 by methods known in the art. Similarly, the CD19 antigen binding domain (e.g., FMC63 scFv) can be replaced with antigen binding domains targeting other antigens by methods known in the art. Patent applications PCT / US2017 / 024843, WO 2014 / 160030 A2, WO 2016 / 187349 A1, PCT / US2016 / 058305, and PCT / US17 / 64379 describe conventional and next-generation CARs targeting several antigens.

[0411] Table 7a. SEQ IDs of nucleic acids and proteins of conventional and next-generation CARs and CAR components

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419] Table 7B: Nucleic acid vectors and components

[0420]

[0421]

[0422] Table 7C: Exemplary CAR / TCR constructs

[0423] Target antigen Name of CAR / TCR construct SEQ ID NO CD19 CD8SP-FMC63-(vL-vH)-Myc-BBz 2822 BCMA CD8SP-BCMA-J6M0-(vL-vH)-Myc-BBz 2823 CD20 CD8SP-CD20-2F2-(vL-vH)-Myc-BBz 2824 CD123 CD8SP-CD123-1172-(vL-vH)-Myc-BBz 2825 CS1 CD8SP-CS1-HuLuc64-(vL-vH)-Myc-BBz 2826 Folate receptor 1 CD8SP-FR1-huMov19-(vL-vH)-Myc-BBz 2827 GM1 CD8SP-GM1-5B2-(vL-vH)-Myc-BBz 2828 IL13Ra2 CD8SP-IL13Ra2-hu107-(vL-vH)-Myc-BBz 2829 IL13Ra2 CD8SP-IL13Ra2-Hu108-(vL-vH)-Myc-BBz 2830 Her2 CD8SP-Her2-Hu4D5-(vL-vH)-Myc-BBz 2831 Mesothelin CD8SP-mesothelin-m912-(vH-vL)-Myc-BBz 2832 MPL CD8SP-MPL-161-(vL-vH)-Myc-BBz 2833 WT1 / MHC I CD8SP-WT1-Ab1-(vL-vH)-Myc-BBz 2834 AFP / MHC complex CD8SP-AFP-76-(vL-vH)-Myc-BBz 2835 NY-ESO / MHC complex NY-ESO-[TCRa]-F-P2A-NYESO-[hTCRb] 2836

[0424] Table 7D: SEQ ID NOs of extracellular domains of proteins that can be expressed on APCs (antigen presenting cells) or conjugated to antigen presenting substrates (APS)

[0425]

[0426]

[0427] The present disclosure provides cell therapy products (e.g., immune effector cells, e.g., T cells, NK cells, CAR-T cells, TCR-T cells) that are genetically modified to contain one or more CARs (or TCRs) targeting cells that cause disease or are associated with the disease (such as cancer cells). This is achieved by having an antigen binding domain specific for cancer-associated antigens on the CAR or TCR. There are two types of cancer-associated antigens (tumor antigens) that can be targeted by CAR and / or TCR: (1) cancer-associated antigens expressed on the surface of cancer cells; and (2) cancer-associated antigens themselves in the cell, but fragments of such antigens (peptides) are presented on the surface of cancer cells by MHC (major histocompatibility complex).

[0428] Thus, cell therapy products (e.g., immune cells) expressing the CARs of the present disclosure can target one or more of the following cancer-associated antigens (tumor antigens): CD5, CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemias or lymphomas but not on hematopoietic progenitor cells, glycosylated CD43 epitope expressed on non-hematopoietic cancers, carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-1 lRa); prostate stem cell antigen (PSCA); testisin serine 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); mutated elongation factor 2 (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); proteasome (macropain) subunit, beta type, 9 (LMP2); glycoprotein 100 (gpl00); oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type A receptor 2 (EphA2);Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7) R); claudin 6 (CLDN6); thyroid-stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); the hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation variant gene 6 on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC);Tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B 1 (CYP1B 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of the IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A, member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL, biotin, c-MYC epitope tag, CD34, LAMP1TROP2, GFRα4, CDH17, CDH6, NYBR1, CDH19, CD200R, Slea (CA19.9;Sialyl Lewis antigen) fucosyl-GM1, PTK7, gpNMB, CDH1-CD324, DLL3, CD276 / B7H3, IL11Ra, IL13Ra2, CD179b-IGLl1, ALK TCRγ-δ, NKG2D, CD32 (FCGR2A), CSPG4-HMW-MAA, Tim1- / HVCR1, CSF2RA (GM-CSFR-α), TGFβR2, VEGFR2 / KDR, LewsAg, TCR-β1 chain, TCR-β2 chain, TCR-γ chain, TCR-δ chain, FITC, luteinizing hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR), chorionic gonadotropin hormone receptor (CGHR), CCR4, SLAMF6, SLAMF4, HIV1 envelope glycoprotein, HTLV1-Tax, CMV pp65, EBV-EBNA3c, influenza A hemagglutinin (HA), GAD, PDL1, guanylate cyclase C (GCC), KSHV-K8.1 protein, KSHV-gH protein, autoantibodies to desmoglein 3 (Dsg3), autoantibodies to desmoglein 1 (Dsg1), HLA, HLA-A, HLA-A2, HLA-B, HLA-C, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, HLA-DR, HLA-G, IGE, CD99, RAS G12V, tissue factor 1 (TF1), AFP, GPRC5D, claudin 18.2 (CLD18A2 or CLDN18A.2), P-glycoprotein, STEAP1, LIV1, nectin-4, CRIPTO, MPL, GPA33, BST1 / CD157, low-conductance chloride channel, integrin B7, Muc17, C16ORF54, VISTA, Muc5Ac, FCRH5, CLDN6, MMP16, UPK1B, BMPR1B, Ly6E, WISP1, and SLC34A2.

[0429] The SEQ ID NOs of several exemplary CAR / TCRs are listed in Table 7C.

[0430] CAR can comprise an antigen binding domain (e.g., an antibody or antibody fragment, a TCR or a TCR fragment) that binds to a tumor-supporting antigen (e.g., a tumor-supporting antigen as described herein). In certain embodiments, the tumor-supporting antigen is an antigen presented on stromal cells or bone marrow-derived suppressor cells (MDSCs).

[0431] The present disclosure encompasses recombinant DNA constructs comprising sequences encoding natural (e.g., TCR) or synthetic immune receptors (e.g., 2nd generation CARs or SIRs).

[0432] In a specific aspect, the CAR can comprise a scFv domain, wherein the scFv can be preceded by an optional leader sequence (such as provided in SEQ ID NO(protein): 1834 and 1835) and followed by an optional hinge sequence and transmembrane region (such as provided in SEQ ID NO: 1854), an intracellular signaling domain comprising SEQ ID NO: 1857, and a CD3 zeta sequence comprising SEQ ID NO: 1857 or SEQ ID NO: 1858, e.g., wherein the aforementioned domains are contiguous and in the same reading frame to form a single fusion protein.

[0433] An exemplary leader sequence is provided as SEQ ID NO:1834.

[0434] An exemplary hinge and transmembrane domain sequence is provided as SEQ ID NO: 1854. An exemplary sequence of the intracellular signaling domain of the 4-1BB protein is provided as SEQ ID NO: 1857. An exemplary CD3 zeta domain sequence is provided as SEQ ID NO: 1858 or SEQ ID NO: 1859.

[0435] The exemplary second generation CAR targeting CD19 is presented in SEQ ID NO: 1903 and 1904. These CAR constructs also encode a puromycin resistance gene (PAC), which is separated from the CAR polypeptide by a T2A cleavage sequence. The names and SEQ IDs of exemplary second generation CARs targeting CD19 and co-expressing JAK3 (SEQ ID NO: 1911 and 1912), STAT5b (SEQ ID NO: 1913), JAK1 (SEQ ID NO: 1914), CARD11 (SEQ ID NO: 1915), STAT3 (SEQ ID NO: 1916) and BRAF (SEQ ID NO: 1917) constitutively active mutants are shown in Table 7a.

[0436] The present disclosure also encompasses immune effector cells expressing next-generation CAR constructs, including K13 (vFLIP) -CAR, SIR (synthetic immune receptor), Ab-TCR, and TFP. Exemplary K13 co-expressing CAR constructs are represented by SEQ ID NOs: 1908 and 1909. These CAR constructs also co-express a puromycin resistance gene (PAC), which is optional and can be deleted. Exemplary SIR constructs co-expressing an optional PAC gene are represented by SEQ ID NOs: 1906 and 1907.

[0437] The names and SEQ IDs of exemplary SIRs (SEQ ID NO: 1918), K13-CARs (SEQ ID NO: 1919), Ab-TCRs (SEQ ID NO: 1924-1925), and TFPs (SEQ ID NO: 1920-1922) that target CD19 and co-express constitutively active mutants of the JAK3-M511I mutant are shown in Table 7a. By replacing the cDNA encoding JAK3-M511I with the cDNA corresponding to the other constitutively active mutants, constructs that co-express other constitutively active mutants can be constructed. The present disclosure includes retroviral and lentiviral vector constructs (SEQ ID NO: 337 and 338) that can be used in various embodiments of the present disclosure.

[0438] The present disclosure also includes RNA constructs that can be directly transfected into cells. A method for producing mRNA used for transfection includes, using specially designed primers to transcribe in vitro (IVT) templates, followed by adding poly A, to produce a construct containing 3' and 5' untranslated sequences ("UTR") (e.g., 3' and / or 5'UTR described herein), 5' caps (e.g., 5' caps described herein) and / or internal ribosome entry sites (IRES) (e.g., IRES described herein), nucleic acids to be expressed and poly A tails (usually 50-2000 base lengths) (SEQ ID NO: 341). The RNA so produced can effectively transfect different types of cells. In one embodiment, the template includes the sequence of CAR. In one embodiment, RNA CAR vectors are transduced into cells, e.g., T cells or NK cells, by electroporation.

[0439] CAR / TCR includes a target-specific binding element, which is additionally referred to as an antigen binding domain. Conventional and next-generation CARs (e.g., SIR, Ab-TCR, TFP, etc.) for many antigens have been described in the art, including in patent applications PCT / US2017 / 024843 and PCT / US17 / 64379, which are incorporated herein by reference in their entirety. The CAR described in these applications can be used in combination with the methods of the present invention to target different antigens for the prevention and treatment of a variety of disease conditions, in which cells associated with the disease or causing the disease express specific antigens targeted by CAR. Similarly, TCRs targeting different antigens and neoantigens are known in the art and can be used in combination with the methods of the present invention. Finally, by using the methods of the present invention, the efficacy and safety of tumor-infiltrating lymphocytes and T cells produced after vaccination with neoantigen peptides can be improved.

[0440] In one embodiment, the antigen binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3 from the antibodies listed above and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3 from the antibodies or single chain variable fragments described in PCT / US2017 / 024843 and PCT / US17 / 64379. In another aspect, the antigen binding domain is a cytokine, receptor, centryn, or non-immunoglobulin antigen binding domain.

[0441] In another aspect, the cell therapy products described herein (e.g., CAR-T cells) can further express another agent, e.g., an agent that enhances the activity of the cell therapy product (e.g., cells expressing CAR). For example, in one embodiment, the agent can be a constitutively active mutant of JAK3 (SEQ ID NOs: 1911 and 1912), STAT5b (SEQ ID NO: 1913), JAK1 (SEQ ID NO: 1914), CARD11 (SEQ ID NO: 1915), STAT3 (SEQ ID NO: 1916), and BRAF (SEQ ID NO: 1917). In another embodiment, the agent can be an inhibitor of BRD9, EZH2, MLL2, MLL3, MLL4, a methylcytosine dioxygenase gene (e.g., Tetl, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL, and / or DR5.

[0442] In another aspect, the present disclosure provides a cell population therapy product, e.g., CAR-T and / or TCR-T cells. In certain embodiments, the cell therapy product comprises a mixture of cells expressing different CARs.

[0443] In another aspect, the present disclosure provides a kind of cell colony, wherein at least one cell in the colony expresses CAR, and the CAR has an antigen binding domain to cancer associated antigen described herein, and the second cell expresses another kind of agent, for example, the agent for enhancing the activity of the cell expressing CAR.In one aspect, the present disclosure provides a method, which includes administering in combination with another agent (for example, kinase inhibitors, such as kinase inhibitors described herein) the cell (for example, CART cells) colony expressing CAR, for example, the mixture of cells expressing different CAR.In another aspect, the present disclosure provides a method, which includes administering in combination with another agent (for example, kinase inhibitors, such as kinase inhibitors described herein) the cell colony, wherein at least one cell in the colony expresses CAR, the CAR has the antigen binding domain of cancer associated antigen described herein, and the second cell expresses another kind of agent, for example, the agent for enhancing the activity of the cell expressing CAR.

[0444] Methods known in the art can be used to deliver nucleic acids encoding different constructs of the present disclosure (e.g., constitutive activity and dominant negative mutants of CAR, SIR, TCR, JAK3, STAT5, etc.) to cells. A method for producing mRNA used for transfection can include transcribing the template in vitro (IVT) with specially designed primers, followed by adding polyadenylic acid to produce a construct (SEQ ID NO: 32) containing 3' and 5' untranslated sequences ("UTR"), 5' caps and / or internal ribosome entry sites (IRES), nucleic acids to be expressed, and polyadenylic acid tails (usually 50-2000 bases in length). The RNA so produced can effectively transfect different types of cells. In one embodiment, the template includes the sequence of CAR.

[0445] In some aspects, non-viral methods can be used to deliver nucleic acids encoding the different constructs described herein into cells or tissues or subjects. In certain embodiments, the non-viral methods include the use of transposons (also referred to as transposable elements). Exemplary nucleic acid delivery methods using transposons include the Sleeping Beauty transposon system (SETS) and the piggyBac (PB) transposon system.

[0446] Methods for constructing and delivering vectors with different CAR configurations, including next-generation CARs, are known in the art and are described in patent applications PCT / US2017 / 024843, WO 2014 / 160030 A2, WO 2016 / 187349 A1, PCT / US2016 / 058305, and PCT / US17 / 64379, which are incorporated herein by reference in their entireties.

[0447] The present disclosure also provides vectors into which the DNA of the present disclosure is inserted. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they allow for long-term stable integration of transgenes and their propagation in daughter cells.

[0448] In the manufacturing process of cell therapy products, immune effector cells (e.g., T cells) can generally be activated and propagated using methods known in the art. Typically, immune effector cell populations (e.g., cells mobilized by plerixafor) are propagated by contact with a surface having attached thereto reagents that stimulate CD3 / TCR complex-related signals and ligands that stimulate costimulatory molecules on the T cell surface.

[0449] In some aspects, the primary stimulation signal and the costimulatory signal of T cell can be provided by different schemes.For example, the reagent providing every kind of signal can be in solution or coupled to surface.When coupled to surface, reagent can be coupled to same surface (that is, with " cis " form) or coupled to separate surface (that is, with " trans " form).Alternatively, a kind of reagent can be coupled to surface, and another kind of reagent is made in solution.

[0450] The present disclosure provides novel antigen presenting cells for activating and propagating immune cells in the manufacturing process of cell therapy products. In one embodiment, cells transduced with nucleic acid encoding CAR (e.g., CAR, e.g., SIR) are propagated by co-culturing with antigen presenting cells. In one embodiment, T cells transduced with nucleic acid encoding CAR (e.g., CAR described herein) are propagated by co-culturing with cells expressing antigens targeted by CAR. In one embodiment, T cells are transduced with nucleic acid encoding CAR and propagated by co-culturing them with cells and / or cell lines derived from mantle cell lymphoma. In one embodiment, T cells are transduced with nucleic acid encoding CD19 CAR (e.g., CD19 CAR described herein, e.g., CAR represented by SEQ ID NO: 2822, 479, 484-498), and propagated by co-culturing them with cells and cell lines derived from mantle cell lymphoma. In one embodiment, T cells are transduced with nucleic acids encoding CD20 CAR (e.g., CD20 CAR described herein, e.g., CAR represented by SEQ ID NO: 2824, 480, or 482) and propagated by co-culturing them with cells and cell lines derived from mantle cell lymphoma. In one embodiment, T cells are transduced with nucleic acids encoding CD22 CAR (e.g., CD22 CAR described herein) and propagated by co-culturing them with cells and cell lines derived from mantle cell lymphoma. In one embodiment, T cells are transduced with nucleic acids encoding BCMA CAR (e.g., BCMA CAR described herein, e.g., CAR represented by SEQ ID NO: 2823) and propagated by co-culturing them with cells and cell lines derived from mantle cell lymphoma. Exemplary cell lines derived from mantle cell lymphoma that can be used to propagate and / or activate CAR-T cells targeting CD19, CD20, CD22, and BCMA include REC-1, GRANTA-519, MINO, and JEKO. In a preferred embodiment, the mantle cell lymphoma cell line is REC-1.

[0451] In one embodiment, T cells are transduced with nucleic acid encoding CAR and propagated by co-culturing them with cells and cell lines that have been treated with drugs (e.g., mitomycin) or irradiation to prevent them from replicating. Methods for making cells and cell lines unable to replicate are known in the art and / or can be determined using methods known in the art.

[0452] In one embodiment, T cells are propagated in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days). In one embodiment, the cells are propagated for a period of 4-9 days. In one embodiment, the cells are propagated for a period of 8 days or less, e.g., 7, 6, or 5 days.

[0453] In one embodiment, cells (e.g., CD19 CAR-T cells described herein) are propagated in culture for 5 days, and the resulting cells are more effective than the same cells propagated in culture for 9 days under the same culture conditions. In one embodiment, CAR-T cells (e.g., CD19 CAR-T cells described herein) are propagated in culture together with mantle cell lymphoma cells (e.g., REC-1 cells) for 14 days, and the resulting cells are more effective than the same CAR-T cells (e.g., CD19 CAR-T cells described herein) propagated in culture under the same culture conditions but without mantle cell lymphoma cells (e.g., REC-1 cells). In one embodiment, CAR-T cells (e.g., CD20 CAR-T cells described herein) are propagated in culture together with mantle cell lymphoma cells (e.g., REC-1 cells) for 14 days, and the resulting cells are more effective than the same CAR-T cells (e.g., CD20 CAR-T cells described herein) propagated in culture under the same culture conditions but without mantle cell lymphoma cells (e.g., REC-1 cells). In one embodiment, CAR-T cells (e.g., CD22 CAR-T cells described herein) are propagated in culture with mantle cell lymphoma cells (e.g., REC-1 cells) for 14 days, and the resulting cells are more effective than the same CAR-T cells (e.g., CD22 CAR-T cells described herein) propagated in culture under the same culture conditions but without mantle cell lymphoma cells (e.g., REC-1 cells). In one embodiment, CAR-T cells (e.g., BCMA CAR-T cells described herein) are propagated in culture with mantle cell lymphoma cells (e.g., REC-1 cells) for 14 days, and the resulting cells are more effective than the same CAR-T cells (e.g., BCMA CAR-T cells described herein) propagated in culture under the same culture conditions but without mantle cell lymphoma cells (e.g., REC-1 cells).

[0454] For example, efficacy can be defined by various T cell functions, such as proliferation, target cell killing, cytokine production, activation, migration or a combination thereof. In one embodiment, compared to the same cells bred in culture for 9 days under the same culture conditions, the cells (e.g., CD19 CAR-T cells described herein) that are bred for 5 days show at least 1, 2, 3 or 4 times of cell doubling after antigen stimulation. In one embodiment, cells (e.g., cells expressing CD19 CAR described herein) are bred in culture for 5 days, and the resulting cells show higher pro-inflammatory cytokine production compared to the same cells bred in culture for 9 days under the same culture conditions, for example, IFN-γ and / or GM-CSF levels. In one embodiment, compared to the same cells bred in culture for 9 days under the same culture conditions, the cells (e.g., CD19 CAR-T cells described herein) that are bred for 5 days show pro-inflammatory cytokine production (e.g., IFN-γ and / or GM-CSF levels) at least 1, 2, 3, 4, 5, 10 times or more of increase (pg / ml).

[0455] Several stimulation cycles may also be needed so that the culture time of T cells can be 60 days or longer. Conditions suitable for T cell culture include suitable culture medium (for example, minimum essential medium or RPMI culture medium 1640, or X-vivo 15 (Lonza)), which may contain the necessary factor for proliferation and viability, including serum (for example, fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGF-β and TNF-α or any other additive for cell growth known to those skilled in the art. Other additives for cell growth include, but are not limited to, surfactants, plasma protein powder (plasmanate) and reducing agents such as N-acetyl-cysteine ​​and 2-mercaptoethanol. Culture medium may include RPMI 1640, AIM-V, DMEM, MEM, a-MEM, F-12, X-Vivo 15 and X-Vivo 20, Optimizer, and added with amino acids, sodium pyruvate and vitamins, without serum or supplemented with an appropriate amount of serum (or plasma) or a set of determined hormones, and / or cytokines sufficient for the growth and propagation of T cells. Antibiotics (e.g., penicillin and streptomycin) are included only in experimental cultures and are not included in cell cultures to be input into the subject. Target cells are maintained under conditions necessary to support growth, such as an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air + 5% CO 2 ).

[0456] In one embodiment, the cells are propagated in an appropriate culture medium (e.g., a culture medium described herein) that includes one or more interleukins that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14-day propagation period, e.g., as measured by a method described herein (such as flow cytometry). In one embodiment, the cells are propagated in the presence of IL-15 and / or IL-7 (e.g., IL-15 and IL-7).

[0457] In one embodiment of the present disclosure, cells (e.g., immune cells, e.g., T cells or NK cells), e.g., immune effector cells, e.g., T cells, e.g., CART-T cells, TCR-T cells or TILs) are propagated in an appropriate culture medium (e.g., a culture medium described herein) comprising one or more BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, Inhibitors of ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, TRAIL (TNFSF10) and / or death receptor 5 (DR5 or TNFRSF10B) that result in at least a 1.5-fold (e.g., 2-fold, 5-fold, 10-fold, 50-fold) increase in T stem cells or T stem memory cells over a 14-day propagation period, as measured, for example, by methods described herein (such as flow cytometry). In one embodiment, the cells are propagated in the presence of IL-15 and / or IL-7 (e.g., IL-15 and IL-7). In one embodiment, the cells are propagated in the presence of an inhibitor of TRAIL and / or DR5. In one embodiment, the TRAIL inhibitor is a TRAIL antibody that blocks or neutralizes the binding or activity of TRAIL to its receptors DR5 and / or DR4. In an exemplary embodiment, the cells are propagated in the presence of a neutralizing antibody to TRAIL. An exemplary neutralizing antibody to TRAIL is represented by the TRAIL antibody MAB375-SP available from R&D Systems. In one embodiment, cells are propagated in the presence of at least 1 ng / ml (e.g., 2 ng / ml, 5 ng / ml, 10 ng / ml, 20 ng / ml, 50 ng / ml) of a TRAIL antibody (e.g., MAB375-SP). In one embodiment, cells are propagated in the presence of a TRAIL antibody (e.g., MAB375-SP) for at least 1 day (e.g., 2 days, 5 days, 10 days, 15 days, 20 days). In one embodiment, the TRAIL inhibitor is a soluble form of a TRAIL receptor.Exemplary soluble TRAIL receptors include: DR5-Fc fusion protein (Sigma-Aldrich; D9563), DR5-SP-ECD-hIgFc (SEQ ID NO: 2428), recombinant human TRAILR1 / TNFRSF10A Fc chimeric protein, CF (R&D Systems), DR4-Fc fusion protein (Sigma-Aldrich; D9438), DR4-SP-ECD-hIgFc (SEQ ID NO: 2441), recombinant human TRAIL R3 / TNFRSF10C Fc chimeric protein (R&D Systems); DcR1-SP-ECD-hIgFc (SEQ ID NO: 2448); recombinant human TRAIL R3 / TNFRSF10C Fc chimeric protein (R&D Systems) and DcR2-ECD-hIgFc (SEQ ID NO: 2455). In one embodiment, the cells are propagated in the presence of at least 1 ng / ml (e.g., 2 ng / ml, 5 ng / ml, 10 ng / ml, 20 ng / ml, 50 ng / ml, 100 ng / ml) of a purified soluble TRAIL receptor, such as a DR5-Fc fusion protein (Sigma-Aldrich; D9563) or a DR4-Fc fusion protein (Sigma-Aldrich; D9438). In one embodiment, the cells are propagated in the presence of a soluble TRAIL receptor (e.g., DR5-Fc, DR4-Fc, DcR1-Fc, or DcR2-Fc) for at least 1 day (e.g., 2 days, 5 days, 10 days, 15 days, 20 days). In certain embodiments, the cells are propagated in the presence of both a neutralizing TRAIL antibody (e.g., MAB375-SP) and a soluble TRAIL receptor (e.g., DR5-Fc, DR4-Fc, DcR1-Fc, or DcR2-Fc). In one embodiment, cells are propagated in the presence of a nucleic acid inhibitor (e.g., shRNA, siRNA, or gRNA) of TRAIL and / or DR5. In one embodiment, cells are propagated in the presence of a TRAIL inhibitor and one or more inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, and AKT.In one embodiment, cells are propagated in the presence of one or more of a TRAIL inhibitor and a CD3 antibody, a CD28 antibody, a 41BB antibody (Utomilumab), a bispecific / multispecific T cell engager (e.g., a bispecific or multispecific engager described herein, e.g., rantomilumab). In one embodiment, cells are propagated in the presence of a TRAIL inhibitor and a bispecific / multispecific T cell engager (e.g., a bispecific or multispecific engager described herein), in the presence of an antigen presenting cell (APC) or an antigen presenting substrate (APS) (e.g., an APC or APS described herein, e.g., REC-1 cells or beads coated with the extracellular domain (amino acid residues 61-867)).

[0458] The present disclosure is also at least partially directed to methods for improving the propagation and / or activation (e.g., in vitro and in vivo propagation and / or activation) of cells (e.g., immune cells, e.g., T cells or NK cells, e.g., immune effector cells, e.g., immune effector T cells, e.g., CAR-T cells or TCR-T cells or TIL) for the purpose of adoptive cell therapy. Non-limiting examples of cells (e.g., immune cells, e.g., T cells or NK cells) that can be activated and / or propagated by the methods of the present disclosure include T cells, CD8+T cells, CD4+T cells, NKT cells, NK cells, monocytes and macrophages, etc. In one embodiment, the cells are mobilized (e.g., Plerixafor-mobilized) cells. In one embodiment, the cells express inhibitors of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1, HDAC2, and AKT.

[0459] In certain embodiments, the method comprises contacting an immune cell (e.g., an immune effector cell, e.g., an immune effector cell described herein, e.g., a T cell, e.g., a CAR-T cell or a TCR-T cell) with a bispecific or multispecific adaptor having two or more antigen binding moieties, wherein at least one antigen binding moiety binds or engages the immune cell and wherein at least one other moiety binds or engages an antigen presenting cell (APC) or an antigen presenting substrate (APS), under conditions that result in activation and / or proliferation of the immune cell. In certain embodiments, one or all antigen-binding moieties of a bispecific or multispecific linker comprise or consist of: (1) an antibody; (2) an antibody fragment (e.g., Fv, Fab, (Fab')2); (3) an antibody heavy chain variable region (vH domain) or a fragment thereof; (4) an antibody light chain variable region (vL domain) or a fragment thereof; (5) a single chain variable fragment (scFv) or a fragment thereof; (6) a single domain antibody (SDAB) or a fragment thereof; (7) a camelid VHH domain or a fragment thereof; (8) a monomeric variable region of an antibody. region; (9) non-immunoglobulin antigen binding scaffolds such as DARPIN, affibody, affilin, adnectin, affitin, obodies, repebody, fynomer, alphabody, avimer, atrimer, centyrin, probetin, anticalin, kunitz domain, armadillo repeat protein or fragment thereof; (10) receptor or fragment thereof; (11) ligand or fragment thereof. In certain embodiments, the two or more antigen binding moieties of the bispecific or multispecific linker are of the same type, for example, scFV or vHH. In certain embodiments, the two or more antigen binding moieties of the bispecific or multispecific linker are of different types, for example, scFV and vHH domain; scFv and centyrin; vHH domain and affibody; scFv, vHH domain and centyrin.

[0460] In one embodiment, the bispecific or multispecific linker is a bispecific antibody molecule, for example, lantumomab. Bispecific antibodies have specificity for no more than two antigens. The bispecific antibody molecule is characterized in that the first immunoglobulin variable domain sequence has binding specificity to the first epitope and the second immunoglobulin variable domain sequence has binding specificity to the second epitope. In one embodiment, the first epitope and the second epitope are on the same antigen, such as the same protein (or subunit of a multimeric protein). In one embodiment, the first epitope and the second epitope overlap. In one embodiment, the first epitope and the second epitope do not overlap. In one embodiment, the first epitope and the second epitope are on different antigens, such as different proteins (or different subunits of a multimeric protein). In one embodiment, the bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence having binding specificity to the first epitope, and a heavy chain variable domain sequence and a light chain variable domain sequence having binding specificity to the second epitope. In one embodiment, the bispecific antibody molecule comprises a half antibody having binding specificity to the first epitope and a half antibody having binding specificity to the second epitope. In one embodiment, the bispecific antibody molecule comprises a half antibody or fragment thereof having binding specificity for a first epitope and a half antibody or fragment thereof having binding specificity for a second epitope.

[0461] In one embodiment, the bispecific antibody molecule comprises a scFv or fragment thereof having binding specificity for a first epitope and a scFv or fragment thereof having binding specificity for a second epitope.

[0462] In certain embodiments, the linker is an antibody molecule that is a multispecific (eg, bispecific or trispecific) molecule. Protocols for generating bispecific or heterodimeric antibody molecules are known in the art.

[0463] In each antibody or antibody fragment (e.g., scFv) of the bispecific antibody molecule, VH can be upstream or downstream of VL. In certain embodiments, the upstream antibody or antibody fragment (e.g., scFv) is arranged such that its VH (VH1) is upstream of its VL (VL1), and the downstream antibody or antibody fragment (e.g., scFv) is arranged such that its VL (VL2) is upstream of its VH (VH2), such that the total bispecific antibody molecule has the arrangement VH1-VL1-VL2-VH2. In other embodiments, the upstream antibody or antibody fragment (e.g., scFv) is arranged such that its VL (VL1) is upstream of its VH (VH1), and the downstream antibody or antibody fragment (e.g., scFv) is arranged such that its VH (VH2) is upstream of its VL (VL2), such that the total bispecific antibody molecule has the arrangement VL1-VH1-VH2-VL2.

[0464] In certain embodiments, the bispecific or multispecific linker targets at least one antigen expressed by the immune cells to be activated and / or propagated (e.g., CD3, CD28, CD27, 41BB, etc.), and at least one other antigen expressed by cells other than the immune cells to be activated and / or propagated (e.g., CD19, mesothelin, Her2, Her3, EGFR viii, etc.). In certain embodiments, the other antigen is expressed or presented by antigen presenting cells (APCs) or antigen presenting substrates (APS) (e.g., beads coated with the extracellular domain of CD19). In certain embodiments, at least one other antigen expressed by an APC or APS (e.g., CD19, CD20 / MS4A1, CD22, CD23, CD123, MPL, BCMA, CS1, CD138, CD38, etc.) is expressed on a hematopoietic cell (e.g., a B-lineage cell, a myeloid lineage cell, or a plasma cell or cell line, e.g., REC-1, NALM6, HL60, K562, BC-1, U266, etc.). In certain embodiments, at least one other antigen expressed by an APC or APS (e.g., Her2, Her3, EGFR, mesothelin, CDH19, CDH6, etc.) is expressed on a non-hematopoietic cell (e.g., a breast cell, a lung cell, a colon cell, a skin cell, etc.) or a cell line (e.g., a breast cancer cell line, e.g., MCF7, a lung cancer cell line, e.g., H460, or a colon cancer cell line, e.g., SW480, etc.).

[0465] Non-limiting examples of antigens expressed by APCs or APSs that can be recognized by the bispecific or multispecific linkers of the present disclosure to activate and / or propagate immune cells include one or more of the following: CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319 and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemias or lymphomas but not on hematopoietic progenitor cells, glycosylated CD43 epitope expressed on non-hematopoietic cancers, carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin-11 receptor alpha (IL-1 lRa); prostate stem cell antigen (PSCA); testisin serine 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); mutated elongation factor 2 (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); proteasome (macropain) subunit, beta type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl); tyrosinase;Ephrin type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7 TEM7R; claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); the hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation variant gene 6 on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN);Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B 1 (CYP1B 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, breakpoint X 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of the IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A, member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL, biotin, c-MYC epitope tag, CD34, LAMP1TROP2, GFRα4, CDH17, CDH6, NYBR1, CDH19, CD200R, Slea (CA19.9;Sialyl Lewis antigen) fucosyl-GM1, PTK7, gpNMB, CDH1-CD324, DLL3, CD276 / B7H3, IL11Ra, IL13Ra2, CD179b-IGLl1, ALK TCRγ-δ, NKG2D, CD32 (FCGR2A), CSPG4-HMW-MAA, Tim1- / HVCR1, CSF2RA (GM-CSFR-α), TGFβR2, VEGFR2 / KDR, Lewis Ag, TCR-β1 chain, TCR-β2 chain, TCR-γ chain, TCR-δ chain, FITC, luteinizing hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR), chorionic gonadotropin hormone receptor (CGHR), CCR4, SLAMF6, SLAMF4, HIV1 envelope glycoprotein, HTLV1-Tax, CMV pp65, EBV-EBNA3c, influenza A hemagglutinin (HA), GAD, PDL1, guanylate cyclase C (GCC), KSHV-K8.1 protein, KSHV-gH protein, autoantibodies to desmoglein 3 (Dsg3), autoantibodies to desmoglein 1 (Dsg1), HLA, HLA-A, HLA-A2, HLA-B, HLA-C, HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, HLA-DR, HLA-G, IGE, CD99, RAS G12V, tissue factor 1 (TF1), AFP, GPRC5D, claudin 18.2 (CLD18A2 or CLDN18A.2), P-glycoprotein, STEAP1, LIV1, nectin-4, CRIPTO, MPL, GPA33, BST1 / CD157, low-conductance chloride channel, integrin B7, Muc17, C16ORF54, VISTA, Muc5Ac, FCRH5, CLDN6, MMP16, UPK1B, BMPR1B, Ly6E, WISP1, and SLC34A2.

[0466] Some embodiments described herein provide, by exposing them to bispecific or multispecific adapters to propagate and / or activate immune T cells, the adapter containing one (or first) antigen binding domain capable of bridging T cells and other (or second) antigen binding domains capable of bridging antigen presenting cells (APC) or antigen presenting substrates (APS). It should be noted that the order of the antigen binding domains of the bispecific adapter can be reversed without affecting its activity. Thus, the bispecific adapter for CD19 can have a configuration CD19 x CD3 or CD3 x CD19. In certain embodiments, the APC is a hematopoietic cell. In certain embodiments, the method further includes exposing immune T cells to an agonist capable of activating co-stimulatory receptors (e.g., CD28, 41BB, CD27, etc.) on T cells, such as an antibody (e.g., Utomilumab) or a ligand (41BBL).

[0467] In certain embodiments, the bispecific / multispecific linker comprises at least one (or first) binding domain that is capable of binding to and activating a T cell receptor (TCR) complex of a T cell. In certain embodiments, the bispecific / multispecific linker comprises at least one (or first) binding domain that is capable of binding to and activating a CD3 subunit of a TCR complex. In certain embodiments, the bispecific / multispecific linker comprises at least one (or one) binding domain that is capable of binding to and activating a CD3-ε subunit of a TCR complex.

[0468] In certain embodiments, the bispecific / multispecific linker comprises at least one (or first) binding domain that is capable of binding to and activating a receptor that provides co-stimulation on T cells (i.e., a co-stimulatory receptor). Exemplary co-stimulatory receptors bound by bispecific linkers include CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, TNFR-I, TNFR-II, Fas, CD30, and CD40.

[0469] In certain embodiments, the bispecific / multispecific adapter activates signaling through a TCR complex in the presence of an APC or APS. In certain embodiments, the bispecific / multispecific adapter activates T cells via signaling through a co-stimulatory receptor in the presence of an APC or APS.

[0470] In certain embodiments, the bispecific / multispecific linker comprises at least one (or second) binding domain capable of binding to a hematopoietic cell. In certain embodiments, the bispecific / multispecific linker comprises at least one (or second) binding domain capable of binding to a hematopoietic cell of the lymphoid lineage. In certain embodiments, the bispecific / multispecific linker comprises at least one (or second) binding domain capable of binding to a hematopoietic cell of the lymphoid lineage. In certain embodiments, the bispecific / multispecific linker comprises at least one (or second) binding domain capable of binding to a hematopoietic cell of the B-lymphoid lineage. Exemplary B-lineage lymphoid cells bound by bispecific / multispecific linkers (e.g., bispecific antibodies) include immature B cells, mature B cells, and plasma cells, and combinations thereof. In certain embodiments, the bispecific / multispecific linker (e.g., bispecific antibodies) comprises at least one (or second) binding domain capable of binding to an antigen expressed on a hematopoietic cell of the B-lymphoid lineage. Non-limiting examples of antigens bound by the second binding domain of a bispecific / multispecific adaptor (e.g., a bispecific antibody) include CD19, CD20 / MS4A1, CD22, CD23, BCMA, CS1 / SLAMF7, CD30, CD32b, CD70, CD79b, CD123, CD33, CD138, CD179b, GPRC5D, Lym1, Lym2, and FCRH5.

[0471] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific linker (e.g., bispecific antibody) binds CD3 epsilon (or CD3 ε), and the at least one other (or second) antigen binding domain binds CD19. In certain embodiments, the bispecific / multispecific linker (e.g., bispecific antibody) is rantuzumab. In certain embodiments, the bispecific / multispecific linker (e.g., bispecific antibody) is a CD19 x CD3 DART described in Moore PA et al., Blood, 2011; 117(17): 4542-4551.

[0472] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds to CD3 epsilon (or CD3 epsilon), and the at least one other (or second) antigen binding domain binds to CD22. In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds to CD3 epsilon (or CD3 epsilon), and the at least one other (or second) antigen binding domain binds to CD20 / MS4A1.

[0473] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds CD3e (or CD3ε) and the at least one other (or second) antigen binding domain binds CD23.

[0474] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds CD3 epsilon (or CD3 ε), and at least one other (or second) antigen binding domain binds BCMA. In certain embodiments, the bispecific antibody is BI 836909 (AMG 420).

[0475] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds CD3e (or CD3ε) and the at least one other (or second) antigen binding domain binds CS1 / SLAMF7.

[0476] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds CD3e (or CD3ε) and the at least one other (or second) antigen binding domain binds CD138.

[0477] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds CD3 epsilon (or CD3 ε), and the at least one other (or second) antigen binding domain binds CD123.

[0478] In certain embodiments, at least one (first) antigen binding domain of the bispecific / multispecific adaptor (e.g., bispecific antibody) binds to CD3e (or CD3ε), and at least one other (or second) antigen binding domain binds to MPL. Table 7E provides the SEQ ID NOs of several bispecific antibodies whose first (or one) antigen binding domain binds to CD3e, CD28, or 41BB, and whose second (or other) antigen binding domain binds to a different antigen, such as CD19, CD20 / MS4A1, CD22, BCMA, CD33, CD123, MPL, folate receptor 1, etc.

[0479] In certain embodiments, activation and propagation of T cells comprises exposing them to the bispecific / multispecific adaptor in the presence of specific cells that express a cognate ligand (e.g., an antigen) that is bound by at least one (second) antigen binding domain of the adaptor.

[0480] In certain embodiments, activation and propagation of T cells comprises exposing them to the bispecific / multispecific linker in the presence of a solid substrate expressing a cognate ligand (e.g., an antigen or an anti-idiotypic antibody) that is bound by at least one (second) antigen binding domain of the linker.

[0481] In certain embodiments, the method comprises activating / propagating immune T cells by exposing them to two different bispecific / multispecific adapters (e.g., bispecific antibodies), wherein at least one antigen binding domain of the first bispecific / multispecific adapter (e.g., bispecific antibody) binds to and activates a T cell receptor (e.g., by binding to CD3ε), and at least one antigen binding domain of the second bispecific / multispecific adapter (e.g., bispecific antibody) binds to and activates a co-stimulatory receptor (e.g., 41BB or CD28), and at least one antigen binding domain of both bispecific / multispecific adapters (e.g., bispecific antibodies) binds to an antigen expressed on hematopoietic cells (e.g., CD19, CD22, CD20 / MS4A1 and / or BCMA, etc.). In an exemplary embodiment, the method comprises activating / propagating immune T cells by exposing them to CD19 x CD3 and CD19 x 41BB bispecific antibodies in the presence of REC-1 cells.

[0482] In an alternative embodiment, the method comprises activating / propagating immune T cells by exposing them to CD19 x CD3 and CD22 x CD28 bispecific antibodies in the presence of REC-1 cells. In another alternative embodiment, the method comprises activating / propagating immune T cells by exposing them to CD20 x CD3 and CD22 x CD28 bispecific antibodies in the presence of REC-1 cells. In various embodiments of the methods of the present disclosure, exemplary combinations of bispecific adapters, activating antibodies (e.g., CD3), APCs, APSs, and cytokines that can be used to activate immune cells (e.g., T cells) are presented in Table 17.

[0483] The aforementioned methods can be implemented in vitro, ex vivo or in vivo.

[0484] In certain embodiments, the immune cell colony used in the methods described herein is obtained (e.g., obtained) from a blood sample from a subject (e.g., a cancer patient). In one embodiment, an immune cell colony is obtained by apheresis. In one embodiment, an immune cell c...

Claims

1. A method of manufacturing an immune effector cell therapy product, the product being manufactured for administering immune effector cells or a population thereof to a subject in need thereof, the method comprising: Obtain blood and / or bone marrow from a donor that has been treated with a mobilizing agent selected from the group consisting of: (a) a CXCR4 antagonist selected from the group consisting of plerixafor and BL-8040; (b) a cytokine selected from the group consisting of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF) and pegfilgrastim; (c) a combination of the CXCR4 antagonist and the cytokine; Isolating the immune effector cells or populations thereof from the blood and / or bone marrow; Transforming the immune effector cells or a population thereof with a heterologous polynucleotide to express or overexpress an endogenous or exogenous immune receptor, wherein the immune receptor comprises at least one antigen binding domain and at least one transmembrane domain; and manufacturing the immune effector cell therapy product.

2. The method according to claim 1, wherein a) administering plerixafor subcutaneously, intravenously or intramuscularly at a dose of 0.20 mg / kg to 5 mg / kg daily for 1-10 days before and / or on the day of obtaining blood and / or bone marrow from the donor; b) BL-8040 was administered subcutaneously at a dose of 1 mg / kg; c) G-CSF is administered subcutaneously or intravenously at a dose of 1-30 μg / kg daily for 1-10 days; d) pegfilgrastim administered subcutaneously at a dose of 6 mg to 12 mg; e) GM-CSF at 250 μg / m per day 2 The dose is administered intravenously or subcutaneously for 1-10 days.

3. The method of claim 1, wherein the immune receptor is selected from the group consisting of a chimeric antigen receptor (CAR), a T cell receptor (TCR), a chimeric TCR (cTCR), a synthetic notch receptor, a natural NK cell receptor, a synthetic NK cell receptor, a natural macrophage receptor, or a synthetic macrophage receptor.

4. The method of claim 1, wherein the immune receptor is a next generation CAR.

5. The method of claim 4, wherein the next generation CAR is selected from the group consisting of SIR, zSIR, Ab-TCR, TAC, super CAR and TFP.

6. The method of claim 1, wherein the immune effector cells are selected from the group consisting of: (a) T cells, (b) B cells, (c) mast cells, (d) monocytes or macrophages, (e) bone marrow-derived phagocytes, (f) dendritic cells, and (g) Immune effector cells derived from hematopoietic stem cells.

7. The method according to claim 6, wherein the T cells are selected from α / β T cells, γ / δ T cells, CD8 + T cells, CD4 + T cells, naive T cells, Pgp + T cells, T-regulatory cells, Th-17 cells, T stem cells, T stem memory cells, tissue-resident T cells, tumor-infiltrating T cells, natural killer T (NKT) cells, or a combination thereof.

8. The method of any one of claims 1 and 3-5, wherein the immune receptor binds to a tumor antigen selected from the group consisting of: CD5, CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemia or lymphoma but not on hematopoietic progenitor cells; glycosylated CD43 epitope expressed on non-hematopoietic cancers; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD 213A2); mesothelin; interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (testosterone or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostate enzymes; Prostatic acid phosphatase (PAP); Elongation factor 2, mutant (ELF2M); Ephrin B2; Fibroblast activation protein alpha (FAP); Insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); Proteasome (precursor, megalin factor) subunit, beta type, 9 (LMP2); Glycoprotein 100 (gpl00); Oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl); Tyrosinase; Ephrin Type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor C class 5 group, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplaque protein 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pan-nexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutants; prostate-specific protein; survivin; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8); melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 lB 1 (CYPlB 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); kidney ubiquitous 1 (RU1); kidney ubiquitous 2 (RU2); legumin; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-containing -like module of mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL; biotin; c-MYC epitope tag; CD34; LAMP1TROP2; GFRα4; CDH17; CDH6; NYBR1; CDH19; CD200R; Slea (CA19.9; sialyl Lewis antigen)fucosyl-GM1; PTK7; gpNMB; CDH1-CD324; DLL3; CD276 / B7H3; IL11Ra; IL13Ra2; CD179b-IGLl1; ALK TCRγ-δ; NKG2D; CD32(FCGR2A); CSPG4-HMW-MAA; Tim1- / HVCR1; CSF2RA(GM-CSFR-α); TGFβR2; VEGFR2 / KDR; Lewis Ag; TCR-β1 chain; TCR-β2 chain; TCR-γ chain; TCR-δ chain; FITC; luteinizing hormone receptor (LHR); follicle-stimulating hormone receptor (FSHR); chorionic gonadotropin hormone receptor (CGHR); CCR4; SLAMF6; SLAMF4; HIV1 envelope glycoprotein; HTLV1-Tax; CMV pp65; EBV-EBNA3c; influenza A hemagglutinin (HA); GAD; PDL1; guanylate cyclase C (GCC); KSHV-K8.1 protein; KSHV-gH protein; autoantibodies against desmoglein 3 (Dsg3); autoantibodies against desmoglein 1 (Dsg1); HLA; HLA-A; HLA-A2; HLA-B; HLA-C; HLA-DP; HLA-DM; HLA-DOA; HLA-DOB; HLA-DQ; HLA-DR; HLA-G; . IGE; CD99; RAS G12V; tissue factor 1 (TF1); AFP; GPRC5D; claudin 18.2 (CLD18A2 or CLDN18A.2); P-glycoprotein; STEAP1; LIV1; catenin-4; CRIPTO; MPL; GPA33; BST1 / CD157; low-conductance chloride channel; integrin B7; Muc17; C16ORF54; VISTA; Muc5Ac; FCRH5; CLDN6; MMP16, UPK1B; BMPR1B; Ly6E, WISP1 and SLC34A2.

9. The method of claim 1, wherein the immune effector cells or populations thereof are isolated from a donor having one or more of the following characteristics: a) Be a healthy donor; b) Suffering from a disease; c) has received treatment for the disease before; d) are at risk of developing a disease; e) The donor is autologous; f) is an allogeneic donor; g) is a candidate for receiving said cell therapy product; h) have previously received chemotherapy drugs or anti-cancer drugs; i) Has previously received one or more of the following agents: immunomodulatory drugs (IMiDs), steroids, antibodies, antibody drug conjugates, bispecific antibodies, targeted therapies, radiation therapy, and / or radiolabeled antibodies.

10. The method of claim 1, wherein the immune effector cells or populations thereof are isolated from a donor having one or more of the following characteristics: a) before administration of the mobilizing agent, the number of cells in the peripheral blood is less than 1000×10 6 / L CD3+ cells; b) before administration of the mobilizing agent, the patient has less than 800×10 6 / L CD4+ cells; c) before administration of the mobilizing agent, the patient has less than 500×10 6 / L CD8+ cells; d) before administration of the mobilizing agent, the peripheral blood has less than 50×10 6 / L CD3+ / CD16+ cells; e) before administration of the mobilizing agent, the patient has less than 50×10 6 / L CD3+ / CD56+ cells; f) having or expected to have less than about 50×10 9 of white blood cells (WBC).

11. The method of claim 1, wherein the immune effector cells or populations thereof are obtained from the donor using leukapheresis and / or bone marrow harvesting.

12. The method of claim 1, wherein the immune effector cells or populations thereof undergo one or more steps selected from the group consisting of: a) washing to remove the plasma fraction; b) placing the cells in an appropriate buffer or culture medium; c) lysis of red blood cells; d) removing monocytes; e) enriching cells expressing P-glycoprotein; f) removing cells expressing the tumor antigen from said population; g) removing cells expressing a checkpoint inhibitor from said population; h) removal of regulatory T cells (TREG); i) T cell selection; j) T cell activation; k) T cell genetic modification; l) propagation in culture for 1-30 days; m) Cryopreservation of propagated immune effector cells or populations thereof.

13. The method of claim 1, wherein the immune effector cell or population thereof is genetically modified to express one or more signaling molecules or gene inhibitors that: a. Enhance the proliferation of immune effector cells; b. Alteration of cytokine secretion by immune effector cells; c. Reduce the dependence of survival and proliferation on exogenous cytokines; d. Enhance the cytotoxicity of immune effector cells; e. Enhance the survival of immune effector cells; f. Blocking apoptosis of immune cells; g. Delay the aging of immune cells; h. Delay the exhaustion of immune cells; When administered to a patient, it enhances the persistence of immune cells in the body; j. When administered to a patient, enhances the effectiveness of immune cells in the body.

14. The method of claim 1, wherein the immune effector cells or populations thereof are genetically modified to have reduced, eliminated or altered expression and / or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes, ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1 HDAC2, JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27, CD28, 41BB, DcR1, DcR2, OX40, GITR, BCMA, TRAIL, DR4 and / or DR5.

15. The method of claim 1, 13 or 14, wherein the immune effector cells or populations thereof are genetically modified to express a constitutively active mutant of one or more of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF.

16. The method of any one of claims 1-7, wherein the immune effector cell therapy product is to be administered to a subject in need thereof.

17. The method of claim 16, wherein the subject is an autologous subject or an allogeneic subject.

18. The method of claim 17, wherein the subject receives one or more of the following: a) Chemotherapy; b) Peripheral blood stem cell transplantation; c) surgery; d) Bispecific / multispecific linkers, with or without co-stimulatory agents; e) Agents that prevent, delay, alleviate or treat toxicity of infused cell therapy products.

19. The method of claim 1, comprising exposing the cell to a bispecific or multispecific linker in the presence of an antigen presenting cell or an antigen presenting substrate.

20. The method of claim 19, wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to and activating a T cell receptor (TCR) complex of a T cell; or wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to and activating a CD3 subunit of a TCR complex; or wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to and activating a receptor on a T cell that provides co-stimulation; or wherein the bispecific or multispecific linker activates signaling through the TCR complex in the presence of an APC or APS; or wherein the bispecific or multispecific linker activates a T cell via signaling through a co-stimulatory receptor in the presence of an APC or APS; or or wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to hematopoietic cells; or wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to immature B cells, mature B cells and plasma cells, and / or a combination thereof; or wherein the bispecific or multispecific linker comprises at least one binding domain capable of binding to an antigen expressed on hematopoietic cells of the B-lymphoid lineage selected from the group consisting of CD19, CD20 / MS4A1, CD22, CD23, BCMA, CS1 / SLAMF7, CD30, CD32b, CD70, CD79b, CD123, CD33, CD138, CD179b, GPRC5D, Lym1, Lym2 and FCRH5.

21. The method of claim 1 or 2, wherein the donor has been treated with the CXCR4 antagonist.

22. The method of claim 1 or 2, wherein the donor has been treated with the cytokine.

23. The method of claim 1 or 2, wherein the donor has been treated with a combination of the CXCR4 antagonist and the cytokine.

24. The method of claim 23, wherein the CXCR4 antagonist is administered after administration of the cytokine.

25. The method of claim 23 or 24, wherein the donor has been treated with a combination of plerixafor and one or more cytokines selected from the group consisting of: a) Granulocyte colony stimulating factor (G-CSF); b) granulocyte-macrophage colony-stimulating factor (GM-CSF); or c) Pegfilgrastim.

26. The method of claim 23 or 24, wherein the donor has been treated with a combination of BL-8040 and one or more cytokines selected from the group consisting of: a) Granulocyte colony stimulating factor (G-CSF); b) granulocyte-macrophage colony-stimulating factor (GM-CSF); or c) Pegfilgrastim.

27. A mobilized immune effector cell or population thereof isolated from the blood and / or bone marrow of a donor that has been treated with a mobilizing agent selected from the group consisting of: (a) a CXCR4 antagonist selected from the group consisting of plerixafor and BL-8040; (b) a cytokine selected from the group consisting of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF) and pegfilgrastim; (c) a combination of the CXCR4 antagonist and the cytokine; The cell is transformed with a heterologous polynucleotide to express or overexpress an endogenous or exogenous immune receptor, wherein the immune receptor comprises at least one antigen binding domain and at least one transmembrane domain.

28. The mobilized immune effector cells or populations thereof according to claim 27, wherein a) administering plerixafor subcutaneously, intravenously or intramuscularly at a dose of 0.20 mg / kg to 5 mg / kg daily for 1-10 days before and / or on the day of obtaining blood and / or bone marrow from the donor; b) BL-8040 was administered subcutaneously at a dose of 1 mg / kg; c) G-CSF is administered subcutaneously or intravenously at a dose of 1-30 μg / kg daily for 1-10 days; d) pegfilgrastim administered subcutaneously at a dose of 6 mg to 12 mg; e) GM-CSF at 250 μg / m per day 2 The dose is administered intravenously or subcutaneously for 1-10 days.

29. The mobilized immune effector cells or populations thereof of claim 27, wherein the immune receptor is selected from the group consisting of a chimeric antigen receptor (CAR), a T cell receptor (TCR), a chimeric TCR (cTCR), a synthetic notch receptor, a natural NK cell receptor, a synthetic NK cell receptor, a natural macrophage receptor, or a synthetic macrophage receptor.

30. The mobilized immune effector cells or populations thereof of claim 27, wherein the immune receptor is a next generation CAR.

31. The mobilized immune effector cells or populations thereof of claim 30, wherein the next generation CAR is selected from the group consisting of SIR, zSIR, TAC, Ab-TCR, super CAR, and TFP.

32. The mobilized immune effector cell or population thereof of claim 27, wherein the immune effector cell is selected from the group consisting of: (a) T cells, (b) B cells, (c) mast cells, (d) monocytes or macrophages, (e) bone marrow-derived phagocytes, (f) dendritic cells, and (g) Immune cells derived from hematopoietic stem cells.

33. The mobilized immune effector cell or population thereof according to claim 32, wherein the T cells are selected from α / β T cells, γ / δ T cells, CD8 + T cells, CD4 + T cells, naive T cells, Pgp + T cells, T-regulatory cells, Th-17 cells, T stem cells, T stem memory cells, tissue-resident T cells, tumor-infiltrating T cells, natural killer T (NKT) cells, or a combination thereof.

34. The mobilized immune effector cells or populations thereof of any one of claims 27 and 29-31, wherein the immune receptor binds to a tumor antigen selected from the group consisting of: CD5, CD19; CD123; CD22; CD30; CD171; CS-1 (SLAMF7, D319 and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(ll)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; glycosylated CD43 epitope expressed on acute leukemia or lymphoma but not on hematopoietic progenitor cells; glycosylated CD43 epitope expressed on non-hematopoietic cancers; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD 213A2); mesothelin; interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (testosterone or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20 / MS4A1; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostate enzymes; Prostatic acid phosphatase (PAP); Elongation factor 2, mutant (ELF2M); Ephrin B2; Fibroblast activation protein alpha (FAP); Insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CA1X); Proteasome (precursor, megalin factor) subunit, beta type, 9 (LMP2); Glycoprotein 100 (gpl00); Oncogene fusion protein composed of the breakpoint cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl); Tyrosinase; Ephrin Type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(l-4)bDGlcp(l-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor C class 5 group, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexose moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplaque protein 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pan-nexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutants; prostate-specific protein; survivin; telomerase; prostate cancer tumor antigen-1 (PCT A-1 or galectin 8); melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 lB 1 (CYPlB 1); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of imprinted site regulator), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); kidney ubiquitous 1 (RU1); kidney ubiquitous 2 (RU2); legumin; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of the IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); mucin-like hormone receptor-like 2 containing an EGF-like module (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); immunoglobulin lambda-like polypeptide 1 (IGLL1), MPL; biotin; c-MYC epitope tag; CD34; LAMP1 TROP2; GFRα4; CDH17; CDH6; NYBR1; CDH19; CD200R; Slea(CA19.9; sialyl Lewis antigen) fucosyl-GM1; PTK7; gpNMB; CDH1-CD324; DLL3; CD276 / B7H3; IL11Ra; IL13Ra2; CD179b-IGLl1; ALK TCRγ-δ; NKG2D; CD32(FCGR2A); CSPG4-HMW-MAA; Tim1- / HVCR1; CSF2RA(GM-CSFR-α); TGFβR2; VEGFR2 / KDR; LewsAg; TCR-β1 chain; TCR-β2 chain; TCR-γ chain; TCR-δ chain; FITC; luteinizing hormone receptor (LHR); follicle-stimulating hormone receptor (FSHR); chorionic gonadotropin hormone receptor (CGHR); CCR4; SLAMF6; SLAMF4; HIV1 envelope glycoprotein; HTLV1-Tax; CMV pp65; EBV-EBNA3c; influenza A hemagglutinin (HA); GAD; PDL1; guanylate cyclase C (GCC); KSHV-K8.1 protein; KSHV-gH protein; autoantibodies against desmoglein 3 (Dsg3); autoantibodies against desmoglein 1 (Dsg1); HLA; HLA-A; HLA-A2; HLA-B; HLA-C; HLA-DP; HLA-DM; HLA-DOA; HLA-DOB; HLA-DQ; HLA-DR; HLA-G; . IGE; CD99; RAS G12V; tissue factor 1 (TF1); AFP; GPRC5D; claudin 18.2 (CLD18A2 or CLDN18A.2); P-glycoprotein; STEAP1; LIV1; catenin-4; CRIPTO; MPL; GPA33; BST1 / CD157; low-conductance chloride channel; integrin B7; Muc17; C16ORF54; VISTA; Muc5Ac; FCRH5; CLDN6; MMP16, UPK1B; BMPR1B; Ly6E, WISP1 and SLC34A2.

35. The mobilized immune effector cells or populations thereof of claim 27, wherein the cells are isolated from a donor having one or more of the following characteristics: a) Be a healthy donor; b) Suffering from a disease; c) has received treatment for the disease before; d) are at risk of developing a disease; e) The donor is autologous; f) is an allogeneic donor; g) is a candidate for receiving said cell therapy product; h) have previously received chemotherapy drugs or anti-cancer drugs; i) Has previously received one or more of the following agents: immunomodulatory drugs (IMiDs), steroids, antibodies, antibody drug conjugates, bispecific antibodies, targeted therapies, radiation therapy, and / or radiolabeled antibodies.

36. The mobilized immune effector cells or populations thereof of claim 27, wherein the cells are isolated from a donor having one or more of the following characteristics: a) before administration of the mobilizing agent, the number of cells in the peripheral blood is less than 1000×10 6 / L CD3+ cells; b) before administration of the mobilizing agent, the patient has less than 800×10 6 / L CD4+ cells; c) before administration of the mobilizing agent, the patient has less than 500×10 6 / L CD8+ cells; d) before administration of the mobilizing agent, the peripheral blood has less than 50×10 6 / L CD3+ / CD16+ cells; e) before administration of the mobilizing agent, the patient has less than 50×10 6 / L CD3+ / CD56+ cells; f) having or expected to have less than about 50×10 9 of white blood cells (WBC).

37. The mobilized immune effector cells or populations thereof of claim 27, wherein the immune effector cells or populations thereof are obtained from the donor using leukapheresis and / or bone marrow harvesting.

38. The mobilized immune effector cells or populations thereof according to claim 27, wherein the cells undergo one or more steps selected from the group consisting of: a) washing to remove the plasma fraction; b) placing the cells in an appropriate buffer or culture medium; c) lysis of red blood cells; d) removing monocytes; e) enriching cells expressing P-glycoprotein; f) removing cells expressing the tumor antigen from said population; g) removing cells expressing a checkpoint inhibitor from said population; h) removal of regulatory T cells (TREG); i) T cell selection; j) T cell activation; k) T cell genetic modification; 1) propagation in culture for 1-30 days; m) Cryopreservation of propagated immune effector cells or populations thereof.

39. The mobilized immune effector cells or populations thereof of claim 38, wherein the cells are genetically modified to express one or more signaling molecules or gene inhibitors, the signaling molecules or gene inhibitors: a. Enhance the proliferation of immune effector cells; b. Alteration of cytokine secretion by immune effector cells; c. Reduce the dependence of survival and proliferation on exogenous cytokines; d. Enhance the cytotoxicity of immune effector cells; e. Enhance the survival of immune effector cells; f. Blocking apoptosis of immune cells; g. Delay the aging of immune cells; h. Delay the exhaustion of immune cells; When administered to a patient, it enhances the persistence of immune cells in the body; j. When administered to a patient, enhances the effectiveness of immune cells in the body.

40. The mobilized immune effector cells or populations thereof of claim 27, wherein the cells are genetically modified to have reduced, eliminated or altered expression and / or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes, ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1 / BLIMP1 HDAC2, JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27, CD28, 41BB, DcR1, DcR2, OX40, GITR, BCMA, TRAIL, DR4 and / or DR5.

41. The mobilized immune effector cells or populations thereof of claim 40, wherein the methylcytosine dioxygenase gene is selected from Tet1, Tet2 and Tet3.

42. The mobilized immune effector cells or populations thereof of claims 27, 40 or 41, wherein the immune effector cells or populations thereof are genetically modified to express constitutively active mutants of one or more genes selected from the group consisting of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and / or BRAF.

43. A composition comprising the mobilized immune effector cells or populations thereof according to any one of claims 27-42, and a pharmaceutically acceptable excipient.

44. Use of the mobilized immune effector cells or populations thereof according to any one of claims 27-42, or the composition according to claim 43, in the preparation of a medicament for treating or preventing a disease in a subject.

45. The use according to claim 44, wherein the subject receives one or more of the following: a) Chemotherapy; b) Peripheral blood stem cell transplantation; c) surgery; d) Bispecific / multispecific linkers, with or without co-stimulatory agents; e) Agents that prevent, delay, alleviate or treat toxicity of infused cell therapy products.

46. ​​Use according to any one of claims 44-45, wherein the disease is selected from the group consisting of cancer, precancerous conditions, autoimmune diseases, inflammatory disorders and transplantation.

47. An immune effector cell therapy product obtained by the method of claim 1, comprising immune effector cells or a population thereof, wherein the cells are human cells.

Citation Information

Patent Citations

  • Booster pump

    CA484499A

  • Modular DNA-binding domains and methods of use

    US8420782B2

  • Modular DNA-binding domains and methods of use

    US8470973B2

  • Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer

    WO2012138475A1

  • Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer

    WO2013126712A1